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Coagulase-negative staphylococci (CONS) are the most common cause of bloodstream 
infections in neonatal intensive care units (NICUs). S. capitis, a species of CONS, has 
recently emerged as a common cause of neonatal disease, in some NICUs causing up to 
40% of all bloodstream infections. A clone of S. capitis called NRCS-A, which is 
multidrug resistant and capable of persistence in NICUs, has been isolated from 
neonates worldwide. Most studies of S. capitis NRCS-A have focused on the genome 
structure, or risk factors for bloodstream infection. We conducted both a retrospective 
and prospective study among neonates admitted to the Dunedin Hospital NICU to 
investigate the risk factors of S. capitis skin colonisation and transmission. 
Methods 
Our studies used the results from an ongoing Dunedin Hospital NICU S. capitis 
surveillance system. We collected data on baseline and weekly neonatal exposures, 
along with S. capitis surveillence test results. We collected weekly data on exposures 
such as medication use, medical history, procedures and devices, enteral feeds, weight, 
type of beds, and bed spaces. Additionally the prospective study collected weekly data 
on family and staff contact.  
The retrospective study analysis categorised participating neonates each week as a case 
or a control depending on whether the neonate became colonised with S. capitis or 
remained non-colonised, respectively. We matched control data to case data based on 
calendar time. A nested case-control analysis with conditional logistic regression was 
used to investigate the differences between cases and controls for baseline and weekly 
exposures. A full analysis of the ongoing prospective study will be performed when 
data collection is complete.  
 iii 
Results 
A progress report of the prospective study described the baseline characteristics of the 
13 participants: 1 case and 12 controls. Our retrospective study nested-case control 
analysis included 26 cases and 203 controls.  
Factors associated with an increased risk of S. capitis colonisation included oral sodium 
chloride use (OR 6.1, 95% CI 1.4-27.1, p=0.02), diagnosed patent ductus arteriosus 
(OR 2.9, 95% CI 1.1-7.9, p=0.04), diagnosed chronic lung disease (OR 4.8, 95% CI 
1.1-22.3, p=0.04), and requirement of invasive mechanical ventilation (OR 3.4, 95% CI 
1.1-10.4, p=0.03).  
Factors associated with decreased risk of S. capitis colonisation included being born as 
a part of a multiple birth (OR 0.14, 95% CI 0.04-0.40, p=<0.001), having an area of 
inflamed skin (OR 0.31, 95% CI 0.13-0.70, p=0.005), having an inflamed axilla (OR 
0.31, 95% CI 0.13-0.70, p=0.005), and enteral feeds with formula (OR 0.29, 95% CI 
0.08-0.99, p=0.05). 
Conclusions 
We found that co-morbidities, such as patent ductus arteriosus and chronic lung 
disease, or devices, such as invasive mechanical ventilation, were associated with an 
increased risk of S. capitis colonisation. Having an inflamed axilla, and antimicrobial 
use were independently more common among neonates that ever became colonised 
than neonates that never became colonised, although in the nested case-control analysis 
neither were associated with a statistically significant increased risk of S. capitis 
colonisation. Overall, our retrospective study showed that neonates with comorbidities, 
which may require more management by medical staff and equipment, were associated 





The Dunedin Hospital NICU initiated a S. capitis surveillance system in September 
2013, although no epidemiologic study had been performed to identify risk factors for 
colonisation. Louise Thorn, Master of Public Health candidate (MPH) designed both a 
retrospective and a prospective study to investigate the risk factors for S. capitis 
colonisation among neonates in the Dunedin Hospital NICU.  
The roles of the candidate: 
- Established the objectives of both the retrospective and prospective studies 
based on communication with Dunedin Hospital NICU staff and supervisors. 
- Prepared and obtained Department of Preventive and Social Medicine, 
University of Otago, Research Advisory Committee (RAC) approval. 
- Prepared and obtained Health and Disability Ethics Committee (HDEC) 
approval for the prospective study. Additionally, sought and received approval 
for minor amendments to the original ethics approval.  
- Designed and edited the case report forms (CRFs) for both the retrospective and 
prospective studies.  
- Responsible for ensuring the Dunedin Hospital NICU staff were coded 
appropriately to protect anonymity in the prospective study. 
- Designed and created a REDCap (service version 8.2.0, Vanderbilt University, 
Tennessee, USA) online database for data entry for both the prospective and 
retrospective studies.  
- Performed the prospective study data entry from the CRFs to the REDCap 
database.  
- Coordinated the prospective study, including regular meetings with data 
collectors for quality control.  
- Undertook all retrospective study data collection from medical records, and data 
entry into the REDCap database.  
- Did basic statistical description of the prospective study participants as a 
progress report of the ongoing prospective study. 
 v 
- Matched controls to cases in the retrospective study nested case-control 
analysis. 
- Performed all statistical analyses of the retrospective study data with guidance 
from a statistician. 
- Full write up a Masters of Public Health thesis.  
- Will prepare and submit a paper for publication in peer-reviewed literature 
describing the retrospective study.  
The roles of others involved in the studies: 
Professor John Crump (supervisor) contributed to study design, preparation of the 
proposal for RAC approval, sourced questionnaires from other Staphylococcus 
transmission and disease studies, and advised on design and analysis of both studies 
and content of the CRFs. Prof Crump provided advice and guidance throughout the 
course of both studies. Prof Crump also contributed considerably to reviews and 
comments on drafts of the thesis.   
Associate Professor Roland Broadbent (supervisor) contributed to establishing 
relationships between the candidate and the NICU staff, advised on both the objectives 
of the study and content of the CRFs. Assoc. Prof Broadbent provided codes and 
timetables for the registrars and consultants. For the retrospective study, he ordered the 
medical records from Dunedin Hospital storage, provided advice regarding the specific 
sources of data for each section of the CRFs, and sourced access to the hospitals online 
database for data that were not available among medical records. He also reviewed 
drafts of the thesis.  
Dr James Ussher (supervisor) contributed to the preparation of the prospective study 
HDEC approval, advised on the study objectives, and the content of the CRFs. He also 
provided the document of neonates S. capitis surveillance test results during the period 
of the retrospective study, and provided data on the number of S. capitis invasive 
infections during both study periods. Dr Ussher reviewed drafts of the thesis and was 
particularly helpful with advice for the laboratory methods and microbiology sections.  
 vi 
Assoc. Prof Katrina Sharples (supervisor) contributed to study design, advised on data 
collection, and provided the sample size calculations. Assoc. Prof Sharples also 
provided advice on the statistical methods for both the prospective and retrospective 
analyses. Assoc. Prof Sharples also reviewed drafts of the thesis.   
Dunedin Hospital NICU charge nurse Juliet Manning was involved in the prospective 
study, which included: advice on the content of the CRFs, helped pilot the CRFs, 
provided nurse codes, trained three other nurses in data collection, and had primary 
responsibility for data collection. Juliet Manning also provided the numbers of 
ineligible neonates admitted to the Dunedin Hospital NICU and the reasons for 
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Although common contaminants of blood cultures, CONS are the most common cause 
of bloodstream infections and sepsis among neonates in NICUs (1-5). CONS are 
commensals of the skin and mucous membranes of humans and animals, but may act as 
opportunistic pathogens when they enter the bloodstream or other normally sterile sites 
(6). S. epidermidis is the species most often implicated in CONS disease (7). However, 
S. capitis is emerging as an important cause of bloodstream infections in neonates (8).  
A strain of S. capitis, called S. capitis pulsotype NRCS-A, was identified not only 
colonising premature neonates but also causing serious infections in a hospital NICU in 
France in 2012 (9). Subsequently, S. capitis NRCS-A was identified to be widespread 
not only in NICUs elsewhere in France but also worldwide (9, 10). The homology 
between the strains isolated from geographically diverse NICUs suggested global 
dissemination of the S. capitis pulsotype NRCS-A clone. Studies have investigated the 
genome structure of S. capitis pulsotype NRCS-A, to understand the clones ability to 
survive and persist in the NICU environment (10, 11). Notably, the NICU-specific S. 
capitis clone is resistant to methicillin, aminoglycosides, and has decreased 
susceptibility to vancomycin (11). S. capitis NRCS-A causes up to 40% of all 
bloodstream infections in NICUs where it is endemic (9, 12). 
Studies have shown that intravascular catheter use is a risk factor for neonatal 
bloodstream infections, while there is also some evidence for bacterial translocation to 
the blood through the gastrointestinal tract (12-14). Colonisation is likely a prerequisite 
for infection with S. capitis pulsotype NRCS-A, so studies of transmission focused on 
colonisation are needed to inform prevention and control. Previous studies have 
identified low birthweight, vancomycin treatment, and almond oil as a skin emollient as 
risk factors for S. capitis colonisation (15, 16).  
Although Butin et al. identified low birthweight, and vancomycin use as independent 
risk factors for gastrointestinal tract (GIT) colonisation (16), they did not collect data 




of antimicrobial use in the NICU, the neonates may still be exposed to the source of S. 
capitis and those born at low birthweight will remain at risk of colonisation. Gras-Le 
Guen et al. identified almond oil as a risk factor for colonisation of blood, aspirate, and 
abscesses of neonates (15). However, they did not establish temporality so could not 
identify whether the almond oil was contaminated before or after the neonates were 
colonised. Moreover, S. capitis continued to be isolated from the Nantes hospital 
NICU, therefore almond oil was not the only source, or reservoir of S. capitis. Although 
the Gras-Le Guen study suggested that staff members were the source of transmission 
from the almond oil to the neonates, no studies to our knowledge have yet investigated 
staff members as a source of S. capitis transmission. 
S. capitis pulsotype NRCS-A has been isolated from neonates in the Dunedin Hospital 
NICU since 2007 (personal communication, James Ussher and Roland Broadbent). We 
sought to identify the risk factors for S. capitis colonisation among neonates in the 
Dunedin Hospital NICU using both retrospective and prospective studies. To our 
knowledge, our studies were the first known epidemiologic studies to examine the risk 
factors of S. capitis skin colonisation and the source of transmission. The studies aimed 
to identify the source of colonisation among people and the NICU environment. 
Additionally, the ongoing prospective study traces staff, bed space, incubator, and 
stethoscope contact with neonates. Identification of the source of transmission may 
provide evidence for modification of NICU practices to reduce transmission of S. 
capitis pulsotype NRCS-A and in turn the proportion of neonates who develop S. 





2 Literature review 
 Coagulase-negative staphylococci, Staphylococcus capitis, 
and Staphylococcus capitis pulsotype NRCS-A 
 Ecology in humans, animals, and the environment 
CONS make up part of the normal skin and mucosal flora of humans and animals (6). 
Staphylococcus species prefer to colonise moist areas of the human body such as the 
axillae, nares, and gastrointestinal tract (17, 18). The skin is a heterogeneous organ with 
variation in skin thickness, and an abundance of glands and hair follicles. This variation 
encourages niche differentiation of bacterial species (6) and some CONS species have 
evolved to colonise particular skin areas. For example, among adults S. auricularis 
predominantly colonises the auditory canal (19) and S. saprophyticus the perineal 
region (20). By contrast, S. epidermidis colonises the entire skin surface (21, 22).  
In addition to being an important part of the human skin flora, CONS colonise the skin 
and mucous membranes of non-human animals including cattle, cats, dogs, goats, 
horses, pigs, poultry, and sheep (6, 23, 24). Certain CONS may be adapted or restricted 
to specific animal species (25), while other CONS are capable of colonising both 
humans and a range of animal species (23). For example, S. kloosii is a CONS species 
predominantly found on animals, including farm animals, wild animals, and some 
marine animals (21, 26, 27). S. kloosii has rarely been isolated from humans (27). 
Transmission of CONS can occur from animals to humans, sometimes posing a public 
health threat (28). For example, S. haemolyticus colonises cats, dogs, horses, and 
human skin (21, 29). In the hospital setting S. haemolyticus is an important cause of 
severe healthcare-associated infections (21). 
 CONS have been isolated from the environment as well as their living hosts. In the 
farming industry, CONS colonise niches such as milking liners, floors, and sawdust 
(30, 31). CONS have also been isolated from food such as dry sausages, raw milk, and 




themselves. Others, such as S. carnosus, may be added during food production to 
produce flavor in food such as sausages and cheese (32-34). In the hospital 
environment, CONS can be isolated from the air and surfaces (35). One study by Neely 
et al. showed that CONS can survive on cotton, polyester, and polyethylene surfaces in 
hospitals (36). Neely et al. demonstrated that CONS persisted on polyethylene surfaces 
for over 90 days (36). While studies demonstrate that CONS are capable of survival and 
persistence in the hospital environment, none demonstrate growth and replication 
independent of humans. This suggests that humans and animals rather than the 
environment are the reservoirs for CONS, but that the environment may serve as a 
transmission source. 
In 1975, Kloos and Bannerman classified several new species of CONS (22). One of 
these species, S. capitis, was named after the human scalp from where it was first 
isolated (22). The 1975 study included 19 adults aged from 14 through 61 years, and 21 
children aged from 2 through 12 years (22). From this sample of adults and children, S. 
capitis was isolated from 26 (65%) of 40 individuals but the proportion from children 
was not provided (22). Among the 26 individuals that carried S. capitis, 47 isolates 
were recovered (22). The strains of S. capitis were predominately isolated from the 
head, with a small number from the nares, axillae, arms, and legs (22). In studies since 
1975, S. capitis has rarely been isolated from adults, and more commonly found on 
infants and children (9). Bannerman et al. identified a S. capitis subspecies named S. 
capitis subsp. urealyticus, named for its positive urease activity (37). The S. capitis 
described by Kloos et al, in 1975 was designated S. capitis subsp. capitis (37). 
Bannerman et al. found that while both S. capitis subsp. urealyticus and S. capitis 
subsp. capitis were most frequently isolated from the head, S. capitis subsp. urealyticus 
was also isolated from other unspecified areas of the body (37).  
As with other species of CONS, S. capitis colonises animals as well as humans. S. 
capitis has been isolated from domestic animals such as cats, dogs, and horses (6), and 
from goats (23). S. capitis has been isolated from the hospital environment, particularly 
in neonatal intensive care units (NIUCs) (38). In a study by Gras-Le Guen et al, S. 
capitis was isolated from a refillable bottle of almond oil used as a skin emollient (38). 




it did not evaluate multiplication, so the role of almond oil as a possible S. capitis 
reservoir is unknown.  
Ecology in neonates 
CONS are the most common commensal isolated from skin and mucosa of neonates 
(39). Within the first days or weeks after birth, premature neonates are rapidly 
colonised with CONS (40). In a 1992 study of 10 neonates, Savey et al found that at 
four to five days after birth CONS were isolated from each of 18 neonatal skin sites 
sampled, and on average made up 81% of the neonates total skin flora (41). CONS are 
also the earliest and most abundant colonisers of the GIT (42, 43). The species of 
CONS depends on skin and environmental contacts (8, 41). For premature infants in 
NICUs, colonisation is often with bacteria endemic to the unit or those that have 
specific factors that facilitate colonisation success (40). Although studies have isolated 
CONS species from neonates skin, the pattern of niche differentiation of specific 
species was not clear (41, 44, 45). Therefore, currently niche differentiation of CONS 
among neonates cannot be determined. I identified six studies that sought to determine 
which body areas of neonates were colonised with the most abundant CONS 
populations (Table 1). Studies focused entirely on healthy infants rather than premature 
neonates were excluded. Evidence suggests substantial differences in types of CONS 








Table 1: Studies of coagulase-negative Staphylococcus skin colonisation among 
neonates, worldwide, 1989-1996 
Author(s), 
year Participants Study design Skin sites tested 
Sites populated 




18  Longitudinal Axilla, ear, nasopharynx, and 
rectum. 
Axilla, and ear. 
Keyworth, 
1992 
9 Longitudinal Forehead, chest, periumbilical 
region, back, upper and lower 
leg, and upper and lower arm.  
No variation in 
numbers across 
sites.  
Savey, 1992 10 Cross-
sectional 
 
Skin: scalp, armpits, neck fold, 
umbilicus, inguinal folds, anal 
cleft, lumbar area, palms of 
hands, inside elbows, soles of 
feet, and popliteal spaces. 
 
 
Mucosa: external auditory 
meatus, nasal cavities, external 
genital organs, pharynx, rectum, 
and faeces. 
Skin: umbilicus, 
neck folds and 
inguinal folds. 
Closely followed 












Umbilicus, anterior nares, foot, 








Skin covering the jugular, 





10  Longitudinal  Ear (anterior and posterior), 
anterior nares, axilla, forearm, 
lower leg, and faeces.  
Faeces, posterior 
ear, and axilla.  
 
The results from the six colonisation studies were inconsistent. Two studies found that 
CONS were the most abundant at the umbilicus (41, 46), while the remaining studies 
showed that CONS were more abundant at the axilla, ear, or the skin covering the 
jugular (47, 48). The discordance is likely due to small sample sizes, little crossover of 
the areas swabbed, and different methods and a lack of standardisation for the surface 
areas swabbed. The majority of studies did not include a follow-up, so changes in 
colonisation over time could not be assessed despite fluctuation in microflora being 
widely recognised (44). Day-to-day variation of bacteria isolated from neonates may be 
due to the repetitive inoculation of bacteria from staff and the environment through 




neonates may also be due to different swabbing techniques, different infection control 
procedures, or different ages of participants. 
Of interest, all studies that collected faecal samples found larger CFUs per mg of 
CONS in the faeces compared to other skin or mucosal sites (41, 44). However, the 
variation in CFUs/area among skin sites suggests that there is no predominant area of 
CONS colonisation and that further more standardised research is needed. 
Alternatively, it is possible that niche differentiation is not established until later in life. 
Spread of CONS from one site to another on the same individual is especially likely 
among neonates due to regular handling by staff (49). Additionally, premature neonates 
have predominantly dry skin that has not differentiated between sites whereas adult 
skin includes diverse characteristics ranging from oily to dry (50). It is likely that 
CONS species are found on all areas of the body then specialise to niche areas later in 
infant development. However, a longitudinal study with a large sample size, swabbing 
many different sites on the body needs to be done to further understand CONS niche 
colonisation on neonates.  
 Microbiology 
In 1940, R. W. Fairbrother categorised the Staphylococcus genus into two groups: 
CONS and coagulase-positive staphylococci (COPS) (51). The classification was made 
based on whether or not the Staphylococcus produced the coagulase enzyme, detected 
by coagulation of blood. Fairbrother designated all CONS strains to the species ‘S. 
saprophyticus’ and all COPS to ‘S. pyogenes’ (51). The idea behind the classification 
was to distinguish between ‘non-pathogenic’ CONS, and COPS, which at the time were 
the only species thought to be capable of clinical disease in humans (51). From the 
1970s onwards, phenotypic and genotypic identification methods improved. These 
advances resulted in the reclassification of staphylococci, including the designation of 
more species. By 2014, more than 40 species of staphylococci had been identified. 
Most were classified as CONS, with the COPS group including seven species (52).  
Following the 1970s, studies investigated the clinical aspects of the staphylococcal 




previously thought. For example, S. lugdunensis exhibited clinical characteristics of 
both groups and was designated as an intermediate species (53). S. schleiferi included 
two subspecies, schleiferi and coagulans, classified as CONS and COPS, respectively 
(54). In the 1990s, Kloos and Bannerman showed that some CONS were clinically 
important. Rather than representing a group of exclusively commensal species, the 
CONS group exhibited both non-pathogenic species and species capable of causing 
serious infections in humans (21). While CONS lack common S. aureus toxins that 
cause damage to the host, CONS do have virulence factors for colonisation and 
persistence (11).  
S. capitis is a gram-positive coccus of approximately 0.8-1.2 µm in diameter (55). They 
are non-motile and do not form spores (55). On trypticase soy agar with 5% sheep 
blood S. capitis has a typical appearance of a CONS with smooth, entire, glistening, 
and opaque colonies (56). S. capitis are facultative anaerobes, with an optimum growth 
temperature of 30-40 ºC (55). A study by Cui et al. (2013) in a hospital NICU found 
that S. capitis subsp. urealyticus was predominant among neonates in the NICU, could 
form biofilms, and was resistant to penicillin, erythromycin, and oxacillin (57). S. 
capitis subsp. capitis was rarely isolated from the NICU, could not form biofilms and 
was susceptible to penicillin, erythromycin, and oxacillin (57). The study by Cui et al, 
was performed among neonates in a NICU environment so may not represent all S. 
capitis strains. However,  Kloos et al (1994) also showed that under constant 
antimicrobial pressure S. capitis subsp. urealyticus developed resistance to penicillin 
and erythromycin faster than S. capitis subsp. capitis (21). 
Biofilm formation is one of the main persistence factors of CONS (1, 2). Biofilms are a 
conglomeration of bacterial cells protected by an extracellular polysaccharide matrix 
that adhere to surfaces (7). Bacteria produce molecules that enable them to adhere to 
either biotic or abiotic surfaces such as human skin or intravascular devices, 
respectively (58, 59). After adhesion, other molecules cause the accumulation of cells 
and the maturation of the biofilm. Polysaccharide intercellular adhesin (PIA) is the 
main molecule that facilitates aggregation of bacterial cells (60, 61). PIA is considered 
a major functional component of staphylococcal biofilms (60, 61). Maturation of the 




immune system and from antimicrobials (62-64). The final step of the biofilm is the 
detachment and dispersal of bacterial cells (65). If the biofilm has formed on an 
intravascular device, the bacteria can slough off into the bloodstream (65). The genes 
that encode biofilm formation are contained in operons such as the ica operon 
(icaADBC), and include the gene for PIA (35). S. epidermidis is the most common 
CONS species implicated in biofilm-associated infections (66). The icaADBC operon is 
commonly found in S. epidermidis isolated from patients with bloodstream or urinary 
tract infections (UTIs) in the hospital, but rarely found in isolates outside of the hospital 
(66) which suggests that the icaADBC operon may have a role in survival in the 
hospital though might not be as necessary in other environments.  
Antimicrobial resistance mechanisms allow microbes to evade the bacteriocidal or 
bacteriostatic effects of antimicrobials (67). Resistance mechanisms include biofilm 
formation, cell wall thickening, decreased entry into the cell through porin loss, 
increased removal from the cell via efflux pumps, modification of the antimicrobial 
target, and the production of enzymes that inactivate antimicrobials (67-69). Bacteria 
can become resistant through genetic mutation or via the acquisition of resistance genes 
from other bacteria (67). Bacterial resistance to antimicrobials has increased in recent 
years. However, not all CONS species are resistant to the same antimicrobials (35). 
Different strains of the same species (11) can be resistant to different antimicrobials 
(35). Resistance to the beta-lactam family of antimicrobials, such as penicillin and 
methicillin, is now common in CONS (70, 71). Penicillin resistance in some 
staphylococci is encoded by the blaZ gene, which produces a beta-lactamase (72, 73). 
The beta-lactamase hydrolyses the beta-lactam ring, inactivating penicillin (73). 
Methicillin, a beta-lactamase-resistant penicillin, was first used in 1961 (74). Less than 
a year after the introduction of methicillin, methicillin-resistance was reported (74). A 
study in 2000 showed that 60-70% of CONS isolates were resistant to methicillin (75). 
Methicillin resistance is most commonly due to the presence of a modified penicillin 
binding protein (PBP2a) to which methicillin cannot bind (62). This modified penicillin 
binding protein is encoded on the gene mecA, which is found on a staphylococcal-
specific gene cassette (SCCmec) (62, 76). SCCmec often contains other genes that 
confer resistance to other antimicrobials (72). SCCmec has been found in 11 CONS 




In 2012 at the University Hospital in Lyon, France, Rasigade et al. reported a high 
prevalence of methicillin-resistant S. capitis causing late onset neonatal sepsis (LONS) 
in neonates in the hospital NICU (9). Early-onset neonatal sepsis (EONS) occurs at or 
within 72 hours after birth and LONS occurs after 72 hours (77). The classification 
helps with diagnosis and management because aetiology varies in predictable patterns 
depending on the timing of onset after birth. Rasigade et al. conducted a retrospective 
laboratory based survey, investigating the bloodstream isolates from neonates in the 
NICU and adults in the intensive care unit (ICU) from 1 January 2004 through 31 
December 2009 (9). Rasigade et al. found that S. capitis was the most common 
organism isolated from the blood cultures of neonates in the NICU, but was rarely 
isolated from the blood cultures of adult ICU patients (9). Using pulsed gel field 
electrophoresis (PFGE), isolates from six other cities in France were identified as the 
same S. capitis pulsotype as the Lyon S. capitis isolate (9). The S. capitis isolates from 
adult ICUs were genetically diverse (9). The NICU-specific S. capitis pulsotype was 
named NRCS-A after the National Reference Centre for Staphylococci in the 
University Hospital in Lyon (9).  
In 2016, Simoes et al performed the first closed genome sequence of S. capitis NRCS-
A isolated from their NICU in Lyon, France, and compared it to S. capitis NRCS-A 
isolates from the United Kingdom (UK), Belgium, and Australia (11). Simoes et al. also 
compared the genome to a strain of S. epidermidis and strains of non-NRCS-A S. 
capitis. The French S. capitis NRCS-A isolate had a chromosome length of 2,522,871 
bp (11). All S. capitis NRCS-A isolates had low G+C content (33.02% to 32.84%), and 
mobile genetic elements called phages and plasmids (11). All isolates of S. capitis 
NRCS-A had one phage, and the UK isolate had two other phages both of which were 
not intact (11). All isolates but the UK isolate had one plasmid, but the plasmids were 
distinct across the three isolates (11). The NRCS-A genome also included known 
virulence factors called Clp proteases and phenol soluble modulin (PSM) beta type 1b, 
both of which cleave proteins (11). S. capitis NRCS-A did not produce toxins or 
contain the secretion systems or serine proteases that are found in the S. aureus genome 
(11). Simoes et al. discovered that S. capitis NRCS-A contained the biofilm operons 
icaABDC and capABC (11). While some studies have previously reported S. capitis to 




that S. capitis NRCS-A formed more biofilm than S. capitis non-NRCS-A strains 
(personal communication, James Ussher).  
Simoes et al reported that all S. capitis NRCS-A isolates contained the Staphylococcus-
specific SCCmec gene cassette that was completely conserved with 100% amino acid 
homology (11). The cassette encoded methicillin resistance via the mecA gene, and a 
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) element specific 
to NRCS-A, but no other resistance genes (11). Interestingly, the S. capitis NRCS-A 
cassette also contained a gene that resembled the nsr gene encoding nisin resistance 
(11). Nisin is an antimicrobial peptide secreted by some gram-positive bacterial species 
that reside in the gut, such as some strains of Lactococcus lactis (11, 78, 79). The nisin 
resistance gene was not found in the S. capitis non-NRCS-A genome (11). Using a 
phenotypic assay, the researchers found that S. capitis NRCS-A was functionally 
resistant to nisin (11). Resistance to nisin may confer S. capitis NRCS-A a competitive 
advantage for colonisation. All S. capitis NRCS-A isolates were resistant to 
aminoglycosides encoded by the aacA-aphD gene and all but the UK isolate encoded 
the bla operon and hence produced the blaZ-encoded beta-lactamase (11). Only the UK 
isolate was resistant to fusidic acid (far1), while the Australian isolate contained the 
msrA and tetK genes for erythromycin and tetracycline resistance (11).  
Another study showed, when exposed to vancomycin in vitro, S. capitis NRCS-A could 
develop stable resistance possibly representing a vancomycin-heteroresistant phenotype 
(80). S. capitis NRCS-A developed resistance faster than other S. capitis strains, and 
resistance persisted after vancomycin selective pressure was removed (80). Resistance 
to vancomycin in S. capitis NRCS-A was associated with cell-wall thickening and 
subsequent resistance to other antimicrobial agents such as daptomycin and teicoplanin 
(10). Resistance to both methicillin and vancomycin in S. capitis is of concern as it 
leaves few choices for management of S. capitis infections (10). Additionally, a recent 
study by Butin et al. has shown that treatment of neonates with vancomycin was a risk 
factor for LONS with vancomycin resistant S. capitis (16). The conservation of genes 
such as the SCC-mec gene cassette between S. capitis NRCS-A from many countries 




S. capitis NRCS-A strains is likely driven by varying patterns of antimicrobial use 
between hospitals and countries. 
 Chain of infection 
The chain of infection is the path by which an agent reaches its susceptible host and 
causes disease. As CONS survive and multiply on the skin and mucous membranes of 
humans, CONS colonisation generally precedes infection. However, there are 
exceptions such as insertion of CONS-contaminated prosthetics. Nevertheless, 
understanding ‘the chain of colonisation’ in many cases is as important as 
understanding ‘the chain of infection.’ As there are over 30 different CONS, the chain 
of colonisation for CONS species are possibly diverse. Therefore, this section focuses 
on S. capitis colonisation in NICUs.  
The hypothesised chain of infection for S. capitis pulsotype NRCS-A in hospital 
NICUs, shown in Figure 1, is an attempt to summarise the reviewed literature as 
described in the following paragraphs. A chain of infection starts with a reservoir where 
the agent usually lives, grows and replicates. Removal of the reservoir will result in 
elimination of the pathogen in a timeframe determined by persistence of the organism 
outside the reservoir. No study has yet confirmed the reservoir or source of 
transmission of S. capitis NRCS-A in NICUs. However, based on our wider understand 
of the ecology of CONS, the reservoir is likely to be human, and likely to be neonates 
as a previous study has shown S. capitis NRCS-A was rarely isolated from adults in 
other units in the hospital (9). In 2014 in the Dunedin Hospital NICU, the Infection 
Prevention and Control team swabbed staff member’s external ear and thumb to assess 
whether any staff could be a reservoir (personal communication, J. Ussher). S. capitis 
NRCS-A was isolated from one staff member out of an unknown number of staff 
members tested (personal communication, J. Ussher). Since the ability of S. capitis to 
grow and multiply on healthcare workers was not tested, their role as a reservoir cannot 
be definitively excluded. This suggests that some staff members are possible reservoirs 
and sources of S. capitis NRCS-A. Additionally, the environment is a source but is 




hypothesis of neonates as the reservoir, the reservoir of S. capitis in NICUs has not 
been comprehensively identified anywhere in the world.  
 
NICU – neonatal intensive care unit 
The portals of exit for S. capitis NRCS-A are likely to be the skin, mucous membranes, 
or faeces. The mode of transmission, as shown in Figure 1, is either direct contact, 
indirect contact with fomites, or foodborne. Direct contact occurs when a human source 
transmits S. capitis to the neonate through physical contact (81). Bjorkqvist et al found 
no evidence that delivery mode by caesarian section versus vaginal delivery, or 
premature rupture of membranes (PROM) influenced colonisation with S. capitis, 
suggesting that transmission during birth is unlikely (40). However, due to the regular 
contact with their child, including skin-to-skin cuddles, and contact with the NICU 
environment when helping with cares, it is possible that parents are a source of S. 
capitis NRCS-A in the NICU. 





Indirect transmission of S. capitis may occur via food and fomites. A fomite is an 
abiotic object that transfers microbial agents to the host (81). The clonality of S. capitis 
NRCS-A (section 2.1.2) may suggest a global point source outbreak, however none 
have been identified. A study by de Goffau et al. investigated microbial growth in 
neonatal incubators by comparing the microbial growth at both the cold and warm spots 
of incubators (82). de Goffau et al. found that the cold spots (up to 6 ºC colder than 37 
ºC) of incubators had higher numbers of colony forming units (CFUs) than the warm 
spots (up to 2 ºC warmer than 37 ºC) (82). Additionally, the CFUs were higher from 
cold spots within incubators with high ambient temperature (≥34ºC) and high humidity 
(≥60%) compared to low ambient temperature (<34ºC) and low humidity (<60%) (82). 
Of the microbes isolated by de Goffau et al, staphylococci were the most common 
group (82). A study by Madar et al. at a hospital in Martin, Slovakia, swabbed the 
stethoscopes of physicians, medical students, and shared stethoscopes from ward 
consulting rooms (83). Madar et al, found that of the 110 stethoscopes swabbed, 101 
(91.8%) were colonised with microbes, and 79 (71.8%) were colonised with CONS 
(83). Unfortunately, neither of these studies investigated the transmission of CONS 
between incubators or stethoscopes and neonates. However, if incubators and 
stethoscopes serve as fomites in S. capitis transmission, it is likely that they would 
facilitate the transfer of S. capitis to the skin rather than the gastrointestinal tract (GIT). 
As discussed in a previous section (section 2.1.1), Gras-Le Guen et al. identified 
refillable almond oil bottles as the source of S. capitis NRCS-A transmission in their 
Nantes Hospital NICU (15). However, they did not conduct studies to confirm 
multiplication in this matrix so were unable to establish a role for almond oil as a 
reservoir. Furthermore, S. capitis NRCS-A continued to be isolated from Nantes 
Hospital NICU patients after removing the almond oil (9).  
Foodborne S. capitis transmission in a hospital NICU could be via maternal breast milk, 
including expressed breast milk. In this case, the portal of entry is the mouth to the 
gastrointestinal tract of the neonate. While uncommon, bacteria such as S. aureus and 
E. coli can pass from expressed breast milk to the nose and throat of the infant and 
cause infection without causing maternal symptoms such as mastitis (84). S. capitis has 
been isolated from human breast milk (85). One study found that 8 (20%) of 40 breast 




of persisting in breast milk (85). Therefore, if breast milk served as a foodborne vehicle 
for S. capitis transmission to neonates, the portal of entry would be the GIT. If the 
breast itself was colonised with S. capitis rather than the milk, the portal of entry would 
be the skin. 
 Hospital infection control 
The Dunedin Hospital NICU follows standard precautions for infection prevention and 
control. The US Centers for Disease Control and Prevention (CDC) states that the 
standard precautions for patient care are common sense practices that protect the 
healthcare worker from infection, and prevent the spread of disease among patients 
(86). Standard precautions include performing hand hygiene, using personal protective 
equipment (PPE) if possible exposure to infectious agents, following respiratory 
hygiene, ensuring appropriate patient placement, properly handling and cleaning patient 
care equipment and devices, and handling textiles and laundry carefully (86). 
Transmission-based contact precautions include appropriate patient placement such as a 
single room for the affected patient, appropriate PPE including gloves and a gown for 
all patient contact, limiting movement of patients, disposable or dedicated patient 
equipment, and frequent cleaning and disinfecting (87). The Dunedin Hospital NICU 
does not follow transmission-based precautions for S. capitis as these focus on 
epidemics, while S. capitis is endemic in the NICU (personal communication, Roland 
Broadbent).  
Hand washing is the basis of personal infection control in hospitals (88). As CONS live 
on the skin of humans, transmission is often through direct contact (as discussed in 
section 2.1.3). Removing infectious bacteria from the hands before touching patients 
reduces transmission (89). The World Health Organisation (WHO) recommends 
washing hands with soap when visibly soiled, or using an alcohol-based rub when not 
soiled (90). The WHO also recommends that hand hygiene is performed before and 
after touching a patient, before touching invasive devices regardless of wearing gloves, 
after touching an abiotic surface or objects around a patient, and after removing gloves 
(90). In a hospital intensive care unit, Conly et al. showed that hand washing protocols 




washed their hands, whereas after seeing patients 28% were compliant with the 
protocol (91). Education programmes among staff in the ICU improved adherence to 
staff hand washing recommendations from before and after seeing patients to 73% and 
81%, respectively (91). Nosocomial infections also dropped from 31% of patients to 
12% after the education programmes (91). Antiseptics like chlorhexidine are sometimes 
used among neonates to prevent microorganisms from the skin entering the 
bloodstream during procedures (92). However, widespread use of antiseptics such as 
chlorhexidine can select for resistant CONS (92). In one study of neonates with 
bloodstream infections 31 (41%) of 51 CONS strains had reduced susceptibility, as 
measured by elevated minimum inhibitory concentrations (MICs), to at least one 
antiseptic regularly used in the NICU (92).  
In the Dunedin NICU, hand washing with Microshield Skincare Cleanser (Schulker 
New Zealand Limited, New Zealand) is required by both parents and staff upon 
entering the NICU (93). Additionally, staff must wash their hands before and after 
patient or equipment contact, and before and after wearing gloves (94). Staff also must 
apply chlorhexidine 0.5% in 70% alcohol gel to their hands and forearms before 
performing any procedures (94). Gloves are worn for all patient contact. All equipment 
including stethoscopes and incubators are cleaned or sterilized between use (94). 
Stethoscopes are used for one neonate only, dismantled, and cleaned between neonates 
(94). Incubators are kept empty for as long as possible between neonates (94). Neonates 
requiring ongoing incubator care have their incubator cleaned weekly with 
Benzalkonium chloride solution 9.63g/L and Down to Earth dishwashing liquid (PZ 
Cussons, Auckland, New Zealand), and resistant staining or adherent marks are 
removed using De-solv-it solution (Vardon Industries, Victoria, Australia) (personal 





 Host defence in premature neonates 
 Neonatal skin 
Skin is a physical barrier that defends the body from light, water loss, and irritants (95). 
Additionally, skin provides resilience to mechanical trauma, sensation, tactile 
discrimination, thermal regulation, acid mantle formation, and infection control (95). At 
birth, neonate’s skin is already equipped with the ability to protect the infant during the 
change in environments from the fluid in the womb to the outside air (95). Soon after 
birth, the skin facilitates the neonate’s colonisation with commensal organisms, while 
preventing the growth of harmful microorganisms (50).  
Neonates are born with innate immune function, particularly within parts of the skin 
like the stratum corneum and the vernix caseosa (96). The stratum corneum is the outer 
layer of the epidermis that provides a protective air-liquid barrier (97). The stratum 
corneum contains host defense proteins called lysozyme and lactoferrin (96, 97). In 
addition, the stratum corneum has an acidic film called the acid mantle that facilitates 
the colonisation of commensal microorganisms, while preventing the growth of 
pathogenic bacteria (98, 99). At birth, a protective cream-like layer called the vernix 
caseosa covers the stratum corneum (98). The vernix is made up of 80% water, lipids, 
and proteins (100, 101). The vernix caseosa also contains lysozyme and other peptides 
associated with antimicrobial activity, and parasite inactivation (97, 99). The vernix 
may also facilitate the development of the acid mantle (97, 98).  
The stratum corneum is established during the fourth month of gestation. However, it 
does not fully mature until the third trimester (102). Before maturation, the stratum 
corneum is deficient in structural proteins, making the skin thin and porous (95, 102). 
Neonates born before the end of the third trimester are susceptible to water loss, 
thermal instability, torn skin, and infection (95). In addition, premature neonates born 
before 28 weeks’ gestation do not have a vernix caseosa (95). It takes approximately 
two to three weeks for the neonate’s skin to mature to the same stage as term infants 
(102, 103). During this period, premature neonate’s immature skin is at risk for 




transepidermal water loss (TEWL) (104, 105). TEWL measures the rate at which water 
crosses the skin layers into the environment (106). High TEWL scores indicate a poor 
skin integrity (107). Some NICUs use creams or emollients, such as sunflower seed oil, 
to cover the skin of premature neonates in an attempt to mimic the function of the 
vernix (107). 
 Other aspects of neonatal host defense 
It is common for neonates admitted to NICUs to be of lower birthweight and lower 
gestational age (GA) than non-NICU neonates. Low GA is a major determinant of 
immune system immaturity (77). Examples of neonatal immune immaturity include 
decreased number and function of immune cells including monocytes, neutrophils, 
lymphocytes, and decreased production of cytokines and antibodies (77). An immature 
immune system means that neonates do not have adequate immune defenses to protect 
against infections (108). In addition, transplacental transfer of maternal antibody is 
lower among premature infants compared with those born at term (64). Stress and 
comorbidities further impair the neonate’s ability to fight infection (109).  
Premature neonates have decreased function of the gastrointestinal mucosa, including 
reduced barrier function, which results in increased permeability (110). For example, 
neonates born before 40 weeks (full term) have reduced numbers of gut epithelial cells 
including a specialized type of epithelial cell called the Paneth cell (111, 112). Paneth 
cells are important for host defense, shaping of the gut microflora, and development of 
gut epithelial cells (111, 113). Paneth cells secrete a protein called α-defensin that is 
important for host defense (111, 112). A study using rat models showed that rats 
without α-defensins had a different microbiota composition and were more likely to 
develop infections than the control group (112, 114). Therefore, the reduction in the 
number of Paneth cells likely contributes to the reduced immune function of premature 




 Neonatal bloodstream infections and sepsis 
 Epidemiology 
CONS are the leading cause of healthcare-associated bacteremia (39) and sepsis in 
NICUs around the world (1-5). Bloodstream infections are the most common type of 
infections in NICUs (115). S. capitis pulsotype NRCS-A is now recognised as a major 
cause of bloodstream infections and sepsis in NICUs (9, 11, 15). In some NICUs where 
S. capitis NRCS-A is endemic, the bacteria colonise the skin of around a third of all 
neonates during their stay, and is associated with bloodstream infections in around a 
tenth of all neonates (16). A bloodstream infection is defined as bacteria in the blood, 
and is diagnosed by a positive blood culture (116). Historically CONS have been 
regarded purely as contaminants of clinical samples rather than as pathogens 
themselves (21). Although the role of CONS in bacteremia and sepsis has now been 
proven, there is still the possibility that the large number of cases reported is an over 
exaggeration due to contamination.  
Low birthweight and low GA are both risk factors for bloodstream infections (5, 12, 
117). Infants born <1500g, the definition of very low birthweight (VLBW), are more 
likely to develop a bloodstream infection during their hospital stay than those ≥1500g 
(115, 118). The combination of reduced immune function, increased likelihood of 
intravascular devices, and longer duration of hospital stay further increases the 
neonate’s susceptibility to infections (118, 119). With advances in neonatal care, 
infants are surviving from lower GAs than ever before (5). The increased survival at 
low GA places more infants at risk of CONS infections.  
Sepsis is a complication of a bloodstream infection. Sepsis is defined as the presence of 
an infection, such as a bloodstream infection, with the systemic inflammatory response 
syndrome (120). Sepsis is a severe immune reaction that can lead to organ failure and 
death (116). Sepsis criteria differ between neonates and adults, therefore adjusted 
criteria for sepsis diagnosis in neonates has been suggested to allow early identification, 
surveillance and epidemiologic studies (116). Haque et al. defines neonatal sepsis in 




foetal inflammatory response syndrome (FIRS) criteria (116): tachypnoea (respiratory 
rate >60bpm), temperature instability (<36ºC or >37.9 ºC), capillary refill time of >3 
seconds, white blood cell count (<4000 x109/L or >34,000 x109/L), C-reactive protein 
(>10pg/ml), IL-6 or IL-8 (>70pg/ml), and 16 sRNA gene PCR positive if PCR of the 
bacterial isolate is available (116). The presence of infection is often confirmed by 
blood culture. Due to the small circulating blood volume of neonates, the volume of 
blood collected from neonates is much smaller than from adults (116, 121). However, 
bacterial counts in the blood (CFU/ml) are much higher in neonates than adults so a 
smaller blood volume is required to achieve adequate sensitivity (122).  
CONS are the most common type of bacteria isolated from premature neonates with 
LONS (12). The prevalence of sepsis in neonates is inversely proportional to the 
neonate’s GA and birthweight (77). A 2002 study by Stoll et al investigated the 
relationship between sepsis prevalence and GA and birthweight, finding that of 6215 
VLBW infants who survived more than three days, 1313 (21%) developed sepsis (12). 
The Stoll study also showed that of 656 neonates born at <25 weeks’ gestation, 300 
(46%) developed LONS (12). The risk of LONS decreased with increasing GA, and of 
407 neonates born at >32 weeks’ GA, only 10 (2%) developed LONS (12). Kaufman et 
al. (2004) showed that premature neonates who develop sepsis have a three times 
greater risk of death than healthy neonates (77).  
 Intravascular devices and bacterial translocation 
A large proportion of neonatal bacteremia in NICUs is associated with intravascular 
catheters or other indwelling devices (12, 14) and the majority of these are caused by 
CONS (14, 123, 124). Intravascular catheters are the likely source of bloodstream 
infections when the bloodstream isolate is the same as the isolate from the catheter tip, 
skin site, or from blood drawn through the catheter (123-125). There are two 
predominant types of catheter-related bloodstream infection; those resulting from 
colonisation of the intravascular device, and those from contamination of the fluid that 
runs through the device (123). Contamination of the device occurs either from skin 




tip during insertion (123). If the tip is contaminated the bacteria enter the bloodstream 
intra-luminally (123).  
Contamination of the catheter tip is often caused by biofilm-forming bacteria that 
adhere to the catheter then slough off into the host bloodstream (123). Bacteria that 
form biofilms account for approximately half of all intravenous-catheter-related 
bloodstream infections (118, 126). Although many neonates with intravenous catheters 
develop bloodstream infections, the catheter may not always be the source of infection. 
One study by de Brito et al (2009) found that the route by which the bacteria entered 
the bloodstream could not be identified in 70% of neonates, as the isolates from the 
blood did not match those isolated from the skin or the catheter (123). Another study by 
Valvano et al showed that the plasmid DNA from isolates from the catheter did not 
match that from blood isolates in three (43%) of seven patients with bacteremia (127).  
As discussed in previous sections, the GIT of premature neonates is heavily and rapidly 
colonised by CONS (section 2.1.1), and neonates have abnormal mucosal permeability 
(section 2.2.2). Therefore, it has been hypothesised that bloodstream infections could be 
caused by CONS translocating across the gut barrier and into the blood (128, 129). In 
this view of pathogenesis, CONS translocate from the gastrointestinal tract to the 
mesenteric lymph nodes, and from there into the bloodstream (Figure 2). Bacterial 
translocation from the GIT to the mesenteric lymph nodes has been demonstrated in 
rats (130, 131). Soeorg et al. studied neonates with LONS to assess bacterial 
translocation from the GIT (13). Of the 22 neonates in the study, 21 (95.5%) 
experienced GIT colonisation by any species of CONS before they developed CONS 
sepsis (13). Eighteen (81.8%) of 22 neonates were colonised with the same species of 
CONS that caused sepsis (13). Analysis showed that 13 (59.0%) of 22 neonates with 
LONS had the same CONS species isolated from the GIT before the blood (13). Other 
studies have shown a similar pattern of CONS species that colonised the GIT before 
being isolated from the blood (128, 132). However, since neonates may be colonised at 














Adapted from Costa et al, 2004 
Colonisation prevention strategies should take into account the possibility that CONS 
bloodstream infections may originate from the skin or GIT. Hospitals have strict 
guidelines for intravascular catheter insertion to prevent infections (133). Such hospital 
guidelines include: choosing a skin site with low bacterial burden; using hand 
disinfection, a mask, gloves, cap and sterile drape; skin disinfection; handling and 
inserting the catheter with aseptic technique; and removing the catheter as soon as it is 
not needed (133). Preventing infection via bacterial translocation is difficult. Use of 
antimicrobials may make the situation worse by selecting for resistant CONS 
populations and damaging the microflora. Therefore, efforts should be targeted towards 
prevention of CONS colonisation at both the skin and the GIT. Studies on prevention 
should focus on identifying the source of colonisation then modifying its exposure 
among neonates. 
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 S. capitis in the Dunedin Hospital NICU 
S. capitis pulsotype NRCS-A has been isolated regularly from neonates in the Dunedin 
Hospital NICU since 2007, supporting the evidence that it is a strain capable of survival 
and persistance. Using whole genome sequencing (WGS), the S. capitis strain in the 
Dunedin Hospital NICU was shown to be the same clone found in other NICUs around 
the world (personal communication, James Ussher). However, the Dunedin Hospital 
strain exhibits some differences to the other strains, particularly the acquisition of a 
plasmid pSC16875, which is present in the majority of isolates (42/64), that contains 
genes for resistance to penicillin, tobramycin, fusidic acid, and reduced susceptibility to 
chlorhexidine (personal communication, James Ussher). The Dunedin Hospital strain 
also harbours the icaADBC operon, which encodes genes that produce proteins 
essential for biofilm formation (personal communication, James Ussher). The Dunedin 
Hospital isolates were phenotypically resistant to amoxicillin and fusidic acid, and 
could produce biofilms (personal communication, James Ussher). In the Dunedin 
Hospital NICU alone, approximately one third of all neonates admitted to the unit have 
become colonised with this strain of S. capitis (personal communication, James 
Ussher). This puts a large proportion of neonates at risk for developing invasive S. 
capitis disease. In September 2013, a screening programme was implemented in the 
Dunedin Hospital NICU to identify colonised neonates and prevent transmission of S. 
capitis. All neonates in the Dunedin Hospital NICU were screened with axillary swabs 
weekly during their stay. In addition, environmental swabs were taken and S. capitis 
NRCS-A was isolated from stethoscopes and incubators (personal communication, 
James Ussher).  
In December 2013, the NICU moved to a new location within Dunedin Hospital and all 
equipment was cleaned before this transition. Despite these measures, S. capitis 
recurred and persisted among neonates in the Dunedin Hospital NICU. Subsequently, 
anonymised voluntary screening of Dunedin Hospital NICU staff members was 
undertaken, and S. capitis NRCS-A was isolated from the hands of one staff member 
(personal communication, James Ussher). The only changes to hand hygiene practices, 
or other infection control procedures since 2013, was the implementation of wearing 




The Dunedin Hospital NICU screening programme for S. capitis is still active in 2018. 
However, currently only neonates born at less than 36 weeks’ gestation are swabbed to 
identify colonisation in those most at risk of invasive infections. Although, S. capitis is 
regularly isolated from neonates, the hospital infection prevention and control team 
have not identified the reservoir, source, or mode of transmission. To our knowledge, 
no studies to date of S. capitis epidemiology in the Dunedin Hospital NICU setting 
have identified the reservoir, source, or mode of transmission, and few have proposed 
risk factors for colonisation (15, 16). Since understanding transmission is essential to 
design prevention and control measures, we sought to identify the risk factors for S. 





3 Hypotheses and aims 
Hypotheses 
Our hypotheses for both the prospective and retrospective studies were based on the 
literature as summarised in our hypothesised chain of infection (Figure 1). There have 
been few studies investigating the risk factors for S. capitis NRCS-A colonisation 
among premature neonates (section 2.4), therefore our hypotheses were broad.  
- We hypothesised that healthcare workers are sources of S. capitis NRCS-A. 
- We hypothesised that antimicrobial exposure is a risk factor for S. capitis 
NRCS-A colonisation among premature neonates. 
- We hypothesised that the NICU environment contains fomites which are 
sources of S. capitis NRCS-A. 
Aim 
The aim of this project was to identify the risk factors for S. capitis NRCS-A 
colonisation among premature neonates in the Dunedin Hospital NICU. The aim was 





4 Methods  
 Study site  
Our study site was the NICU in Dunedin Hospital, New Zealand. Dunedin Hospital 
serves the Otago and Southland Regions, with an approximate catchment population of 
315,000 residents (Statistics New Zealand, 2015). The Dunedin Hospital NICU has 16 
rooms and 26 bed spaces, as shown on the floorplan in Figure 3. Approximately 68 
clinical staff are employed by the NICU: 44 nursing staff, 10 consultants, and 14 
registrars. Trainees including house officers, medical students, and student nurses 
rotate through the NICU. Allied health professionals include lactation specialists, 
radiographers, and speech language therapists. During the period from 1 September 
2013 through 31 March 2015, 352 neonates were admitted to the NICU, and 236 were 
swabbed at least once (personal correspondence, Roland Broadbent). Of 236 neonates 
admitted, 58 (24.6%) were identified to develop S. capitis colonisation and of those, 4 













































































































 S. capitis surveillance among neonates 
A surveillance programme seeking to identify NICU neonates with S. capitis 
colonisation was established in September 2013 in conjunction with the Dunedin 
Hospital Infection Prevention and Control Service. Colonisation status was sought by 
weekly axillary swab. From September 2013 through March 2015, all neonates were 
swabbed. From April 2015, testing was restricted to neonates born at < 32 weeks’ 
gestation. Since neonates born at <32 weeks’ gestation were at highest risk from 
invasive infection (from review of local data and personal communication, Roland 
Broadbent), they were targeted for surveillance. From July 2017, all neonates who were 
<34 weeks’ gestation at birth were swabbed every Monday. In order to monitor S. 
capitis transmission among a larger proportion of neonates beyond those at greatest risk 
for invasive infection, from December 2017 surveillance was extended to neonates <36 
weeks’ gestation at birth. COPAN Transystem ä (COPAN Italia, Brescia, Italy) sterile 
swabs were used to collect axillary swabs. Inoculated swabs were transported to the 
laboratory in the COPAN Transystem ä capped tube containing Amies transport 
medium without charcoal.  
Nursing staff selected one axilla per neonate and collected swabs using washed and 
gloved hands. The nurse gently wiped the neonate’s entire uncleaned axilla in either a 
circular or stroking pattern. If any exudate was present, this was also collected on the 
swab. The nurse sent the swab in the transport tube labelled with body site of the swab, 
date, and neonate’s identifying information to Southern Community Laboratories 
(SCL), Dunedin. All NICU neonates who met the gestational age criterion of the 
surveillance period were scheduled an axillary swab every Monday until either S. 
capitis was detected or the neonate was discharged from the NICU. S. capitis 
surveillance was not a study procedure, but we were able to access the weekly swab 





 Laboratory methods 
SCL staff performed culture of axillary swabs, species identification and antimicrobial 
susceptibility testing of isolates. Swabs were plated on trypticase soy agar with 5% 
sheep blood and incubated in ambient air at 37°C overnight. Several colonial variants 
suspicious for S. capitis were chosen for identification based on varied size, 
opaqueness, smoothness, and clarity. Identification of S. capitis isolates was done using 
matrix associated laser desorption ionisation time of flight mass spectrometry (MALDI-
ToF-MS) (Bruker Daltonics, Massachusetts, USA). Material from the colony 
resembling coagulase-negative Staphylococcus was placed on the polished steel target 
plate (Bruker Daltonics) and allowed to dry at room temperature. The dried spot was 
then overlaid with 1μL of α-cyano-4-hydroxycinnamic acid (HCCA) matrix solution 
(Bruker Daltonics) and allowed to dry for a further 15 minutes at room temperature. 
Mass spectra were generated with a Microflex LT, (Bruker Daltonics) using MALDI 
Biotyper™ automation control (Bruker Daltonics). Species identification was 
automatically performed using the Bruker BiotyperTM software and library. Isolates of S. 
capitis were confirmed as the NICU endemic clone by pulse-field gel electrophoresis at 
the Institute of Environmental Science and Research (ESR), Wellington, New Zealand. 
After establishing that S. capitis pulsotype NRCS-A could be accurately distinguished 
from other S. capitis by the presence of the mecA gene (personal communication, James 
Ussher), from August 2017 preliminary identification of the endemic NICU clone was 
undertaken by phenotypic antimicrobial susceptibility testing. Disk diffusion testing 
according to standards and interpretive criteria of the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) was used to detect resistance to 
cefoxitin as a marker of mecA gene presence (134). Results were reported to Health 
Connect South, an online database containing electronic clinical records. The NICU 





 Study design: prospective study 
We conducted a prospective cohort study among admissions to the Dunedin Hospital 
NICU to determine the risk factors for S. capitis colonisation among premature 
neonates. Recruitment and data collection commenced on 1 July 2017 and is ongoing 
at the time of thesis submission. Data collected from 1 July 2017 through 28 February 
2018 are described as a progress report in this thesis.  
 Study design: retrospective study 
As we did not meet the sample size required for the prospective study, we investigated 
our study aim (section 3) by conducting a retrospective cohort study among admissions 
to the Dunedin Hospital NICU from 9 September 2013 through 9 March 2015. 
Extraction of retrospective data took place from 12 December 2017 through 16 
February 2018.  
 NICU admissions and S. capitis colonised neonates 
We collected the total number of admissions during both the retrospective and 
prospective studies. Juliet Manning provided these data from monthly admissions 
reports compiled by the NICU office administrator.  We collected the number of 
admissions for the whole study period, and per month. We also collected the number of 
neonates colonised with S. capitis, and the number of neonates with invasive S. capitis 
infections during the study periods. Dr James Ussher provided these data from the 








 Study population: prospective study 
The prospective study population included all neonates <34 weeks’ gestation at birth 
admitted to the Dunedin Hospital NICU and their birth mother if she was involved in 
the care of their child. Guardians other than the birth mother were not included as 
participants in the study. 
Eligibility criteria 
Inclusion criteria 
- Neonates were eligible for enrollment if their admission to the NICU lasted 
for two or more weekly axillary swabs (8-14 days post-admission). 
Exclusion criteria 
- Neonates were not eligible for enrollment if their first axillary swab was 
positive for S. capitis pulsotype NRCS-A. 
 Study population: retrospective study 
The study population included all neonates admitted to the Dunedin Hospital NICU, 
who had at least one axillary swab from 9 September 2013 through 9 March 2015.  
Eligibility criteria 
Inclusion criteria 
- Neonates were eligible for enrollment if their admission to the NICU 







- Neonate’s first axillary swab was positive for S. capitis pulsotype 
NRCS-A. 
- Neonates admitted to the NICU before the surveillance began. 
- Neonates swabbed more than once but did not receive their scheduled 
second swab. 
 Sample size determination 
Based on number of neonates admitted in the Dunedin Hospital NICU in previous 
years, for both the prospective and retrospective studies we expect to have a sample 
size of about 75 neonates over a 6-month period that meet our inclusion criteria (remain 
in the unit for at least two rounds of swabbing). We expect about 38% to become 
colonised, therefore, 29 colonised neonates over a 6-month period. With this number of 
cases, we will have 80% power to detect OR of 3.6 if the prevalence of the risk factor is 
0.4 and OR of 5 if the prevalence of exposure is 0.1. If there is a single risk factor we 
anticipate the OR to be large, however the study will be underpowered to detect 






Colonised neonate definition: an individual neonate that ever had a positive S. capitis 
swab result. 
Non-colonised neonate definition: an individual neonate that never had a positive S. 
capitis swab result.   
Colonised and non-colonised neonates were categorised for each exposure week of 
their stay in the NICU as a case or a control for that week. The exposure week was an 
arbitrary period a week prior to a positive or negative S. capitis swab result. The 
exposure week was measured from 6am Monday to 5.59am the following Monday. 
Axillary swab results on both the Monday of, and the Monday following, the exposure 
week were necessary to determine if the neonate’s exposure week was a case or a 
control. The exposure weeks and swabbing pattern are shown in Figure 4.  
Case definition: A week in which an eligible neonate had a negative swab result on 
the starting Monday of the exposure week, and a positive swab result on the following 
Monday. 
Control definition: A week in which an eligible neonate had a negative swab result on 
the starting Monday of the exposure week, and a negative swab result on the following 
Monday. 
Cases and controls were included in a nested case-control analysis. The same eligible 
neonate could contribute both case and control data to the nested case-control analysis. 
Eligible neonates contributed control data until they became a case, were discharged 
from the NICU, or missed a swab. Eligible neonates could only contribute case data 






+ - positive; − - negative; NICU – neonatal intensive care unit. 
Swabs and CRFs continued every week until the neonate missed a swab, had a positive S. 
capitis test result, or was discharged from the NICU.  
 
 Recruitment: prospective study 
We recruited neonates and their birth mothers from among Dunedin Hospital NICU 
admissions throughout the prospective study as they became eligible. Consent for 
participation in the study was sought after receiving a negative result from the first 
swab, and if the neonate was expected to remain in the NICU through the next Monday, 
ascertained by nursing or medical staff. NICU clinical staff recruited all neonate and 
birth mother participants. Recruitment included the issuing of forms to eligible 
participants, witness of signature on the consent form, and answering family queries. 
 Participants: retrospective study 
I identified neonates for participation in our retrospective study using results from the 
S. capitis surveillance programme during the study period, and their Dunedin Hospital 
medical records. If the neonate met the eligibility criteria (section 4.8) they were 
included as a participant in the retrospective study, there was no contact with neonates, 
or their parents or guardians. 
Figure 4: Study eligibility and data collection process, prospective and 




 Data collection: prospective study 
 Case report forms 
We sought validated and widely used questionnaire instruments from past studies of 
staphylococcal transmission and disease in NICU settings. We obtained questionnaires 
from the Prevention and Response Branch, Division of Healthcare Quality Promotion, 
US Centers for Disease Control and Prevention. The questionnaires were used for 
epidemiologic studies of a range of pathogens, including Staphylococcus spp. 
Following a review of S. capitis literature, I adapted these questionnaires to address the 
hypotheses of our study. I designed protocol-driven case report forms (CRFs) for 
weekly data collection by clinical staff. I created three types of CRFs: 1) the S. capitis 
test result CRF (Appendix 1); 2) the baseline CRF (Appendix 2); and 3) the weekly 
CRF (Appendix 3). With the close involvement of Associate Professor Roland 
Broadbent and NICU charge nurse Juliet Manning, CRFs were reviewed, piloted, and 
edited prior to the initiation of our study. Juliet Manning was the NICU staff member 
with primary responsibility for overseeing data collection. Three clinical staff members 
were trained for data collection, including a specialised research nurse and two other 
nurses who were interested in the research. Juliet Manning trained the staff by 
reviewing every question in each form with the trainees, and instructing them on the 
data sources for each section. I created a manual of CRF guidelines (Appendix 4) to 
explain explicitly how to ask questions and record responses. After piloting, the CRF 
guidelines were incorporated into the CRFs as instructions at the start of each section 
and each question. Additionally, I reviewed the first CRF with the staff member after 
data collection to ensure accurate completion.  
S. capitis swab result CRF 
I created the S. capitis swab results CRF (Appendix 1) to collect the result from the 
weekly S. capitis swab test. The form included the participant identification number, 
the date of the swab test and the result: negative or positive for S. capitis. A NICU 
clinical staff member completed the CRF when the swab test results were made 





The baseline CRF (Appendix 2) collected information for both the neonate and their 
mother in the domains listed below:  
- Infant demographics including sex, date of birth, date of admission, gestational 
age, birthweight, ethnicity, and number of siblings.  
- Information about the birth including delivery type, devices used during the 
birth (e.g., forceps), multiple births, where the birth took place, and the type of 
facility.  
- Maternal demographics including date of birth and ethnicity.  
- Maternal antimicrobial use during pregnancy.  
- The pregnancy and parturition history including events such as cerclage, group 
B Streptococcus colonisation, and premature rupture of membranes.  
The data in the baseline CRF form were collected from the neonate’s admission forms, 
and by interview of the birth mother. The baseline CRF was completed after consent 
was obtained, but before data collection for the first weekly CRF. If the birth mother 
was not involved in their child’s care or did not give consent for her own participation 
in the study, we did not collect data regarding the mother’s demographics, 
antimicrobial use, or history of the pregnancy and parturition. 
Weekly CRF 
The weekly CRF (Appendix 3) covered the exposure week: a 7-day period from 6am 
Monday to 5.59am the following Monday. These times were chosen to match the 
approximate time the swab tests were taken each Mondays. Domains of data collected 
in the weekly CRF included: 
- Infant comorbidities, procedures, and devices.  
- Antimicrobial use, and other medications including injectables. 
- Parental contact, and contact with other neonates (e.g. twin).  




- Environment such as bed space number, incubator number, cot number, 
stethoscope number, infant weight, equipment use, number of cares, and 
equipment used during cares. 
- Other procedures such as apnoeas requiring stimulation, other nursing 
procedures (e.g., urine collection), or other procedures by allied health 
professionals (e.g., head ultrasound scans). 
- Consultant and registrar contact including the staff member title (‘consultant’ or 
‘registrar’), the shift time, the type of examination or procedure, and the 
duration of the contact. 
- Nurse contact including the nurse code, the shift time, and the details of any 
other neonates being cared for by the same nurse on the same shift. The details 
of other neonates included bed space number and S. capitis status: positive, 
negative, or unknown. 
- The condition of the skin on the birth mother’s breast. 
The trained NICU clinical staff members collected the data for the weekly CRF. The 
data were collected from the medical records for each neonate. Incubator, cot, and 
stethoscope numbers were recorded from either equipment serial numbers or 
identification numbers attached to the equipment by staff members. The last section of 
the weekly CRF collected maternal data regarding the skin on the mother’s breast, and 
were sought by interview of the birth mother. The clinical staff completed this section 
at the start of the week to reduce recall error. Additionally, we recorded neonate contact 
of staff members in the weekly CRF. We used the term ‘contact’ to mean either direct 
physical contact with the neonate by the staff member or contact with equipment, such 
as stethoscopes, at least once during their shift or examination. We collected data on 
nurses, consultants, and registrars who routinely worked in the NICU. No data were 
collected on trainees or allied health professions as their shifts were not routine, and did 
not regularly require contact with the neonates. Roland Broadbent or Juliet Manning 
assigned the staff members a code so that specific staff members could not be 
identified. Roland Broadbent supplied the consultant and registrar timetables, so the 




The weekly CRF was completed at the end of the exposure week. The first exposure 
week from which we sought data was the week between the first and second axillary 
swab, which is shown in Figure 4. The data for the first CRF were collected on the 
Monday or Tuesday after the exposure week, following informed consent and 
completion of the baseline CRF. This continued each week for as long as the neonate 
remained eligible for weekly surveillance. For neonates with a positive swab result, the 
final CRF captured information from the exposure week before the S. capitis positive 
swab. If the neonate remained S. capitis negative, the last CRF captured information 
from the exposure week before the negative swab. If the participant was discharged 
from the unit between swabs, we did not collect data from the partial week.  
 Data collection: retrospective study 
 Baseline data 
We modified the baseline CRF from the prospective study (Appendix 2) for the purpose 
of the retrospective study (Appendix 5). The changes to the baseline CRF included: 
- Added eligibility section including eligibility yes or no; swab result if not 
eligible, and if the swab was positive for S. capitis, date of the positive swab. 
- Added availability of weekly data section including availability yes or no. If the 
neonate was eligible but data was not available we collected the number of 
weeks of data lost, swab result, and the date of the positive swab if positive for 
S. capitis. 
- Added section on the neonates stay in the NICU including date of admission, 
date of discharge, if the neonate was alive or deceased at discharge, and reason 
for discharge. 
- Removed all sections in the prospective CRF regarding the mother. The mother 
was not included in the retrospective study as we did not have ethical approval 





In order to collect data for the whole study population, the baseline CRF was completed 
for all neonates, irrespective of eligibility status. The birth record that formed part of 
the neonate’s medical record was a source document for the neonate’s demographic 
information such as sex, gestational age, birthweight, delivery data, and birthplace. If 
the neonate was not born in Dunedin Hospital, a NICU admission form was completed 
by nursing staff upon the neonate’s admission and was a source document for the same 
data as the birth record. The free-form Dunedin Hospital NICU discharge letter, written 
by a registrar, was a source document for neonate demographic information including 
sex, gestational age, birthweight, date of admission, and date of discharge. The 
Southern District Health Board NICU care plan booklet is supplied for every neonate 
admitted to the NICU and is completed by nursing staff. The NICU care plan booklet 
was a source document for sex, ethnicity, gestational age, birthweight, delivery type, 
and family information. If the data were discordant between the sources, the birth 
record data was used as the main source, or if unavailable the NICU admission form 
was used. The data for the axillary swab test was extracted from a Microsoft Excel 
spreadsheet (Microsoft Corporation, Washington, USA) of test results provided by Dr 
James Ussher. When medical records were unavailable, data were collected from the 
online copy of the neonate’s discharge letter through the Health Connect South online 
database. Health Connect South was also a source for S. capitis surveillance swab test 
results for all neonates. 
 Weekly data 
We modified the weekly CRF (Appendix 3) from the prospective study for the purpose 
of the retrospective study (Appendix 6). After communication with Roland Broadbent 
and Juliet Manning regarding the accuracy of the data within the neonate’s medical 
records, several sections were removed or altered as follows: 
- We removed parental and family contact sections, as not all staff recorded the 
type of contact and duration of contact consistently.  
- Enteral feeding data sought changed to total number of feeds, type, and route in 




the latter was not consistently recorded and was thought unlikely to contribute 
additionally to the quality of data.  
- We removed incubator, cot, stethoscope numbers, and equipment as the 
identification numbers were not recorded in the medical records. 
- We removed neonate cares, and other nursing procedures as it was not 
consistently recorded and was thought unlikely to contribute additionally to the 
quality of data.  
- Consultant contact, registrar contact, and nurse contact were removed as we did 
not have consent to trace staff contact, and contact was not reliably recorded in 
the medical records. 
- Apnoea requiring stimulation data sought was changed to the period of the last 7 
days from the last 24 hours. Apnoeas data were contained on a structured sheet, 
including the date, the apnoea event, and the stimulation required, therefore 
were likely to be accurate. 
As with the baseline CRF, we included a section for the swab test result for the 
exposure week, and the date of the axillary swab collection. We collected information 
in the weekly CRF for eligible neonates only. The data sources were the neonate’s 
medical records, the Microsoft Excel spreadsheet of S. capitis positive swab results, and 
Health Connect South. We used the nurse, consultant, registrar, and allied health 
professional staff entries in the neonate’s medical record to collect information on 
medical history, NICU procedures, and external procedures (e.g., head ultrasound 
scans). NICU category 4 or 5 charts are daily medical charts filled out by the nursing 
staff: category 5 are double-sided charts for the most intensive neonates, and category 4 
are one-sided charts for the less intensive neonates. The category 4 and 5 charts were 
used as the source documents for information for medical history, NICU procedures, 
enteral feeds, bed space number, and if the neonate occupied an incubator or a cot.  
Information on NICU procedures were sought from record sheets for laboratory tests, 
blood transfusions, phototherapy, and retinopathy of prematurity. Medication sheets 
that contained medication administration details were part of the neonate’s medical 
records and were the source for data on the use of antimicrobials, other medications, 




weight, the date, and a freehand growth plot. Data on apnoeas requiring stimulation 
were collected from a sheet that contained details on the date, apnoea or bradycardia 
event, and the intervention required. Data on external procedures, if not found in the 
nursing entries, were collected from copies of the procedure test results. The test results 
were loose sheets in the medical records that contained the date, type of test, and the 
results.  
As with the prospective study, the retrospective weekly CRF was completed for the 
exposure week. The first exposure week was 6am Monday of the neonate’s first swab 
to 5.59am Monday of their second swab. This continued until the neonate missed a 
swab, had a positive S. capitis swab result, or was discharged from the NICU. The 
retrospective weekly CRF was completed upon receipt of the medical notes and after 
completion of the baseline CRF. The weekly CRFs were completed in chronological 
order for each neonate.  
 Data management: prospective study 
We developed codes for all clinical staff in regular contact with neonate participants. 
Associate Professor Roland Broadbent supplied the codes and shift timetables for the 
consultants and registrars and charge nurse of the NICU, Juliet Manning, supplied the 
nurse codes. I created another set of codes to ensure it was not possible to trace the 
supplied codes back to the individual staff members. To create the consultant and 
registrar codes I used C or R, respectively, followed by a randomly generated number 
(e.g., R07). To create the nurse codes, two unique letters (e.g., IL) were randomly 
generated for each staff member. No randomly generated letter pairs matched the codes 
provided by Juliet Manning. I kept a Microsoft Word document (Microsoft 
Corporation, Washington, USA) with the link between the codes on a password 
protected computer in the Centre for International Health (CIH) offices.  
Trained NICU staff completed paper CRFs. Juliet Manning notified me once forms 
were completed, and I collected the forms from the NICU. I entered the data into a 
study database designed using the University of Otago REDCap database (service 




computer at the CIH offices. I reviewed forms for completeness and accuracy. If any 
data were missing or unclear, I contacted the clinical staff member who completed the 
forms for a response and personally amended the forms based on their feedback. The 
CRFs were stored in a locked filing cabinet in the CIH offices for the remainder of the 
study.  
Once the progress report of the prospective study is complete, the documents with the 
link between the staff codes will be transferred from the computer in the CIH offices to 
a password protected computer in Juliet Manning’s office in the Dunedin Hospital 
NICU. The CRFs from March 2018 onwards will be stored in a locked file cabinet in 
the NICU offices until the prospective study is complete. Additionally, access to the 
REDCap database was transferred to Juliet Manning and Roland Broadbent for the 
remainder of the prospective study. 
 Data management: retrospective study 
The Microsoft Excel spreadsheet (Microsoft Corporation, Washington, USA) of test 
results provided by Dr James Ussher included the neonate’s unique National Health 
Index (NHI) identification number. From the Excel spreadsheet, I made a list of all 
neonates who had been swabbed at least once during the retrospective study period. 
Using the neonate’s NHIs, Associate Professor Roland Broadbent ordered the notes 
from the clinical records team in Dunedin Hospital. We ordered 20-30 records per 
week. For each weekly batch of notes, the Dunedin Hospital clinical records team 
provided a sheet of paper with the NHIs of each neonate in the batch. The sheet was 
marked next to each NHI if the records were unavailable. I assigned each neonate a 
retrospective study ID, starting at R001, R002, and so on. In the retrospective study, I 
did not collect data on paper CRFs but instead entered the data directly into the 
REDCap online database on a password protected computer at the offices of the 
Women’s and Children’s Health Department. I created a Microsoft Word (Microsoft 
Corporation, Washington, USA) participant identification document on a password 
protected computer at the CIH offices, that matched the study ID, and the NHI. If any 




number to the neonate and find the missing information. The participant identification 
document was deleted when statistical analysis was completed. 
 Statistical analysis 
Data were downloaded from the University of Otago REDCap service version 8.2.0 (© 
Vanderbilt University, Tennessee, USA) into Stata/IC version 15.1 (StatCorp, College 
Station, TX, USA). Data on Dunedin Hospital NICU admissions and S. capitis 
colonised neonates were provided by Juliet Manning and James Ussher on a Microsoft 
Excel spreadsheet (Microsoft Corporation, Washington, USA) that were imported into 
Stata/IC. Datasets for the prospective study included test result CRFs, baseline CRFs, 
and weekly CRFs. Data sets for the retrospective study included baseline data and 
weekly data.  
 NICU admissions and S. capitis colonised neonates 
Data on Dunedin Hospital NICU admissions and S. capitis colonised neonates were 
used to create epidemic curves for the both the retrospective and prospective study 
periods. The epidemic curves show the total number of admissions compared to the 
number of neonates with S. capitis positive swab results per month during the study 
periods. The incidence rate (cases per admission months) for the prospective study was 
compared the incidence rate for the retrospective study using a Poisson regression 
model.  
 Prospective study  
Describing the prospective study population 
We used baseline data to describe the characteristics of the participants including both 
colonised neonates and non-colonised neonates from our prospective study progress 
report. Test result data was used to classify participants as colonised neonates or non-
colonised neonates. Descriptions of the baseline data for each group were presented as 
numbers and proportions for categorical or binary variables, or means and standard 




Once the prospective study is complete, we will perform a nested case-control analysis 
using conditional logistic regression. This analysis is not part of this thesis. 
 Retrospective study  
Describing the retrospective study population 
We used baseline data to describe the characteristics of our study population. In order 
to assess selection bias we compared i) total eligible neonates and total ineligible 
neonates; ii)  eligible colonised neonates and eligible non-colonised neonates; and iii)  
eligible neonates with available weekly data and eligible neonates without available 
weekly data. Descriptions of the baseline data for each group, and the total, were 
presented as numbers and proportions for categorical or binary variables, or means and 
standard deviations (sd) for continuous variables.  
Eligible neonates with available data 
Eligible neonates with available weekly data were used to investigate S. capitis risk 
factors. We first identified and labelled the exposure weeks for each infant as either 
case or control based on our case and control definitions. To control for the 
hypothesised patterns of S. capitis cases in the Dunedin Hospital NICU over time, we 
matched controls to the case exposure week on calendar time using modified risk-set 
matching. The modification was necessary to obtain a sufficient number of matched 
controls. For each case week, we included all control weeks for the four weeks previous 
to the case’s positive swab. An individual neonate could provide multiple weeks of 
control data per case, for as many cases as applicable. Individual neonates could 
provide both case and control data. Additionally, an individual neonate could have their 
control data matched to their case data. The cases and their controls were assigned a set 
number for grouping purposes. All sets were merged into a matched case-control 
dataset. Baseline data were then merged to the dataset based on retrospective study ID 
number. The final dataset included cases, controls matched to case exposure week and 




Among the neonates who provided case data, control data, or both, we identified the 
individual colonised and non-colonised neonates. We used baseline data to describe 
their characteristics, antimicrobial use, and inflamed skin over the neonate’s entire stay 
in the NICU. Numbers and proportions were presented as described for the 
retrospective study population.  
The baseline and weekly data in the matched dataset were grouped into sections 
including: baseline data, antimicrobials, other medications, medical history, procedures 
and devices, other procedures, enteral feedings, weight, type of bed, bed space 
numbers, and room numbers. Numbers and proportions and means and sd were 
presented as described above for each section. For unadjusted and adjusted analyses we 
used conditional logistic regression, to estimate the matched odds ratios, 95% 
confidence intervals and p-values. We used robust standard errors to account for 
correlations between repeat measures on the same neonate within a matched set. The 
set number was used to group the matched cases and controls. Unadjusted conditional 
logistic regression was performed on all variables that had three or more observations 
in each exposure category and had data for both cases and controls. If variables with 
too few data points were included, the estimates were too small to interpret or the 
model did not converge so no estimates were available. 
The sample size was too small to do a full multivariable analysis, so I adjusted the 
analysis for two main known confounders in addition to calendar week. Low GA, low 
birthweight, and length of stay in the NICU are all strongly associated with increased 
risk of CONS infections among neonates (12). Low GA at birth, low birthweight, and 
length of stay were also associated with risk of S. capitis colonisation among neonates 
in the Dunedin Hospital NICU (personal communication, James Ussher and Roland 
Broadbent), therefore likely to be confounders in our analysis. I adjusted for GA, and 
then for both GA at birth and length of stay. I did not include birthweight as birthweight 
and GA at birth were highly correlated in our study, therefore confounding was likely 
explained by GA. We chose GA at birth instead of birthweight as many of the 
treatments in the NICU are based on GA rather than birthweight. We used categorical 
variables of GA and length of stay for the adjusted analysis as we thought a linear 




not sufficient data to model the relationship more accurately. GA was categorised into 
≤32 weeks and >32 weeks as neonates born at ≤32 weeks’ gestation is the definition of 
very preterm (135). Length of stay was arbitrarily set at ≤40 days and >40 days, as 40 
days was the mean length of stay and there was not sufficient data to create more than 
two categories.  
The adjusted conditional logistic regression models were fit for all exposure variables 
with ten or more observations in each exposure level, and data for both cases and 
controls. As with the unadjusted analysis, if too few data points were included in the 
analysis, the estimates were too small to interpret or the model did not converge so no 
estimates were available.  
ORs, 95% CIs and p-values for all variables with enough data for adjusted analyses 
were presented in a table which included unadjusted analyses, analyses adjusted for 
GA, and analyses adjusted for GA and length of stay. 
In order to examine patterns in location of cases over calendar time, I created a study 
week number for each week of the retrospective study. Our study began on Monday 9 
September 2013, therefore the week from Monday 9 September through Monday 16 
September was assigned as study week 0. Our study ended the week of 23 March 2015 
through 30 March 2015, which was assigned as study week 83. Study weeks were used 
for a diagram of the NICU to show the bed space and room in which neonates became 
positive for S. capitis over time. The number of S. capitis positive neonates per study 
neonate week per room was also included in the case bed space diagram as a measure 
of incidence. Incidence was calculated as the number of cases over the number of 
controls per room over the study period. Study weeks were also included in a diagram 
of the cases born as a part of a multiple birth to show the number of weeks between 





 Consent, ethics, and funding: prospective study 
Consent 
I designed a participant consent form (Appendix 7) to record consent. Additionally, I 
created a participant information sheet (PIS) (Appendix 8) to inform the parents or 
guardians of the objectives of the study and the details of their participation. The 
neonate’s participation was not dependent on the birth mother’s participation. I 
collected the consent forms from the Dunedin Hospital NICU office. Consent forms 
were secured in a locked file cabinet in the CIH offices. 
Ethics 
We obtained ethics approval from the New Zealand Health and Disability Ethics 
Committee via the full review pathway (reference number 17/NTB/59). A copy of the 
approval letter is included in Appendix 9. Additionally, we attained Locality 
Authorisation from Health Research South (Appendix 10) for our study to proceed in 
Dunedin Hospital NICU (project ID: 01343). This process was aided by Associate 
Professor Roland Broadbent. We sought Maori Consultation from the Ngai Tahu 
Research Consultation Committee (Appendix 11).  
Funding 
I was provided with office space in the CIH offices and a computer (loaded with 
Stata/IC software for data analysis) by the Department of Preventive and Social 
Medicine, University of Otago. Data collection was hosted by staff of the Dunedin 
Hospital NICU who provided support for participant consent and enrollment and 
resources for study materials. Southern Community Laboratories provided S. capitis 





 Ethics and funding: retrospective study 
Ethics  
Ethics approval was obtained from the University of Otago Human Ethics Committee 
(Health) via the ‘Minimal Risk Health Research – Audit and Audit related studies’ 
pathway (reference number HD16/050). A copy of the approval letter is included 
(Appendix 12). The study also had locality authorisation from Health Research South 
(Appendix 13) for the study to take place in Dunedin Hospital (project ID: 01282). 
Ethics approval and locality authorisation were obtained by Dr. James Ussher and 
Associate Professor Roland Broadbent. I was added to the approvals so that I was able 
to undertake the study.  
Funding 
I was provided with office space in the Women’s and Children’s Health Department in 
the Children’s Pavilion in Dunedin Hospital. Medical records were provided by the 






 NICU admissions and S. capitis colonised neonates 
The number of admissions and number of neonates colonised with S. capitis per month 
during the 2013-15 retrospective study period and the 2017-18 prospective study period 
are shown in Figure 5. Of the 58 neonates colonized with S. capitis during the 
retrospective study, 46 were born ≥32 weeks’ gestational age, 10 were born ≥34 weeks’ 
gestational age, and 2 were born ≥36 weeks’ gestational age.  
The incidence rate of cases per admission over the retrospective study period was 16 
per 100 admissions. The incidence rate of cases per admission over prospective study 
period was 3 per 100 admissions. The incidence rate during the retrospective study 
period was 5.2 (95% CI 2.3-10.8) times higher than the incidence rate during the 
prospective study period (p<0.001).  
A progress report from the ongoing prospective study is presented at the end of the 
Results chapter. The data collection for the retrospective study is complete and a full 








Months of the year are marked with their initial; Retrospective study period – September 2013 
through March 2015; Prospective study period – July 2017 through February 2018. 
 
* S. capitis swab tests for all neonates began September 2013.  
† S. capitis swab tests restricted to neonates <32 weeks gestational age, April 2015.  
‡ S. capitis swab tests extended to neonates <34 weeks gestational age, July 2017.  





Figure 5: Epidemic curve of the admissions and neonates colonised with S. capitis, 





 The retrospective study population 
Of 352 neonates admitted to the Dunedin Hospital NICU September 2013 through 
March 2015, 236 (66.3%) neonates were swabbed at least once during their stay and of 
these 117 (49.6%) were eligible for participation. Of 119 (50.4%) ineligible neonates, 
88 (73.3%) were swabbed once, 16 (13.3%) had a positive first swab none of which 
were readmissions, 9 (7.5%) were admitted to the Dunedin Hospital NICU before the 
study began, and 6 (5.0%) did not receive their scheduled second swab. The flow 
diagram of admissions and their eligibility for inclusion is shown in Figure 6. 
Of 117 eligible neonates, medical records were available for 64 (54.7%). Of 64 
neonates with medical records, 26 (40.6%) were of neonates colonised with S. capitis 
and 38 (59.4%) were of neonates not colonised with S. capitis. Of 53 (45.3%) neonates 
with unavailable medical records, 16 (30.2%) were of neonates colonised with S. 
capitis and 37 (69.8%) were of neonates not colonised with S. capitis. All unavailable 
medical records were due to asbestos contamination of medical record storage rooms in 
Dunedin Hospital preventing safe access and use (136).  
Of the 58 neonates that were colonised with S. capitis NRCS-A during the retrospective 









































Figure 6: Flow diagram of the neonates and their eligibility for inclusion in the 
retrospective study, Dunedin Hospital NICU, September 2013 through March 
2015  
Not eligible (n = 119) 
 
Swabbed once (n = 88) 
First swab positive (n = 16) 
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 Eligible and ineligible neonates 
Table 2 shows the baseline characteristics of all 236 neonates who were swabbed at 
least once during their stay in the NICU, including 117 neonates who were eligible for 
the study, and 119 neonates who were ineligible. Among the 117 eligible neonates, 73 
(62.4%) were New Zealand European compared to 87 (73.1%) among the 119 
ineligible neonates. Twenty-four (20.5%) among the eligible neonates were Māori, 
compared to 10 (8.4%) among the ineligible neonates. The mean (standard deviation) 
gestational age at birth was 33.0 (± 0.4) weeks for eligible neonates and 35.7 (± 0.4) 
weeks for ineligible neonates. The mean (standard deviation) birthweight was 1,981 (± 
77.7) g for eligible neonates and 2,667 (± 89.9) g for ineligible neonates. Among the 
eligible neonates, 31 (26.5%) were born as a part of a multiple birth, compared to 21 
(17.7%) among ineligible neonates. The mean (standard deviation) length of stay was 





Table 2: Baseline characteristics of participants swabbed at least once by 
eligibility status, Dunedin Hospital NICU, September 2013 through March 2015 
NICU - neonatal intensive care unit; sd – standard deviation; GA – gestational age. 
*Other ethnicities included: European not further defined (n=11), Asian not further defined 
(n=2), Eurasian not further defined (n=2), Southeast Asian (n=2), Fijian Indian (n=1), Middle 
Eastern not further defined (n=1), North American/German (n=1), Pacific not further defined 
(n=1), Papa New Guinean (n=1), South African (n=1), Swiss European (n=1), Syrian (n=1), 
Tokelauan (n=1), UK European (n=1), and Venezuelan (n=1). 
† Delivery type missing for one neonate. 
 
  
 All neonates  n = 236 
Eligible  
n = 117 
Ineligible 
n = 119 
Demographics n (%) n (%) n (%) 
Sex       
Female 116 (49.2) 54  (46.2) 62 (52.1) 
Ethnicity       
New Zealand European 160 (67.8) 73  (62.4) 87 (73.1) 
Māori 34 (14.4) 24  (20.5) 10 (8.4) 
Cook Island Māori 4 (1.7) 2  (1.7) 2 (1.7) 
Tongan 4 (1.7) 1  (0.9 ) 3 (2.5) 
Indian 2 (0.9) 1  (0.9) 1 (0.8) 
Chinese 1 (0.4) 1  (0.9) 0 (0.0) 
Samoan 1 (0.4) 1  (0.9) 0 (0.0) 
Niuean 0 (0.0) 0  (0.0) 0 (0.0) 
Other* 28 (11.9) 13  (11.1) 15 (12.6) 
Birth       
GA, weeks, mean (sd) 34.3 (± 0.3) 33.0  (± 0.4) 35.7 (± 0.4) 
Birth weight, g, mean (sd) 2,327 (± 63.4) 1,981 (± 77.7) 2,667 (± 89.9) 
Delivery type †       
Caesarian section 130 (55.1) 67 (57.3) 63 (52.9) 
Vaginal delivery tools       
None 92 (87.6) 43 (87.8) 49 (87.5) 
Forceps 7 (3.0) 5 (4.3) 2 (1.7) 
Ventouse 9 (3.8) 2 (1.7) 7 (5.9) 
Multiple births  52 (22.0) 31  (26.5) 21 (17.7) 
Born in Dunedin Hospital  209 (88.6) 104  (88.6) 105 (88.2) 
In the NICU       
Length of stay, days, mean (sd) 22.6 (± 1.4) 30.5 (± 2.0) 14.7 (± 1.9) 
Vital status at discharge       




 Eligible colonised and non-colonised neonates 
Table 3 shows the baseline characteristics of the 117 eligible, 42 colonised, and 75 non-
colonised neonates. Among the colonised neonates, 14 (33.3%) were female. Among 
the non-colonised neonates, 40 (53.3%) were female. Among the colonised neonates, 
24 (57.1%) were New Zealand European compared to 49 (65.3%) among the non-
colonised neonates. 
The mean (standard deviation) gestational age at birth was 29.6 (± 0.5) weeks for 
colonised neonates and 34.8 (± 0.4) weeks for non-colonised neonates. The mean 
(standard deviation) birthweight was 1,348 (± 82.2) g for colonised neonates and 2,335 
(± 89.1) g for non-colonised neonates. The mean (standard deviation) length of stay 
was 42.9 (± 3.5) days for colonised neonates and 23.6 (± 2.0) days for non-colonised 
neonates. Birth was by caesarean section for 30 (71.4%) colonised neonates and 37 
(59.3%) non-colonised neonates. Fifteen (35.7%) colonised neonates were born as a 





Table 3: Baseline characteristics of the eligible neonates by colonised and non-
colonised status, Dunedin Hospital NICU, September 2013 through March 2015 
NICU - neonatal intensive care unit; sd – standard deviation; GA – gestational age. 
* Other ethnicities included: European not further defined (n=6), Asian not further defined 
(n=1), North American/German (n=1), Pacific not further defined (n=1), Syrian (n=1), 




 Eligible n =117 
Colonised 
n = 42 
Non-colonised 
n = 75 
Demographics n (%) n (%) n (%) 
Sex       
Female 54  (46.2) 14  (33.3) 40 (53.3) 
Ethnicity       
New Zealand European 73  (62.4) 24  (57.1) 49  (65.3) 
Māori 24  (20.5) 9  (21.4) 15  (20.0) 
Cook Island Māori 2  (1.7) 2  (4.8) 0  (0.0) 
Chinese 1  (0.9) 1  (2.4) 0  (0.0) 
Indian 1  (0.9) 0  (0.0) 1  (1.3) 
Samoan 1  (0.9) 0  (0.0) 1  (1.3) 
Tongan 1  (0.9 ) 0  (0.0) 1  (1.3) 
Niuean 0  (0.0) 0  (0.0) 0  (0.0) 
Other* 13  (11.1) 6  (13.7) 6 (8.0) 
Birth       
GA, weeks, mean (sd) 33.0  (± 0.4) 29.6  (± 0.5) 34.8 (± 0.4) 
Birth weight, g, mean (sd) 1,981 (± 77.7) 1,348  (± 82.2) 2,335 (± 89.1) 
Delivery type       
Caesarian section 67 (57.3) 30 (71.4) 37 (49.3) 
Vaginal delivery tools       
None 43 (87.8) 11 (26.2) 32 (43.2) 
Forceps 5 (4.3) 1 (2.4) 4 (5.3) 
Ventouse 2 (1.7) 0 (0.0) 2 (2.7) 
Multiple births 31  (26.5) 15  (35.7) 15  (21.3) 
Born in Dunedin Hospital  104  (88.6) 38  (90.5) 66  (88.0) 
In the NICU       
Length of stay, days, mean (sd) 30.5 (± 2.0) 42.9  (±3.5) 23.6 (± 2.0) 
Vital status at discharge       




 Eligible neonates with or without weekly data 
Weekly data were available for eligible neonates among whom we could access 
medical records. Of the 64 neonates with available weekly data, 26 (40.6%) were 
colonised neonates, and 38 (59.4%) were non-colonised neonates. Of the 53 neonates 
without available weekly data, 16 (30.2%) were colonised neonates, and 37 (69.8%) 
were non-colonised neonates. Table 4 shows the baseline characteristics of eligible 
neonates with or without weekly data. Among the neonates with available weekly data, 
28 (43.8%) were female. Among the neonates without available weekly data, 26 
(49.1%) were female. Seventeen (26.6%) neonates with available weekly data were 
Māori, compared to 7 (13.2%) neonates without available weekly data. Fifteen (23.4%) 
neonates with available data were born as part of a multiple birth compared to 16 
(30.2%) among the neonates without available data. The mean (standard deviation) 
length of stay was 37.4 (±3.2) days for neonates with weekly data and 22.2 (±1.5) days 





Table 4: Baseline characteristics of the eligible neonates by availability, Dunedin 
Hospital NICU, September 2013 through March 2015 
 NICU - neonatal intensive care unit; sd – standard deviation; GA – gestational age. 
* Other ethnicities included: European not further defined (n=6), Asian not further defined 
(n=1), North American/German (n=1), Pacific not further defined (n=1), Syrian (n=1), 
Tokelauan (n=1), UK European (n=1), and Venezuelan (n=1).  





Available weekly data 
n= 64 
Unavailable weekly data 
n = 53 
Demographics n (%) n (%) 
Sex     
Female 28 (43.8) 26 (49.1) 
Ethnicity     
New Zealand European 39 (60.9) 35 (66.1) 
Māori 17 (26.6) 7 (13.2) 
Cook Island Māori 1 (1.6) 1 (1.9) 
Chinese 1 (1.6) 0 (0.0) 
Indian 0 (0.0) 1 (1.9) 
Samoan 1 (1.6) 0 (0.0) 
Tongan 1 (1.6) 0 (0.0) 
Niuean 0 (0.0) 0 (0.0) 
Other * 4 (6.3) 9 (17.0) 
Birth     
GA, weeks, mean (sd) 32.7 (±0.5) 33.2 (±0.6) 
Birthweight, g, mean (sd) 1,906 (±108.3) 2,070 (±110.8) 
Delivery type     
Caesarian section 36 (56.3) 31 (58.5) 
Vaginal delivery tools †     
None 24 (85.7) 20 (90.9) 
Forceps 3 (4.7) 2 (3.8) 
Ventouse 2 (3.1) 0 (0.0) 
Multiple births  15 (23.4) 16 (30.2) 
Born in Dunedin Hospital  56 (87.5) 48 (90.6) 
In the NICU     
Length of stay, days, mean (sd) 37.4 (±3.2) 22.2 (±1.5) 
Vital status at discharge     




 Nested case-control study 
Of the 64 neonates with available weekly data, 26 (40.6%) colonised neonates were 
included in the nested case-control study as cases, and 38 (59.4%) non-colonised 
neonates were potential controls. Each of the cases were matched to controls based on 
the matching criteria (section 4.17.3). This gave a total of 203 weeks of control data, 
contributed by 38 individual neonates, median number of controls per case of 7.8, range 
(1, 21). Among the 38 individual neonates that contributed control data, 24 (63.2%) 
were non-colonised neonates, and 14 (36.8%) were colonised neonates who also 
contributed case data. Fourteen (36.8%) non-colonised neonates did not contribute 
weekly data, as their control weeks did not meet matching criteria with cases. Of the 
203 weeks of control data, 120 (59.1%) weeks were contributed by colonised neonates, 
and 83 (40.9%) weeks were contributed by non-colonised neonates. Of the 14 colonised 
neonates that contributed case and control data, all 14 had control data matched to their 
own case data.  
 Nested case-control unadjusted analysis 
Baseline characteristics of colonised and non-colonised neonates that contributed 
weekly data 
Table 5 shows the baseline characteristics for the 26 colonised neonates and 24 non-
colonised neonates who contributed weekly data to the matched case-control analysis. 
Of colonised neonates, 5 (19.2%) were female whereas 12 (50.0%) non-colonised 
neonates were female. The mean (standard deviation) gestational age at birth for 
colonised neonates was 29.7 (± 0.6) weeks and for non-colonised neonates was 34.4 (± 
0.7) weeks. The mean (standard deviation) birthweight for colonised neonates was 
1,374 (±108.9) g, and for non-colonised neonates was 2,198 (±155.4) g. Caesarean 
sections were the mode of delivery for 20 (76.9%) colonised neonates and 11 (45.8%) 
non-colonised neonates. The mean (standard deviation) length of stay was 50.5 (± 4.9) 





Table 5: Baseline characteristics of colonised and non-colonised neonates that 
contributed data to the matched case-control analysis, Dunedin Hospital NICU, 
September 2013 through March 2015 
NICU – neonatal intensive care unit; sd – standard deviation; GA – gestational age. 
* Ethnicity missing for one non-colonised neonate. 




 Colonised neonates n = 26 
Non-colonised neonates 
n = 24 
Demographics n (%) n (%) 
Sex     
Female 5  (19.2) 12 (50.0) 
Ethnicity*     
Non-Māori 20  (76.9) 16 (66.7) 
Māori   6 (23.1) 7 (29.2) 
Birth     
GA, weeks, mean (sd) 29.7  (± 0.6) 34.4 (± 0.7) 
≤32 weeks  18 (69.2) 5 (20.8) 
>32 weeks  8 (30.8) 19 (79.2) 
Birth weight, g, mean (sd)  1,374  (±108.9) 2,198 (±155.4) 
≤1500g  19 (73.1) 3 (12.5) 
>1500g  7 (26.9) 21 (87.5) 
Delivery type     
Caesarian section 20 (76.9) 11 (45.8) 
Vaginal delivery tools †     
None  6 (23.1) 11 (45.8) 
Forceps 0 (0.0) 1 (4.2) 
Ventouse 0 (0.0) 1 (4.2) 
Multiple births  8  (30.8) 7 (29.2) 
Born in Dunedin Hospital 25  (96.2) 21 (87.5) 
In the NICU     
Length of stay, days, mean (sd) 50.5 (± 4.9) 30.2 (± 5.3) 
≤40 days 11 (42.3) 19 (79.2) 
>40 days 15 (57.7) 5 (20.8) 
Vital status at discharge     




Figure 7 shows number of weeks in the NICU before colonised neonates had their 
positive swab result for S. capitis. Among the 26 cases, 11 (42.3%) became colonised 
with S. capitis during their first exposure week. The number of neonates that became 
colonised reduced per week of stay in the NICU. No neonates became cases after their  
fifth week in the NICU. 
 
 
Baseline characteristics of cases and controls 
Table 6 shows the baseline characteristics for the 26 cases and the 203 matched 
controls. The odds of being born at ≤32 weeks’ gestation was 3.5 times higher among 
cases than among controls (OR 3.5, 95% CI 1.3-9.6, p=0.02). The odds of being born 
≤1500g was 4.0 times higher among cases than among controls (OR 4.0, 95% CI 1.1-
14.9, p=0.04). The odds of being born as a part of a multiple birth was 76% lower 
among cases than among controls (OR 0.24, 95% CI 0.08-0.67, p=0.007). The 
difference between cases and controls for length of stay was not statistically significant 
(OR 1.5, 95% CI 0.67-3.4, p=0.3).  
Figure 7: Number of weeks in the NICU before colonised neonates had their positive 




Table 6: Baseline characteristics of cases and controls, Dunedin Hospital NICU, 
September 2013 through March 2015 






Demographics n (%) n (%) OR (95% CI)  
Sex        
Female 5  (19.2) 54 (26.6) 0.68  (0.23-2.1) 0.5 
Ethnicity*        
Non-Māori 20  (76.9) 157  (77.3) 1.3 (0.50-3.4) 0.6 
Māori   6 (23.1) 45 (22.2) 1 (reference)  
Birth        
Gestational age        
weeks, mean (sd) 29.7  (± 0.6) 31.1 (± 0.2) 0.84  (0.75-0.94) 0.003 
≤32 weeks  18 (69.2) 98 (48.3) 3.5 (1.3-9.6) 0.02 
>32 weeks  8 (30.8) 105 (51.7) 1 (reference)  
Birth weight        
g, mean (sd) † 1,374 (±108.9) 1,546 (± 41.3) 0.9 (0.8-1.0) 0.1 
≤1500g  19 (73.1) 103 (50.7) 4.0 (1.1-14.9) 0.04 
>1500g  7 (26.9) 100 (49.3) 1 (reference)  
Delivery type        
Caesarian section 20 (76.9) 162 (79.8) 2.2  (0.41-12.4) 0.4 
Vaginal delivery        
None  6 (23.1) 34 (16.8) 0.61 (0.13-3.0) 0.5 
Forceps 0 (0.0) 3 (1.5) NA  
Ventouse 0 (0.0) 4 (2.0) NA  
Multiple births  8  (30.8) 120  (59.1) 0.24  (0.08-0.67) 0.007 
Born in Dunedin 
Hospital 
25  (96.2) 186  (91.6) 4.1  (0.60-27.8) 0.2 
In the NICU        
Length of stay        
days, mean (sd) 50.5 (± 4.9) 48.2 (± 1.8) 1.0 (0.99-1.0) 0.3 
≤40 days 11 (42.3) 95 (46.8) 1 (reference)  
>40 days 15 (57.7) 108 (53.2) 1.5  (0.67-3.4) 0.3 
Vital status at 
discharge 
       
Deceased 1 (3.9) 0 (0.0) NA  
Unadjusted OR, 95% CI and p-values were estimated using conditional logistic regression to 
account for the matching. Controls (n=203) are all the controls from the matched case-control 
sets. 
NA - no cases, or cell numbers less than 3; NICU – neonatal intensive care unit; sd – standard 
deviation. 
*Ethnicity missing for one non-colonised neonate. 







Antimicrobial use  
Antimicrobial use by cases and controls is presented in Table 7. The differences 
between cases and controls during the exposure week were not statistically significant 
for the use of any specific antimicrobials. None of the cases used fusidic acid compared 
to 36 (17.7%) of the controls. The OR and 95% CI could not be estimated for fusidic 
acid due the lack of cases.  
Table 7: Unadjusted analysis of medication use in cases and controls, Dunedin 
Hospital NICU, September 2013 through March 2015. 






 n (%) n (%) OR (95% CI)  
Any antimicrobial 19  (73.1) 113 (55.7) 1.9 (0.54-6.6) 0.3 
Antibacterials        
Amoxicillin 13 (50.0) 68 (33.3) 1.5 (0.58-3.9) 0.4 
Gentamicin 8 (30.8) 35 (17.2) 1.4 (0.52-3.7) 0.5 
Fusidic acid 0 (0.0) 36 (17.7) NA  
Metronidazole 1 (3.9) 32 (15.8) 0.2 (0.03-1.9) 0.2 
Amikacin 4 (15.4) 23 (11.3) 1.5 (0.41-5.3) 0.5 
Chloramphenicol 1 (3.9) 9 (4.4) 1.1 (0.13-8.6) 1.0 
Cefotaxime 2 (7.7) 6 (3.0) 1.9 (0.23-15.9) 0.5 
Augmentin 0 (0.0) 0 (0.0) NA  
Ceftazadime 0 (0.0) 0 (0.0) NA  
Erythromycin 0 (0.0) 0 (0.0) NA  
Penicillin 0 (0.0) 0 (0.0 NA  
Vancomycin 0 (0.0) 0 (0.0) NA  
Antifungals        
Fluconazole 14 (53.9) 69 (33.8) 2.1 (0.85-5.4) 0.1 
Nystatin 0 (0.0) 6 (3.0) NA  
Clotrimazole 0 (0.0) 2 (1.0) NA  
S. capitis resistance       
Composite * 13 (50.0) 84 (41.4) 1.2 (0.45-3.3) 0.7 
Unadjusted OR, 95% CI and p-values were estimated using conditional logistic regression to 
account for the matching. Controls (n=203) are all the controls from the matched case-control 
sets. 
NA - no cases, or cell numbers less than 3; NICU – neonatal intensive care unit. 
* Composite antimicrobial includes antibacterials against which S. capitis has resistance: 





Antimicrobial use among colonised and non-colonised neonates that contributed 
weekly data 
Table 8 shows the antimicrobial use among the 26 colonised neonates and 24 non-
colonised neonates that contributed data to the matched case-control analysis. Among 
the 26 colonised neonates, 23 (88.5%) used any antimicrobial. Among the 24 non-
colonised neonates, 7 (29.2%) used any antimicrobial. The composite variable of 
antimicrobials to which S. capitis is resistant includes amoxicillin, gentamicin, fusidic 
acid, metronidazole, and cefotaxime. Antimicrobials to which S. capitis is resistant 
were used by 20 (76.9%) colonised neonates, and 5 (20.8%) non-colonised neonates. 
Table 8: Antimicrobials used by colonised and non-colonised neonates that 
contributed data to the matched case-control analysis, Dunedin Hospital NICU, 
September 2013 to March 2015 
Antimicrobials Colonised neonates n= 26 
Non-colonised neonates 
n= 24 
 n (%) n (%) 
Any antimicrobial 23 (88.5) 7 (29.2) 
Antibacterial     
Amoxicillin 20 (76.9) 4 (16.7) 
Gentamicin 15 (57.7) 3 (12.5) 
Fusidic acid 3 (11.5) 1 (4.2) 
Metronidazole 5 (19.2) 0 (0.0) 
Amikacin 6 (23.1) 0 (0.0) 
Chloramphenicol 2 (7.7) 1 (4.2) 
Cefotaxime 4 (15.4) 1 (4.2) 
Antifungal     
Fluconazole 15 (57.7) 2 (8.3) 
Nystatin 1 (3.8) 1 (4.2) 
Clotrimazole 0 (0.0) 1 (4.2) 
S. capitis resistance     
Composite * 20 (76.9) 5 (20.8) 
NICU – neonatal intensive care unit. 
* Composite antimicrobial includes antibacterials against which S. capitis has resistance: 







Medications other than antimicrobials used by cases and controls, and the univariate 
analysis are shown in Table 9. Probiotics are used to promote healthy gut microflora 
and prevent necrotising enterocolitis (NEC) (137).  Infloran probiotics contain 
Bifidobacterium bifidum and Lactobacillus acidophilus. The odds of infloran probiotic 
use was 5.2 times higher among cases than among controls (OR 5.2, 95% CI: 1.5–18.0, 
p=0.009). Caffeine was used among neonates to reduce apnoeas of prematurity, 
extubation failure, and patent ductus arteriosus (PDA) (138-140). The odds of caffeine 
use was 5.2 times higher among cases than among controls (OR 5.2, 95% CI: 1.1-24.5, 
p=0.04).  
Vitadol C is a vitamin supplement which contains vitamin A, vitamin D, and vitamin C. 
The odds of Vitadol C use was 1.5 times higher among cases than among controls (OR 
1.5, 95% CI: 0.15-5.4, p=0.9). The odds of oral sodium chloride (NaCl) use was 10 
times higher among cases than among controls (OR 10.0, 95% CI 2.0-48.8, p=0.004). 
The diuretics combination of chlorthiazide and spironolactone are used to reduce the 
risk of development of chronic lung disease (CLD) in neonates. The odds of 
chlorthiazide and spironolactone use was 4.3 times higher among cases than among 
controls (OR 4.3, 95% CI: 1.5-13.0, p=0.009). The ORs and 95% CIs for all of the non-
antimicrobial topical creams could not be calculated accurately as there were no 
observations for the cases. 
Table 9: Unadjusted analysis of other medication use in cases and controls, 
Dunedin Hospital NICU, September 2013 through March 2015 






 n (%) n (%) OR (95% CI)  
Any medication 25  (96.2) 193 (94.6)  0.76 (0.07-7.9) 0.8 
Infloran probiotics* 23 (88.5) 129 (63.6) 5.2 (1.5-18.0) 0.009 
Caffeine 21 (80.8) 125 (61.6) 5.2 (1.1-24.5) 0.04 
Micelle E † 7 (26.9) 44 (21.7) 2.5 (0.73-8.8) 0.1 
Glycerine 0 (0.0) 43 (21.2) NA  
Gaviscon infants ‡ 1 (3.9) 4 (2.0) 1.3 (0.15-10.4) 0.8 
Dopamine 0 (0.0) 4 (2.0) NA  
Insulin 0 (0.0) 4 (2.0) NA  
Ibuprofen 1 (3.9) 0 (0.0) NA  
Supplements        










Supplements n (%) n (%) OR (95% CI)  
Phosphate 2 (7.7) 21 (10.3) 1.2 (0.24-5.4) 0.9 
Iron 1 (3.9) 19 (9.4) 1.5 (0.05-48.0) 0.8 
Oral NaCl 4 (15.4) 7 (3.5) 10.0 (2.0-48.8) 0.004 
KCl 1 (3.9) 10 (4.9) 0.38 (0.04-3.5) 0.4 
Calcium 
gluconate 
0 (0.0) 5 (2.5) NA  
Duocal paste ǁ  0 (0.0) 3 (1.5) NA  
Pain relief        
Sucrose ¶ 3 (11.5) 8 (3.9) 1.9 (0.44-7.7) 0.4 
Morphine 0 (0.0) 2 (1.0) NA  
Paracetamol 1 (3.9) 0 (0.0) NA  
Topical creams        
Sudocrem ◊ 0 (0.0) 4 (2.0) NA  
Bepanthen ƒ 0 (0.0) 4 (2.0) NA  
Zinc oxide 0 (0.0) 2 (1.0) NA  
Diuretics        
Chlorthiazide and 
spironolactone 
3 (11.5) 7 (3.5) 4.3 (1.5-13.0) 0.009 
Frusemide 1 (3.9) 3 (1.5) 6.1 (0.83-44.9) 0.08 
Amiloride 0 (0.0) 3 (1.5) NA  
Injectables       
TPN 16 (61.5) 91 (44.8) 1.9 (0.46-7.6) 0.4 
Lipids 16 (61.5) 89 (43.8) 2.0 (0.49-8.4) 0.3 
Dextrose 12 (46.2) 67 (33.0) 1.0 (0.45-2.4) 0.9 
IV NaCl  9 (34.6) 39 (19.2) 1.6 (0.59-4.4) 0.4 
Glucose 3 (11.5) 17 (8.4) 0.96 (0.26-3.5) 1.0 
Heparinised 
saline 
3 (11.5) 10 (4.9) 1.2 (0.26-5.9) 0.8 




0 (0.0) 5 (2.5) NA  
Unadjusted OR, 95% CI and p-values were estimated using conditional logistic regression to 
account for the matching. Controls (n=203) are all the controls from the matched case-control 
sets. 
NA - no cases, or cell numbers less than 3; NICU – neonatal intensive care unit; TPN – total 
parental nutrition. 
* Infloran probiotics contains Bifidobacterium bifidum and Lactobacillus acidophilus. 
† Micelle E is a vitamin E formulation given for prevention of retinopathy of prematurity.  
‡ Gaviscon infants contains sodium alginate and sodium bicarbonate. 
§ Vitadol C contains vitamin A, vitamin D and vitamin C. 
ǁ  Duocal paste a nutritional supplement that contains protein and carbohydrate  
¶ Oral sucrose is given as a pain relief for minor procedures. 
◊ Sudocrem contains zinc oxide and benzyl alcohol. 






 Medical history 
The unadjusted analysis of medical history of the cases and controls is shown in Table 
10. Temperature instability is defined by a neonate’s requirement for external 
temperature control using incubator controls, or an adjustment of their amount of 
clothing. The odds of temperature instability was 2.7 times higher among cases than 
among controls (OR 2.7, 95% CI 1.0-6.8, p=0.04). The odds of skin inflammation was 
72% lower among cases than among controls (OR 0.28, 95% CI 0.1-0.7, p=0.009). The 
difference between cases and controls for skin inflammation was not statistically 
significant for any specific body sites. The odds of cardiac abnormalities was 2.6 times 
higher among cases than among controls (OR 2.6, 95% CI: 1.1-6.0, p=0.03). The odds 
of PDA was 4.2 times higher among cases than among controls (OR 4.2, 95% CI: 1.6-
10.7, p=0.003). The differences between cases and controls were not statistically 
significant for any other cardiac abnormalities in the exposure week. The odds of CLD 
was 8.5 times higher among cases than among controls (OR 8.5, 95% CI: 0.6-10.5, 
p=0.009).   
Table 10: Unadjusted analysis of the medical history of cases and controls, 
Dunedin Hospital NICU, September 2013 through March 2015 
 Cases n = 26 
Controls 
n = 203 Unadjusted  
p- 
value 
 n (%) n (%) OR 95% CI  
Feed intolerance 6 (23.1) 59 (29.1) 0.5 (0.13-1.7) 0.2 
Gastric aspirate 6 (23.1) 58 (28.6) 0.5 (0.14-2.1) 0.4 
Temperature instability* 13 (50.0) 49 (24.1) 2.7 (1.0-6.8) 0.04 
Skin injury 5 (19.2) 41 (20.2) 0.95 (0.32-2.9) 0.9 
Sepsis workup 5 (19.2) 27 (13.3) 1.9 (0.71-5.3) 0.2 
Intracranial haemorrhage 0 (0.0) 14 (6.9) NA  
Hypoglycaemia 0 (0.0) 12 (5.9) NA  
Renal impairment 0 (0.0) 12 (5.9) NA  
Flaky skin 1 (3.9) 7 (3.5) 0.8 (0.07-8.1) 0.8 
Sepsis diagnosis 2 (7.7) 3 (1.5) 8.6 (0.86-86.2) 0.07 
Neonatal encephalopathy 0 (0.0) 4 (2.0) NA  
Umbilical flare 1 (3.9) 2 (1.0) NA  
Retinopathy of prematurity 0 (0.0) 0 (0.0) NA  
Area of inflamed skin       
Yes, total 8 (30.8) 119 (58.6) 0.28 (0.11-0.73) 0.009 
Axilla 2 (7.7) 48 (23.7) 0.28 (0.06-1.4) 0.1 
Eye 3 (11.5) 30 (14.8) 1.2 (0.33-4.3) 0.8 
Buttocks 2 (7.7) 27 (13.3) 0.38 (0.08-1.9) 0.2 




 Cases n = 26 
Controls 
n = 203 Unadjusted  
p- 
value 
Area of inflamed skin n (%) n (%) OR 95% CI  
Ear 0 (0.0) 7 (3.5) NA  
Full body 0 (0.0) 5 (2.5) NA  
Groin 1 (3.9) 3 (1.5) 1.7 (0.26-11.8) 0.6 
Oral thrush 0 (0.0) 4 (2.0) NA  
Neck 1 (3.9) 2 (1.0) NA  
Gastrointestinal disease       
Yes, total 0 (0.0) 18 (8.9) NA  
Necrotising enterocolitis 0 (0.0) 14 (6.9) NA  
Bowel ischaemia 0 (0.0) 4 (2.0) NA  
Cardiac abnormalities        
Yes, total 13 (50.0) 55 (27.1) 2.6 (1.1-6.0) 0.03 
Patent ductus arteriosus  12 (46.2) 31 (15.3) 4.2 (1.6-10.7) 0.003 
Murmur 5 (19.2) 37 (18.2) 0.94 (0.35-2.5) 0.9 
Septal defects 1 (3.9) 14 (6.9) 0.5 (0.05-5.5) 0.6 
Ventricular  impairment 1 (3.9) 8 (3.9) 1.1 (0.13-9.9) 0.9 
Artery impairment 0 (0.0) 2 (1.0) NA  
Valve impairment 1 (3.9) 0 (0.0) NA  
Tachycardia 1 (3.9) 0 (0.0) NA  
Pulmonary disease        
Yes, total 12 (46.2) 96 (47.3) 1.7 (0.44-6.7) 0.2 
RDS 12 (46.2) 88 (42.4) 2.5 (0.61-10.5) 0.2 
Chronic lung disease 4 (15.4) 8 (3.9) 8.5 (1.6-42.9) 0.009 
Pulmonary hypoplasia 1 (3.9) 3 (1.5) 5.1 (0.79-33.5) 0.09 
Emphysema 1 (3.9) 0 (0.0) NA  
Pneumothorax 1 (3.9) 0 (0.0) NA  
Pulmonary haemorrhage 0 (0.0) 1 (0.5) NA  
Unadjusted OR, 95% CI and p-values were estimated using conditional logistic regression to 
account for the matching. Controls (n=203) are all the controls from the matched case-control 
sets. 
NA - no cases, or cell numbers less than 3; RDS – respiratory distress syndrome. 
* Temperature instability is defined by a neonate’s requirement for external temperature control 







Inflamed skin of colonised and non-colonised neonates that contributed weekly 
data 
Table 11 shows the areas of inflamed skin for colonised and non-colonised neonates 
who contributed weekly data to the matched case-control analysis. Among the 26 cases, 
12 (46.2%) had an area of inflamed skin. Among the 24 controls, 16 (66.7%) had an 
area of inflamed skin. Five (19.2%) colonised neonates and one (4.2%) non-colonised 
neonate had an inflamed axilla. Four (15.4%) cases and one (4.2%) control had 
inflamed skin at the site of an intravenous line.   
Table 11: Areas of inflamed skin identified among colonised and non-colonised 
neonates, Dunedin Hospital NICU, September 2013 through March 2015 
Inflamed skin Colonised neonates n= 26 
Non-colonised neonates 
n= 24 
 n (%) n (%) 
Any area 12 (46.2) 16 (66.7) 
Axilla 5 (19.2) 1 (4.2) 
Eye 3 (11.5) 3 (12.5) 
Buttocks 3 (11.5) 11 (45.8) 
IV line  4 (15.4) 1 (4.2) 
Ear 1 (3.8) 0 (0.0) 
Full body 1 (3.8) 2 (8.3) 
Groin 1 (3.8) 2 (8.3) 
Oral thrush 0 (0.0) 2 (8.3) 
Neck 1 (3.8) 1 (4.2) 
NICU – neonatal intensive care unit; IV – intravenous. 
 
 Procedures and devices 
The descriptive data for cases and controls, along with the unadjusted analysis for 
procedures and devices are shown in Table 12. The differences between cases and 
controls was not statistically significant for the use of peripherally inserted central 
catheters, umbilical artery catheters, or umbilical venous catheters. The odds of 
requiring invasive mechanical ventilation was 5.3 times higher among cases than 
among controls (OR 5.3, 95% CI: 1.6-17.7, p=0.007). Compared with no phototherapy, 
the odds of phototherapy for 3-6 days was 3.3 times higher among cases than among 




Table 12: Unadjusted analysis of the procedures and devices required by cases 
and controls, Dunedin Hospital NICU, September 2013 through March 2015 
 Cases n = 26 
Controls 




 n (%) n (%) OR (95% CI)  
Nasogastric tube  16  (61.5) 142 (70.0) 0.64 (0.22-2.1) 0.5 
Peripheral  IV cannula  16  (61.5) 128 (63.1) 0.5 (0.14-1.7) 0.3 
Orogastric tube  16  (61.5) 112 (55.2) 1.2 (0.27-4.8) 0.8 
Nasal CPAP  14  (53.9)  117 (57.6) 1.0 (0.33-3.0) 1.0 
PICC  16  (61.5) 77 (37.9) 2.2 (0.69-7.1) 0.2 
UVC  7  (26.9) 23 (11.3) 1.5 (0.44-4.9) 0.5 
UAC 3  (11.5) 10 (4.9) 1.2 (0.26-5.9) 0.8 
Invasive mechanical 
ventilation 
5  (19.2) 6 (3.0) 5.3 (1.6-17.7) 0.007 
Endotracheal intubation 2  (7.7) 4 (2.0) 3.0 (0.76-11.5) 0.1 
Nasal cannula 0  (0.0) 6 (3.0) NA  
ROP screen 0  (0.0) 4 (2.0) NA  
Blood tests          
Number, mean (sd) 12.2 (± 2.3) 8.5 (±0.6) 1.0 (0.98-1.1) 0.3 
Phototherapy        
None 16 (61.5) 135 (66.5) 1 (reference)  
1-2 days 5 (19.2) 58 (28.6) 0.48 (0.19-1.2) 0.1 
3-6 days 5 (19.2) 10 (4.9) 3.3 (1.1-9.6) 0.03 
RBC transfusion        
Number, mean (sd) 1.2 (± 0.2) 1.6 (±0.2) NA  
Apnoeas *        
Number, mean (sd) 8.8 (± 1.8) 10.7 (± 0.7) 1.0 (0.90-1.1) 1.0 
Type of stimulation        
Gentle  15 (57.7) 111 (54.7) 1.5 (0.63-3.4) 0.4 
Moderate  3 (11.5) 42 (20.7) 0.54 (0.14-2.0) 0.4 
Vigorous  0 (0.0) 8 (3.9) NA  
Funnel/facial O2 11 (42.3) 105 (51.7) 0.92 (0.42-2.0) 0.8 
Unadjusted OR, 95% CI and p-values were estimated using conditional logistic regression to 
account for the matching. Controls (n=203) are all the controls from the matched case-control 
sets. 
NA - no cases, or cell numbers less than 3; IV – intravenous; CPAP – continuous positive 
airway pressure; PICC – peripherally inserted central catheter; UVC – umbilical vein catheter; 
UAC – umbilical artery catheter; ROP - retinopathy of prematurity; sd – standard deviation; O2 
– oxygen. 








Procedures performed outside the NICU or by allied health professionals  
The data regarding procedures performed outside of the NICU or by allied health 
professionals are shown in Table 13. The odds of having a head ultrasound scan 
(HUSS) was 2.5 times higher among cases than among controls (OR 2.5, 95% CI 1.1-
5.8, p=0.03). Procedures that were only performed among either cases or controls did 
not produce interpretable ORs or 95% CIs. 
Table 13: Unadjusted analysis of procedures performed outside the NICU or by 
allied health professionals required by cases and controls, Dunedin Hospital 
NICU, September 2013 through March 2015 
 Cases n = 26 
Controls 




 n (%) n (%) OR (95% CI)  
Radiography  12  (46.2) 89 (43.8) 0.86 (0.32-2.3) 0.8 
Head ultrasound scan  13  (50.0) 48 (23.7) 2.5 (1.1-5.8) 0.03 
Echocardiogram  4  (15.4) 26 (12.8) 0.95 (0.29-3.1) 0.9 
Abdominal ultrasound  1  (3.9) 19 (9.4) 0.14 (0.01-1.7) 0.1 
Hearing screen 0  (0.0) 9 (4.4) NA  
Eye check  0  (0.0) 8 (3.9) NA  
Lumbar puncture 0  (0.0) 2 (1.0) NA  
Electroencephalogram 0  (0.0) 1 (0.5) NA  
Spinal ultrasound scan 1 (3.9) 0 (0.0) NA  
Unadjusted OR, 95% CI and p-values were estimated using conditional logistic regression to 
account for the matching. Controls (n=203) are all the controls from the matched case-control 
sets. 
NA - no cases, or cell numbers less than 3; NICU – neonatal intensive care unit. 
 
 Enteral feeds 
Descriptive information and unadjusted odds ratios comparing enteral feeds among 
cases and controls is shown in Table 14. Enteral feeds for neonates in the Dunedin 
Hospital NICU included breast milk, expressed breast milk, donor breast milk, or 
formula. The odds of being fed with formula was 66% lower among cases that among 
controls (OR 0.34, 95% CI 0.13-0.88, p=0.03). Neonates were fed via a nasogastric 
tube, orogastic tube, breast, bottle, syringe, cup, or finger. Neonates that are unable to 
use regular teats due to a cleft palate use Haberman teats. No case, and three (1.5%) 
controls used Haberman teats to assist with bottle feeds. The difference between cases 




 Table 14: Unadjusted analysis of enteral feedings method by cases and controls, 
Dunedin Hospital NICU, September 2013 through March 2015 
 Unadjusted OR, 95% CI and p-values were estimated using conditional logistic regression to 
account for the matching. Controls (n=203) are all the controls from the matched case-control 
sets. 
NA - no cases, or cell numbers less than 3; sd – standard deviation; NGT – nasogastric tube; 
OGT – orogastric tube 










 n (%) n (%) OR (95% CI)  
Number of feeds per 
week, mean (sd) 
28.9 (± 2.8) 28.4 (± 1.0) 1.0 (0.99 – 1.1) 0.2 
Type of food *        
Expressed breast milk 23 (88.5) 165 (81.3) 1.7 (0.50 – 5.6) 0.4 
Breast milk 6 (23.1) 48 (23.7) 1.1 (0.37 – 3.2) 0.9 
Donor breast milk 0 (0.0) 0 (0.0) NA  
Human milk fortifier 6 (23.1) 55 (27.1) 1.6 (0.50-5.3) 0.4 
Formula 6 (23.1) 100 (49.3) 0.34 (0.13 – 0.88) 0.03 
Mode of feeding        
NGT 13 (50.0) 123 (60.6) 0.61 (0.22 – 1.7) 0.3 
OGT  16 (61.5) 113 (55.7) 1.5 (0.27 – 8.0) 0.7 
Breast feeds 6 (23.1) 49 (24.1) 1.1 (0.37 – 3.1) 0.9 
Bottle 2 (7.7) 31 (15.3) 0.43 (0.09 – 2.1) 0.3 
Syringe 3 (11.5) 36 (17.7) 0.40 (0.11 – 1.4) 0.1 
Cup 1 (3.9) 18 (8.9) 0.30 (0.03 – 3.3) 0.3 
Finger 0 (0.0) 6 (3.0) NA  




 Weight during the exposure week  
The number of times the neonates were weighed, the average weight over the exposure 
week and the unadjusted odds ratios comparing cases and controls are shown in Table 
15. There was no statistically significant difference between cases and controls for 
either the number of times the neonates were weighed during the exposure week, or for 
their average weight. 
Table 15: Unadjusted analysis of the weight cases and controls, Dunedin Hospital 
NICU, September 2013 through March 2015 
 Cases 
n = 26 
Controls 
n = 203 
Unadjusted p-
value 
 n (%) n (%) OR (95% CI)  
Times weighed        
0 1 (3.9) 0 (0.0) NA  
1 2 (7.7) 12 (5.9) 1 (reference)  
2 9 (34.6) 71 (35.0) 1.2 (0.2-7.0) 0.8 
3 11 (42.3) 97 (47.8) 0.86 (0.17-4.3) 0.9 
4 3 (11.5) 23 (11.3) 1.4 (0.17-11.1) 0.8 
Average weight        
g, mean (sd) *  1,610 (±140.5) 1,826 (± 48.8) 0.97 (0.90-1.0) 0.4 
Unadjusted OR, 95% CI and p-values were estimated using conditional logistic regression to 
account for the matching. Controls (n=203) are all the controls from the matched case-control 
sets. 
NA - no cases, or cell numbers less than 3; NICU – neonatal intensive care unit; sd – standard 
deviation. 
*Average weight was per 100g for the univariate analysis. 
 Type of bed, bed spaces, and rooms 
The unadjusted analysis of the type of bed, bed spaces, and rooms that were occupied 
by cases and controls is shown in Table 16. The difference between cases and controls 
was not statistically significant for the type of bed they occupied, nor if they changed 
from incubator to cot.  
The Dunedin Hospital NICU has 16 rooms and 26 bed spaces for neonates (Figure 3). 
The rooms occupied most often are shown in Figures 8 and 9. The differences between 




Table 16: Bed spaces occupied during cases and controls, Dunedin Hospital NICU, 
September 2013 through March 2015 






 n (%) n (%) OR (95% CI)  
Type of bed        
Incubator 21 (80.8) 162 (79.8) 1.2 (0.34-4.4) 0.8 
Cot 8 (30.8) 86 (42.4) 0.48 (0.14-1.6) 0.2 
Change, incubator to cot 4 (15.4) 61 (30.1) 0.30 (0.07-1.3) 0.1 
Bed space *        
2 0 (0.0) 0 (0.0) NA  
3 0 (0.0) 4 (2.0) NA  
4 0 (0.0) 0 (0.0) NA  
5a 2 (7.7) 12 (5.9) 1.8 (0.28-10.9) 0.5 
5b 0 (0.0) 8 (3.9) NA  
5c 0 (0.0) 8 (3.9) NA  
5d 0 (0.0) 3 (1.5) NA  
6a 3 (11.5) 13 (6.4) 0.72 (0.20-2.5) 0.6 
6b 2 (7.7) 0 (0.0) NA  
7a 0 (0.0) 13 (6.4) NA  
7b 2 (7.7) 24 (11.8) 1.0 (0.24-4.4) 1.0 
7c 4 (15.4) 24 (11.8) 1.7 (0.56-5.2) 0.4 
7d 2 (7.7) 16 (7.9) 0.76 (0.14-4.2) 0.8 
8 0 (0.0) 2 (1.0) NA  
9 2 (7.7) 15 (7.4) 0.79 (0.17-3.6) 0.8 
10 1 (3.9) 13 (6.4) 0.51 (0.05-5.3) 0.6 
11a 4 (15.4) 44 (21.2) 0.95 (0.31-2.9) 1.0 
11b 5 (19.2) 30 (14.8) 1.4 (0.49-3.8) 0.5 
11c 2 (7.7) 14 (6.9) 1.6 (0.34-7.6) 0.5 
11d 4 (15.4) 11 (5.4) 1.7 (0.32-8.6) 0.5 
Bed space changes        
0 20 (76.9) 141 (69.5) 1 (reference)  
1 4 (15.4) 46 (22.7) 0.41 (0.12-1.4) 0.2 
2 2 (7.7) 16 (7.9) 0.68 (0.12-3.8) 0.7 
Rooms        
5 2 (7.7) 29 (14.3) 0.45 (0.07-2.7) 0.4 
6 5 (19.2) 14 (6.9) 1.2 (0.41-3.6) 0.7 
7 7 (26.9) 78 (38.4) 0.58 (0.20-1.7) 0.3 
11 15 (57.7) 94 (46.3) 1.6 (0.74-3.7) 0.2 
Unadjusted OR, 95% CI and p-values were estimated using conditional logistic regression to 
account for the matching. Controls (n=203) are all the controls from the matched case-control 
sets. 
NA - no cases, or cell numbers less than 3, NICU – neonatal intensive care unit. 






 Movement of cases between bed spaces  
This section investigates the bed spaces occupied by the cases. Figure 8 shows the bed 
spaces cases occupied, and the change of bed spaces for individual cases during the 
exposure week. Figure 8 also shows the incidence rate of S. capitis positive neonates 
per study neonate week per room. The incidence rates ranged from 0.07-0.4, with the 
lowest in room 5 and the highest in room 6. During the 83 week retrospective study, 
there were 10 weeks from 9 December 2013 (study week 13) to 10 February 2013 
(study week 22) with at least one new case per week. Room 11 had the most 
consecutive weekly cases. In room 11, a 4 different neonates became a case each week 








- The study week number that cases had their exposure week 16 - Cases 
- Bed space movement of a single case during their exposure week 
- Cases whose exposure weeks occur in consecutive weeks in the same room 
0.3 - Incidence rate of the number of S. capitis positive neonates per study neonate week  
per room. Calculated as the number of cases over the number of controls per room 
throughout the study period 
Figure 8: Diagram of the bed spaces the cases occupied during the exposure 
week, Dunedin Hospital NICU, 9 September 2013 (week 0) through 31 March 




Among the neonates born as a part of a multiple birth, all were twins. Among the 
neonates with a twin that became a case, all became a case within one week of their 
twin. Twin cases in our study and the bed spaces they occupied are shown in Figure 9. 
Three of the four sets of twins shared the same room during their exposure weeks. One 
set of twins were both in bed space 7b, in a twin cot, during week 15 when the first twin 
















- Bed space movement of a single case during their exposure week 
16 - The study week number that cases had their exposure week 
-  
- Cases whose exposure weeks occur in consecutive weeks in the same room 
-  
 
- Cases whose exposure weeks occur in consecutive weeks in the same room 
-  
 
- Cases whose exposure weeks occur in consecutive weeks in the same room 
-  
 
Figure 9: Diagram of the bed spaces the twins that became cases occupied 





 Nested case-control adjusted analysis 
The analyses adjusted for GA, and GA and length of stay for all variables with ten or 
more observations are shown in Table 17. After adjustment for both GA and length of 
stay, the odds of being born as a part of a multiple birth was 86% lower among cases 
than among controls (OR 0.14, 95% CI 0.04-0.40, p=<0.001). After adjusting for GA 
the odds of metronidazole use was 92% lower among cases than among controls (OR 
0.08, 95% CI 0.01 – 0.90, p=0.04). However, after adjusting for length of stay and GA 
the difference between cases and controls for metronidazole use was no longer 
statistically significant (OR 0.08, 95% CI 0.01-1.1, p=0.06).  
The difference between cases and controls for Infloran probiotic use was no longer 
statistically significant after adjusting for GA (OR 3.5, 95% CI 0.69-17.6, p=0.1). The 
difference between cases and controls for caffeine use was no longer statistically 
significant after adjusting for GA (OR 2.9, 95% CI: 0.50-7.0, p=0.2). After adjusting 
for GA and length of stay, the odds of oral NaCl use was 6.1 times higher among cases 
than among controls (OR 6.1, 95% CI 1.4-27.1, p=0.02). The difference between cases 
and controls for chlorthiazide and spironolactone use was no longer statistically 
significant after adjusting for GA (OR 2.8, 95% CI 0.85-9.1, p=0.09).  
The difference between cases and controls for temperature instability was no longer 
statistically significant after adjusting for GA (OR 3.7, 95% CI 0.76-17.9, p=0.1). After 
adjusting for GA and length of stay, the odds of having an area of inflamed skin was 
69% lower among cases than among controls (OR 0.31, 95% CI 0.13-0.70, p=0.005). 
The difference between cases and controls for specific areas of inflamed skin were not 
statistically significant after unadjusted analysis. However, after adjusting for GA, the 
odds of having an inflamed axilla was 91% lower among cases than among controls 
(OR 0.09, 95% CI 0.02-0.44, p=0.003). The difference between cases and controls for 
having an inflamed axilla remained statistically significant after adjusting for GA and 
length of stay (OR 0.31, 95% CI 0.13-0.70, p=0.005).  
The difference between cases and controls for cardiac abnormalities was no longer 




adjusting for GA, the odds of having a PDA was 2.9 times higher among cases than 
among controls (OR 2.9, 95% CI 1.1-7.9, p=0.04). The difference between cases and 
controls for CLD was no longer statistically significant after adjusting for GA (OR 4.9 
95% CI 0.97 – 24.3, p=0.06). However, after adjusting for both GA and length of stay 
the odds of having CLD was 4.8 times higher among cases than among controls (OR 
4.8, 95% CI 1.1-22.3, p=0.04).  
After adjusting for GA and length of stay, the odds of requiring invasive mechanical 
ventilation was 3.4 times higher among cases than among controls (OR 3.4, 95% CI 
1.1-10.4, p=0.03). The difference between cases and controls for 3-6 days of 
phototherapy, compared to no phototherapy, was no longer statistically significant after 
adjusting for GA and length of stay (OR 2.5, 95% CI 0.71-8.4, p=0.2). The difference 
between cases and controls for requirement of a head ultrasound scan was also not 
statistically significant after adjusting for GA and length of stay (OR 1.3, 95% CI 0.33-
5.3, p=0.7). 
The difference between cases and controls for having enteral feeds with formula was no 
longer statistically significant after adjusting for GA (OR 0.50, 95% CI 0.19-1.3, 
p=0.2). However, after adjusting for both GA and length of stay the odds of having 
enteral feeds with formula was 71% lower among cases than among controls (OR 0.29, 




Table 17: Gestational age and length of stay adjusted analysis of cases and controls, Dunedin Hospital neonatal intensive care unit, 
September 2013 through March 2015 
 Unadjusted  p-value Adjusted for gestational age p-value 
Adjusted for 
gestational age and 
length of stay 
p-value 
Baseline characteristics OR 95% CI  OR 95% CI  OR 95% CI  
Female 0.68  (0.23-2.1) 0.5 0.50 (0.15-1.6) 0.2 0.48 (0.14-1.5) 0.2 
Ethnicity          
Non- Māori 1.3 (0.50-3.4) 0.6 1.5 (0.50-4.6) 0.5 1.7 (0.48-6.2) 0.4 
Māori 1 (reference)  1 (reference)  1 (reference)  
Delivery type           
Caesarean section 2.2 (0.41-12.4) 0.4 1.2 (0.17-8.3) 0.9 1.2 (0.16-8.5) 0.9 
Multiple birth 0.24  (0.08-0.67) 0.007 0.14 (0.05-0.41) <0.001 0.14 (0.04-0.4) <0.001 
Born in Dunedin Hospital 4.1 (0.60-27.8) 0.2 3.5 (0.54-23.0) 0.2 4.1 (0.68-24.7) 0.1 
Antimicrobials          
Any antimicrobials 1.9 (0.54-6.6) 0.3 1.0 (0.20-5.7) 0.9 1.1 (0.20-5.6) 0.9 
Antibacterials          
Amoxicillin 1.5 (0.58-3.9) 0.4 1.4 (0.52-3.9) 0.5 1.4 (0.51-3.9) 0.5 
Gentamicin 1.4 (0.52-3.7) 0.5 1.5 (0.56-3.8) 0.4 1.6 (0.57-4.3) 0.4 
Metronidazole 0.22 (0.03-1.9) 0.2 0.08 (0.01-0.90) 0.04 0.08 (0.01-1.1) 0.06 
Amikacin 1.5 (0.41-5.3) 0.5 1.1 (0.23-5.3) 0.9 1.0 (0.18-5.5) 1.0 
Chloramphenicol 1.1 (0.13-8.6) 1.0 2.1 (0.20-21.4) 0.5 2.0 (0.21-19.2) 0.5 
Cefotaxime 1.9 (0.23-15.9) 0.5 2.2 (0.22-22.1) 0.5 2.2 (0.20-23.0) 0.5 
Antifungals          
Fluconazole 2.1 (0.85-5.4) 0.1 0.37 (0.04-3.4) 0.4 0.35 (0.04-3.4) 0.4 
S. capitis resistance          
Composite * 1.2 (0.45-3.3) 0.7 1.0 (0.34-3.1) 1.0 1.0 (0.34-3.2) 1.0 
Other medications          
Any other medications 0.76 (0.07-7.9) 0.8 0.36 (0.03-3.7) 0.4 0.30 (0.03-3.3) 0.3 
Infloran probiotics † 5.2 (1.5-18.0) 0.009 3.5 (0.69-17.6) 0.1 3.5 (0.75-16.3) 0.1 
Caffeine 5.2 (1.1-24.5) 0.04 2.9 (0.50-7.0) 0.2 2.9 (0.53-15.5) 0.2 






 Unadjusted  p-value Adjusted for gestational age p-value 
Adjusted for 
gestational age and 
length of stay 
p-value 
Other medications OR 95% CI  OR 95% CI  OR 95% CI  
Supplements          
Vitadol C § 0.47 (0.15-1.4) 0.2 0.60 (0.19-1.9) 0.4 0.53 (0.16-1.8) 0.3 
Iron 1.5 (0.05-48.0) 0.8 0.94 (0.02-37.1) 1.0 0.87 (0.02-33.4) 0.9 
Supplements          
Oral NaCl 10.0 (2.0-48.8) 0.004 6.1 (1.3-29.2) 0.02 6.1 (1.4-27.1) 0.02 
Pain relief          
Sucrose ǁ  1.9 (0.44-7.7) 0.4 2.0 (0.58-7.2) 0.3 2.1 (0.57-8.1) 0.3 
Diuretics          
Chlorthiazide + spironolactone 4.3 (1.5-13.0) 0.009 2.84 (0.94-8.6) 0.06 2.8 (0.85-9.1) 0.09 
Injectables          
Total parental nutrition 1.9 (0.46-7.6) 0.4 0.69 (0.18-2.7) 0.6 0.64 (0.15-2.8) 0.6 
Lipids 2.0 (0.49-8.4) 0.3 0.74 (0.18-3.1) 0.7 0.69 (0.15-3.2) 0.6 
Dextrose 1.0 (0.45-2.4) 0.9 1.1 (0.47-2.5) 0.8 1.1 (0.47-2.5) 0.8 
Glucose 0.96 (0.26-3.5) 1.0 0.51 (0.11-2.5) 0.4 0.48 (0.09-2.5) 0.4 
IV NaCl  1.2 (0.41-3.4) 0.8 1.2 (0.37-3.4) 0.8 1.1 (0.34-3.4) 0.9 
Heparinised saline 1.2 (0.26-5.9) 0.8 0.64 (0.11-3.7) 0.6 0.60 (0.10-3.6) 0.6 
Medical history          
Feed intolerance 0.5 (0.13-1.7) 0.2 0.31 (0.08-1.2) 0.08 0.29 (0.07-1.1) 0.07 
Gastric aspirate 0.5 (0.14-2.1) 0.4 0.36 (0.09-1.5) 0.2 0.33 (0.08-1.4) 0.1 
Temperature instability ¶ 2.7 (1.0-6.8) 0.04 3.0 (0.99-9.1) 0.05 3.7 (0.76-17.9) 0.1 
Skin injury 0.95 (0.32-2.9) 0.9 0.75 (0.25-2.2) 0.6 0.75 (0.24-2.3) 0.6 
Sepsis workup 1.9 (0.71-5.3) 0.2 1.9 (0.74-5.0) 0.2 1.9 (0.74-4.90) 0.2 
Area of inflamed skin 0.28 (0.11-0.73) 0.009 0.30 (0.13-0.69) 0.004 0.31 (0.13-0.70) 0.005 
Axilla 0.28 (0.06-1.4) 0.1 0.09 (0.02-0.44) 0.003 0.09 (0.02-0.44) 0.003 
Eye 1.2 (0.33-4.3) 0.8 2.85 (0.51-15.8) 0.2 2.8 (0.51-15.0) 0.2 
Buttocks 0.38 (0.08-1.9) 0.2 0.87 (0.15-5.0) 0.9 0.91 (0.15-5.6) 0.9 
IV line  0.3 (0.04-2.5) 0.3 0.26 (0.05-1.4) 0.1 0.26 (0.05-1.4) 0.1 
Cardiac abnormalities 2.6 (1.1-6.0) 0.03 2.1 (0.80-5.5) 0.1 2.1 (0.78-5.5) 0.1 






 Unadjusted  p-value Adjusted for gestational age p-value 
Adjusted for 
gestational age and 
length of stay 
p-value 
Cardiac abnormalities OR 95% CI  OR 95% CI  OR 95% CI  
Murmur 0.94 (0.35-2.5) 0.9 0.70 (0.22-2.2) 0.5 0.71 (0.22-2.3) 0.6 
Septal defects 0.5 (0.05-5.5) 0.6 0.37 (0.03-4.3) 0.4 0.35 (0.03-4.5) 0.4 
Pulmonary disease 1.7 (0.44-6.7) 0.2 1.1 (0.37-3.3) 0.9 1.0 (0.33-3.3) 0.9 
Respiratory distress syndrome 2.5 (0.61-10.5) 0.2 1.5 (0.47-4.8) 0.5 1.4 (0.40-5.2) 0.6 
Chronic lung disease 8.5 (1.6-42.9) 0.009 4.9 (0.97-24.3) 0.06 4.8 (1.1-22.3) 0.04 
Procedures and devices          
Nasogastric tube  0.64 (0.22-2.1) 0.5 1.8 (0.33-10.2) 0.5 1.9 (0.30-11.21) 0.5 
Peripheral IV  0.5 (0.14-1.7) 0.3 0.43 (0.12-1.5) 0.2 0.40 (0.09-1.68) 0.2 
Orogastric tube  1.24 (0.27-4.8) 0.8 0.26 (0.05-1.4) 0.1 0.27 (0.05-1.36) 0.1 
Nasal CPAP  1.0 (0.33-3.0) 1.0 0.26 (0.06-1.2) 0.09 0.23 (0.05-1.10) 0.07 
PICC 2.2 (0.69-7.1) 0.2 0.53 (0.05-5.4) 0.6 0.54 (0.05-6.05) 0.6 
Umbilical vein catheter 1.5 (0.44-4.9) 0.5 0.91 (0.29-2.9) 0.9 0.89 (0.28-2.82) 0.8 
Umbilical artery catheter 1.2 (0.26-5.9) 0.8 0.34 (0.11-3.7) 0.6 0.60 (0.10-3.63) 0.6 
Invasive mechanical ventilation 5.3 (1.6-17.7) 0.007 3.4 (1.2-9.9) 0.02 3.4 (1.1-10.4) 0.03 
Blood tests           
Number, mean  1.02 (0.98-1.07) 0.3 0.99 (0.94-1.0) 0.8 0.99 (0.94-1.04) 0.7 
Phototherapy           
None 1 (reference)  1 (reference)  1 (reference)  
1-2 days 0.48 (0.19-1.2) 0.1 0.50 (0.19-1.3) 0.1 0.52 (0.19-1.4) 0.2 
3-6 days 3.3 (1.1-9.6) 0.03 2.2 (0.73-6.6) 0.2 2.5 (0.71-8.4) 0.2 
Apnoeas requiring stimulation           
Number, mean  1.0 (0.90-1.1) 1.0 0.97 (0.87-1.1) 0.6 0.97 (0.87-1.1) 0.6 
Type of stimulation          
Gentle stimulation 1.47 (0.63-3.43) 0.4 0.82 (0.31-2.2) 0.7 0.81 (0.32-2.1) 0.7 
Moderate stimulation 0.54 (0.14-2.02) 0.4 0.24 (0.05-1.1) 0.07 0.23 (0.05-1.1) 0.07 
Funnel/facial O2 0.92 (0.42-2.02) 0.8 0.43 (0.16-1.2) 0.1 0.44 (0.17-1.1) 0.09 
Radiography 0.86 (0.32-2.3) 0.8 0.53 (0.20-1.4) 0.2 0.41 (0.12-1.40) 0.2 
Head ultrasound scan  2.5 (1.1-5.8) 0.03 1.4 (0.38-5.0) 0.6 1.33 (0.33-5.26) 0.7 







 Unadjusted  p-value Adjusted for gestational age p-value 
Adjusted for 
gestational age and 
length of stay 
p-value 
Other procedures OR 95% CI  OR 95% CI  OR 95% CI  
Abdominal ultrasound  0.14 (0.01-1.7) 0.1 0.20 (0.02-2.2) 0.2 0.20 (0.02-2.08) 0.2 
Enteral feedings          
Total number of feeds 1.0 (0.99-1.1) 0.2 1.0 (0.98-1.1) 0.3 1.02 (0.98-1.06) 0.3 
Type of food          
Expressed breast milk 1.7 (0.50-5.6) 0.4 2.3 (0.56-9.4) 0.2 3.27 (0.68-15.82) 0.1 
Breast milk 1.1 (0.37-3.2) 0.9 2.1 (0.67-6.4) 0.2 2.64 (0.70-9.92) 0.2 
Human milk fortifier 1.6 (0.50-5.31) 0.4 1.4 (0.36-5.3) 0.6 1.44 (0.36-5.83) 0.6 
Formula 0.34 (0.13-0.88) 0.03 0.50 (0.19-1.3) 0.2 0.29 (0.08-0.99) 0.05 
Mode of feeding          
Nasogastric tube 0.61 (0.22-1.70) 0.3 2.5 (0.32-19.7) 0.4 2.44 (0.34-17.80) 0.4 
Orogastric tube 1.48 (0.27-7.98) 0.7 0.29 (0.04-2.0) 0.2 0.29 (0.04-1.94) 0.2 
Breast feeds 1.08 (0.37-3.12) 0.9 2.1 (0.67-6.35) 0.2 2.63 (0.70-10.0) 0.2 
Bottle 0.43 (0.09-2.12) 0.3 0.64 (0.10-4.0) 0.6 0.60 (0.08-4.5) 0.6 
Syringe 0.40 (0.11-1.38) 0.1 0.80 (0.21-3.1) 0.7 0.86 (0.17-4.4) 0.9 
Cup 0.30 (0.03-3.25) 0.3 0.50 (0.05-4.6) 0.5 0.52 (0.05-5.1) 0.6 
Weight          
Times weighed          
1 1 (reference)  1 (reference)  1 (reference)  
2 1.2 (0.21-7.0) 0.8 1.4 (0.41-4.8) 0.6 1.4 (0.39-4.9) 0.6 
3 0.86 (0.17-4.3) 0.9 1.0 (0.29-1.7) 1.0 1.0 (0.29-3.6) 1.0 
4 1.4 (0.17-11.1) 0.8 1.0 (1.13-7.8) 1.0 0.98 (0.12-8.1) 1.0 
Average weight ◊          
g, mean  1.0 (1.0-1.0) 0.4 1.0 (1.0-1.0) 0.4 1.0 (1.0-1.0) 0.4 
Type of bed          
Incubator 1.2 (0.34-4.4) 0.8 0.60 (0.13-2.8) 0.5 0.59 (0.12-2.9) 0.5 
Cot 0.48 (0.14-1.6) 0.2 1.4 (0.40-5.1) 0.6 1.4 (0.39-5.0) 0.6 
Changed from incubator to cot 0.30 (0.07-1.3) 0.1 0.54 (0.11-2.7) 0.5 0.55 (0.11-2.8) 0.5 
Bed spaces          






 Unadjusted  p-value Adjusted for gestational age p-value 
Adjusted for 
gestational age and 
length of stay 
p-value 
Bed spaces OR 95% CI  OR 95% CI  OR 95% CI  
6a 0.72 (0.20-2.5) 0.6 0.85 (0.21-3.5) 0.8 0.83 (0.19-3.7) 0.8 
7b 1.0 (0.24-4.4) 1.0 4.1 (0.69-24.4) 0.1 4.3 (0.69-27.5) 0.1 
7c 1.7 (0.56-5.2) 0.4 3.7 (0.99-13.5) 0.05 3.6 (0.95-13.6) 0.06 
7d 0.76 (0.14-4.2) 0.8 0.90 (0.18-4.3) 0.9 0.87 (0.16-4.7) 0.9 
9 0.79 (0.17-3.6) 0.8 0.43 (0.06-2.9) 0.4 0.35 (0.04-2.9) 0.3 
10 0.51 (0.05-5.3) 0.6 0.31 (0.03-3.7) 0.4 0.28 (0.02-3.3) 0.3 
11a 0.95 (0.31-2.9) 0.9 0.56 (0.19-1.7) 0.3 0.57 (0.19-1.7) 0.3 
11b 1.4 (0.49-3.8) 0.5 0.88 (0.32-2.4) 0.8 0.92 (0.32-2.7) 0.9 
11c 1.6 (0.34-7.6) 0.5 1.5 (0.43-5.2) 0.5 1.5 (0.43-5.1) 0.5 
11d 1.7 (0.32-8.6) 0.5 4.0 (0.69-22.6) 0.1 4.2 (0.78-23.5) 0.1 
Bed space changes          
0 1 (reference)  1 (reference)  1 (reference)  
1 0.41 (0.12-1.4) 0.2 0.49 (0.13-2.0) 0.3 0.49 (0.12-2.0) 0.3 
2 0.68 (0.12-3.8) 0.7 1.2 (0.19-7.0) 0.9 1.2 (0.18-7.2) 0.3 
Rooms           
5 0.45 (0.07-2.7) 0.4 0.75 (0.11-5.2) 0.8 0.75 (0.11-5.2) 0.8 
6 1.2 (0.41-3.6) 0.7 1.8 (0.51-6.2) 0.4 1.8 (0.48-6.7) 0.4 
7 0.58 (0.20-1.7) 0.3 1.2 (0.30-5.1) 0.8 1.2 (0.27-5.2) 0.8 
11 1.6 (0.74-3.7) 0.2 1.2 (0.49-2.8) 0.7 1.4 (0.45-4.5) 0.6 
Unadjusted OR, 95% CI and p-values were estimated using conditional logistic regression to account for the matching. Adjusted analysis was not performed 
for variables that had no cases, or cell number <10. CPAP – continuous positive airway pressure; PICC – peripherally inserted central catheter. 
* Composite includes antibacterials against which S. capitis has resistance: amoxicillin, gentamicin, fusidic acid, metronidazole, and cefotaxime. 
† Infloran probiotics contains Bifidobacterium bifidum and Lactobacillus acidophilus. 
‡ Micelle E is a vitamin E formulation given for prevention of retinopathy of prematurity.  
§ Vitadol C contains vitamin A, vitamin D and vitamin C. 
ǁ  Oral sucrose is given as a pain relief for minor procedures. 
¶ Temperature instability was defined by a neonate’s requirement of clothing changes or incubator temperature changes to regulate their temperature. 




 Prospective study population 
The prospective study progress report period includes 1 July 2017 through 28 February 
2018. The admissions and total number of S. capitis colonised neonates for the 
prospective study report period is shown in Figure 5. The flow diagram of admissions 
and their eligibility for inclusion in the prospective study is shown in Figure 10. Of the 
222 neonates admitted to the NICU during the report period, 29 (13.1%) were swabbed 
at least once. Of the 193 (85.8%) not swabbed, 164 (85.0%) did not meet the 
gestational age criterion for receiving a swab test, 13 (6.7%) did not receive a swab test 
for unknown reasons, 9 (4.7%) were discharged before receiving their scheduled swab 
test, and 7 (3.6%) were transferred to another hospital before receiving their scheduled 
swab test. Among the 29 neonates swabbed at least once, 20 (69.0%) were eligible for 
participation. Of the 9 (31.0%) neonates ineligible for participation, 5 (55.6%) were 
excluded on the basis of not being admitted for long enough to receive ≥2 swabs, and 4 
(44.4%) because of a positive initial swab. 
Of the 20 eligible neonates, informed consent was provided for 13 (65.0%). Among the 
13 participating neonates, one (7.7%) was colonised with S. capitis and 12 (92.3%) 
were not colonised. Of the 7 (35.0%) neonates not included because of lack of consent, 
6 (85.7%) were on the basis of the parents declining consent for the neonate’s 
participation, and one (14.3%) because the neonate was transferred before the informed 
consent process could be completed. For all of the neonate participants their birth 






































Figure 10: Flow diagram of the neonates and their eligibility of participation in the 
prospective study, Dunedin Hospital NICU, July 2017 through February 2018 
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 Baseline characteristics of the study cohort 
Table 18 shows the baseline characteristics for all participants, colonised, and non-
colonised neonates during the prospective study report period. Among the 13 
participants, 11 (84.6%) were New Zealand European, one (7.7%) was an ‘other’ 
ethnicity and one (7.7%) was supressed to protect confidentiality. The colonised 
neonate’s gestational age was 27.9 weeks, while the mean (standard deviation) 
gestational age for non-colonised neonates was 31.0 (±0.8) weeks. The colonised 
neonate’s birthweight was 1,075g and the mean (standard deviation) birthweight for 
non-colonised neonates was 1,427 (±122.8) g.  
Table 19 shows the baseline characteristics of the mothers of all participants, colonised, 
and non-colonised neonates. The mother of the colonised neonates did not use 
antimicrobials during pregnancy. Among the mothers of the non-colonised neonates, 4 
(33.3%) used antimicrobials during pregnancy. The mother of the colonised neonate 
had group B Streptococcus colonisation confirmed by positive combined vaginal and 
rectal swab. Among the mothers of the non-colonised neonates, none were positive for 
group B Streptococcus, 1 (8.3%) had chorioamnionitis and 1 (8.3%) had an infection 









Table 18: Baseline characteristics of all neonatal participants, colonised, and non-
colonised neonates, Dunedin Hospital NICU, July 2017 through March 2018 
NICU- neonatal intensive care unit; GA – gestational age; sd – standard deviation. 
NA – did not collect date of discharge. 




 All participants 
n = 13 
Colonised 
neonates 
n = 1 
Non-colonised 
neonates 
n = 12 
Demographics n (%) n (%) n (%) 
Sex       
Female 9 (69.2) 1 (100.0) 8 (66.7) 
Ethnicity *       
New Zealand European 12 (92.3)    11 (91.7) 
Māori 0 (0.0)  0 (0.0) 
Samoan 0 (0.0)  0 (0.0) 
Cook Island  Māori 0 (0.0)  0 (0.0) 
Tongan 0 (0.0)  0 (0.0) 
Niuean 0 (0.0)  0 (0.0) 
Chinese 0 (0.0)  0 (0.0) 
Indian 0 (0.0)  0 (0.0) 
Other: Kiribae/Tuvalu 1 (7.7)  1 (8.3) 
Birth       
GA, weeks, mean (sd) 30.8 (±0.78) 27.9 (±0.0) 31.0 (±0.81) 
Birthweight, g, mean (sd) 1,400 (±116.2) 1,075 (±0.0) 1,427 (±122.8) 
Delivery type       
Caesarian section 10 (76.9) 1 (100.0) 9 (75.0) 
Vaginal delivery tools       
Forceps 1 (7.7) 0 (0.0) 1 (8.3) 
Ventouse 0 (0.0) 0 (0.0) 0 (0.0) 
Multiple births  4 (30.8) 0 (0.0) 4 (33.3) 
Born in Dunedin Hospital  12 (92.3) 1 (100.0) 11 (91.7) 
In the NICU       
Length of stay, days, mean 
(sd) 
NA NA NA 
Vital status at discharge       
Deceased, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 
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Table 19: Baseline characteristics of the mothers of all participants, colonised and 
non-colonised, Dunedin Hospital NICU, July 2017 through March 2018 
NICU- neonatal intensive care unit; IUGR – intrauterine growth restriction; PROM – premature 
rupture of membranes. 
 
  
 All participants 
n = 13 
Colonised 
neonates 
n = 1 
Non-colonised 
neonates 
n = 12 
Current pregnancy       
Used any antimicrobials 4 (30.8) 0 (0.0) 4 (33.3) 
Types of antimicrobials       
Metronidazole 2 (15.4) 0 (0.0) 2 (16.7) 
Amoxicillin 1 (7.7) 0 (0.0) 1 (8.3) 
Cephazolin 1 (7.7) 0 (0.0) 1 (8.3) 
Erythromycin 1 (7.7) 0 (0.0) 1 (8.3) 
Gentamicin 1 (7.7) 0 (0.0) 1 (8.3) 
Medical history        
Cerclage 0 (0.0) 0 (0.0) 0 (0.0) 
Chorioamnionitis 1 (7.7) 0 (0.0) 1 (8.3) 
Gestational diabetes 0 (0.0) 0 (0.0) 0 (0.0) 
IUGR 4 (30.8) 0 (0.0) 4 (33.3) 
PROM 6 (46.2) 0 (0.0) 6 (50.0) 
Group B Streptococcus 1 (7.7) 1 (100.0) 0 (0.0) 
Premature delivery 13 (100.0) 1 (100.0) 12 (100.0) 
Maternal infection 1 (7.7) 0 (0.0) 1 (8.3) 
Family       
Number of other live births       
0 10 (76.9) 1 (100.0) 9 (75.0) 
1 2 (15.4) 0 (0.0) 2 (16.7) 
2 1 (7.7) 0 (0.0) 1 (8.3) 
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6  Discussion 
Following adjustment for GA and length of stay, the retrospective study showed that 
premature neonates requiring oral NaCl supplementation, with a PDA, having CLD, or 
requiring invasive mechanical ventilation had greater odds for S. capitis colonisation. 
By contrast those who were members of a multiple birth, had inflamed skin, and who 
were formula fed had lower odds of S. capitis colonisation. Direct comparison of 
proportions of colonised with uncolonised neonates showed greater use of 
antimicrobials, including those to which the S. capitis strain was resistant, among 
colonised neonates. In addition, although individual bed spaces and rooms were not 
associated with increased risk for infection, examination of colonisation status of 
neonates over time within the Dunedin Hospital NICU demonstrates frequent new 
colonisation in the same room in consecutive weeks. This suggests that transmission 
may occur between neonates sharing the same room. Furthermore, S. capitis-colonised 
neonates are often moved rooms during the week that they become colonised. While 
the retrospective analysis had a number of limitations that will be addressed by the 
ongoing prospective study, on balance our results suggest that neonates requiring 
frequent contact due to more intensive medical management are at greater risk for 
colonisation. 
Oral NaCl supplementation is used among neonates born at low GA to offset the 
leakage of sodium from the kidneys (141). The nested case-control study adjusted 
analysis showed that oral NaCl supplementation was associated with increased odds of 
S. capitis colonisation. A study by Al-Dahhan et al  found that NaCl supplements in 
premature neonates improved their postnatal weight gain, with no undesirable side 
effects (142). However, they did not look at bacterial colonisation as an outcome of 
using NaCl. Oral NaCl use as a risk factor for CONS colonisation of neonates has not 
yet been investigated in any known published literature. Oral NaCl is likely a marker of 
the most premature, medically dependent, and frequently handled neonates. It is also 
plausible that high doses of oral NaCl could have an effect on the neonatal gut 
osmolality. Studies have shown that chronic high salt intake changed the bacterial count 
and the composition of the intestinal microflora in mice and increased the gut 
permeability (143, 144). Kloos et al found that 90% of S. capitis isolates were capable 
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of growth at NaCl concentrations of up to 10%. Therefore, it is possible that the change 
in the intestinal microflora induced by oral NaCl supplementation favours S. capitis 
colonisation (55).  
The ductus arteriosus connects the pulmonary artery to the aorta and closes naturally 
within 4 days of birth for more than 95% of neonates with a birthweight >1,500g, but 
among neonates born ≤1,500g, only 34% of ductus arteriosus close within 4.3 days 
(145). Neonates with PDA represent members of a group of more medically dependent 
and frequently handled neonates for which S. capitis colonisation risk may be mediated 
by more frequent and prolonged contact than by the PDA pathophysiology itself. 
However, PDA has been associated with decreased blood flow velocity in the gut, 
which is associated with feed intolerance (146, 147). Neonates who have feed 
intolerance take longer to achieve full enteral feeds, which may affect the neonate’s 
intestinal microflora (146). However, as neither the number of feeds per week or feed 
intolerance were significantly associated with colonisation the theory needs further 
investigation. 
Both CLD and the requirement for invasive mechanical ventilation were associated 
with increased odds of S. capitis colonisation in the nested case-control adjusted 
analysis. Invasive mechanical ventilation is used to manage the breathing of neonates 
with respiratory distress syndrome (RDS) and CLD commonly resulting from 
bronchopulmonary dysplasia (BPD) (148), defined on the basis of the requirement for 
ventilation ≥28 days after birth (148). Furthermore, invasive mechanical ventilation is 
also a risk factor for lung injury and inflammation (149). Requirement of invasive 
mechanical ventilation is common among neonates born at <28 weeks’ GA (149). 
Studies have shown that the use of non-invasive mechanical ventilation, such as nasal 
continuous positive airway pressure (CPAP), compared to invasive mechanical 
ventilation, is associated with a lower risk of nosocomial infections (150). In our 
adjusted analysis, we found that nasal CPAP was <1, although the association was not 
statistically significant, while invasive mechanical ventilation was associated with a 
statistically significant increased risk for S. capitis colonisation. It is possible that 
colonisation could occur from contaminated equipment. WGS of the Dunedin Hospital 
S. capitis NRCS-A strain showed that the S. capitis strain encodes the icaADBC operon 
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for biofilm formation (section 2.4), therefore it is possible that the strain is able to 
persist on equipment and indirectly transmit to neonates (personal communication, 
James Ussher). If the ventilation equipment was contaminated it would colonise the 
skin or the gastrointestinal tract (GIT).  
It is likely that oral NaCl supplementation, PDA, CLD, and invasive mechanical 
ventilation are markers of a subgroup of neonates with greater medical dependency 
whose risk factors for S. capitis colonisation are mediated by increased contact from 
staff and medical devices that are required for management of comorbidities. Premature 
neonates with complications require monitoring equipment and more regular checks by 
staff (personal communication, Roland Broadbent), with equipment such as 
stethoscopes that may be a source of S. capitis transmission in NICUs. S. capitis was 
isolated from stethoscopes and incubators in the Dunedin Hospital NICU between 
January 2014 through June 2014 (personal communication, James Ussher). Neonates 
with PDA, and CLD or invasive mechanical ventilation are also more likely to require 
acute care. In emergency situations, medical staff may need to attend neonates without 
standard precautions such as hand washing being possible, further increasing risk for S. 
capitis colonisation.  
The nested case-control analysis showed that being born as a part of a multiple birth 
was associated with reduced odds of S. capitis colonisation. Studies have shown that 
neonates born as a part of a multiple birth are more likely to have similar microflora 
than non-multiple birth neonates (151, 152). One study found no difference between 
multiple birth neonates and singletons for episodes of LONS (151). Similar microflora 
between multiple birth neonates could be due to shared maternal contact, or identical 
maternal expressed breast milk (152). Additionally, neonates born as a part of a 
multiple birth may have contact with each other in the NICU, as shown in Figure 9 
when one set of twins occupied the same cot, which does not occur between singletons. 
Members of the same twin pair regularly occupy the same room in the NICU, have 
shared equipment such as thermometers, and are cared for by the same staff members 
(personal communication, Roland Broadbent), which may facilitate transmission of S. 
capitis. One study found that a set of triplets had similar microflora regardless of two of 
the three being genetically identical (monochorionic monoamniotic) (152). Suggesting 
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that the retrospective study findings are more likely to be explained by common 
transmission, or lack thereof, than rather than protective genetic factors.  
All multiple births in our retrospective study were twins, and all twin pairs were either 
both colonised or both non-colonised. The nested case-control analysis had eight cases 
that were part of a multiple birth. Of the eight cases, each twin became colonised with 
S. capitis within one week of the other (Figure 9). This observation suggests that 
transmission of S. capitis between twins is common. That being part of a multiple birth 
was protective against colonisation is likely an artefact of study design related to 
repeated baseline data among the controls due to risk set matching. At least one of the 
twins was in the NICU for one or more weeks as a control, and provided control data 
for themselves and their twin. This creates a bias towards multiple birth data being 
repeated among control data.  
Adjusted analysis of the retrospective case-control study found that having an area of 
inflamed skin was associated with lower risk of S. capitis colonisation. In particular, 
inflamed axillary skin was protective against S. capitis colonisation after adjusting for 
GA and length of stay. To our knowledge, no epidemiologic studies have investigated 
skin inflammation as a risk factor for S. capitis or CONS colonisation of neonates. It is 
possible that skin inflammation, whether due to an infectious or non-infectious process, 
is hostile to S. capitis. However, there is presently little evidence to support this 
hypothesis. In the Dunedin Hospital NICU during the period of the retrospective study, 
persistently inflamed skin was often treated with topical fusidic acid, an antimicrobial 
against which the endemic S. capitis strain is resistant (personal communication, 
Roland Broadbent). While it is plausible that topical fusidic acid may simultaneously 
disrupt the protective effect of the normal skin and select for the endemic S. capitis 
strain, we were unable to perform an unadjusted or adjusted analysis as no cases used 
fusidic acid during the exposure week. Therefore, estimates were too small to interpret 
or the model did not converge so no estimates were available. The role of topical 
fusidic acid and other antimicrobial use is being examined in the ongoing prospective 
study. 
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Neonates enrolled in the retrospective study were fed with breast milk, expressed breast 
milk, or formula. Human milk fortifier was added to the breast milk or expressed breast 
milk for 6 (23.1%) cases and 55 (27.1%) controls. We found that enteral feeds with 
formula were associated with a reduced risk of S. capitis colonisation. Other studies 
have shown that it is possible for staphylococci to pass from the mother’s expressed 
breast milk to the nose, throat, and bloodstream of neonates, with no evidence of 
mastitis in the mother (153), and that S. capitis has been isolated from human breast 
milk samples (85). The staphylococci could have transferred to the neonates through 
contaminated equipment associated with the storage of the expressed breast milk, such 
as pumps and bottles, or from the mother milk itself (153). Alternatively, breast feeding 
represents a period of extended direct skin contact with the mother that does not occur 
during formula or expressed breast milk feeding. Therefore, it is plausible that neonates 
fed with formula are protected against colonisation from bacteria in expressed breast 
milk, or from the maternal breast and skin. Against that, breast milk feeding was not 
associated with increased odds of colonisation in the adjusted analysis. 
We had hypothesised that antimicrobial exposure might be associated with S. capitis 
colonisation due to its impact on the gut microflora (154, 155) and the evidence from 
other studies that altered microflora was a risk factor for LONS (155), including LONS 
due to vancomycin resistant S. capitis (16). In addition, WGS of the Dunedin Hospital 
S. capitis NRCS-A isolate showed that the strain was resistant to penicillin, tobramycin, 
fusidic acid, and had reduced susceptibility to chlorhexidine (section 2.4). Therefore, it 
is possible that exposure to these antimicrobials may select for S. capitis colonisation 
among neonates. However, while antimicrobial use, including use of antimicrobials to 
which the endemic S. capitis strain was resistant, was more common among colonised 
than non-colonised neonates, no significant difference in antimicrobial use was seen in 
either the unadjusted nested case-control analysis or after adjusting for GA and length 
of stay. This finding is consistent with antimicrobial requirements being greater among 
the most premature neonates than those born at later GAs, and suggests that 
antimicrobial exposure may not be the major the major driver of colonisation risk in the 
NICU setting. However, it is possible that antimicrobials were a risk factor for S. 
capitis colonisation but were not detected because the one week exposure period was 
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too short to detect an effect. An analysis with longer exposure periods may be possible 
in the future.  
Location in a particular room or bed space during the exposure week was not associated 
with increased odds of S. capitis colonisation in the nested case-control adjusted 
analysis. However, the diagram of the rooms and bed spaces (Figure 8) showed that S. 
capitis colonisation regularly occur in consecutive weeks in the same room. For 
example, in room 11 a different neonate had a positive test result for S. capitis each 
week for four weeks. Certain rooms in the Dunedin Hospital NICU, such as room 11, 
are occupied by the most fragile neonates, and neonates in the same room oftern share 
equipment and nursing staff (personal communication, Roland Broadbent). There were 
fewer S. capitis positive swabs across consecutive weeks in other rooms, such as room 
5, although the incidence rate of S. capitis positive neonates per study neonate-week per 
room was lower in room 5 compared to room 11. As neonates moved bed spaces 
frequently throughout their stay in the Dunedin Hospital NICU (personal 
communication, Roland Broadbent), and I did not collect data on bed spaces occupied 
by cases after they became positive so I was unable to investigate possible transmission 
to negative neonates in the same room after the case’s exposure week.  
 Strengths and Limitations  
A strength of our study design for both the retrospective and prospective studies was 
that we were able to establish temporality between exposure and outcome. We designed 
our eligibility criteria to establish exposure weeks during which colonisation status was 
known. Although having two axillary swab tests were necessary to investigate risk 
factors of colonisation, this eligibility criterion reduced our retrospective study sample 
size by half. Additionally, the medical records of almost half of our eligible neonates 
were stored in Dunedin Hospital storage rooms that were contaminated with asbestos. 
There was no way to access these records. The number of colonised neonates excluded 
from the retrospective study nested case-control analysis, included 16 neonates who 
were positive at their first swab and 16 whose weekly data were unavailable. Our 
nested case-control analysis had small numbers of neonates and therefore wide 
confidence intervals and concern for type II error, meaning the study may have failed to 
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detect true associations. Conversely, we examined many exposure variables, which 
would lead to inflation of the Type I error and a risk of false positive findings. We have 
not made formal adjustments for the multiple comparisons, but the results should be 
interpreted accordingly. The threshold for statistical significance was set at 0.05, so for 
one test there was a 5% chance the finding is a false positive association. With the large 
numbers of repeated statistical tests it is highly likely that there will be at least one false 
positive finding.    
Our retrospective study showed differences between the eligible neonates and the 
ineligible neonates in terms of ethnicity, GA, birth weight, length of stay, and multiple 
births. Of the 119 ineligible neonates, 88 (73.3%) were not included because they were 
only swabbed once during their stay in the NICU, therefore were likely discharged or 
transferred within 14 days. This may have introduced selection bias as the relationship 
between the risk factors and the outcomes for the ineligible group are unknown, so may 
have been different than among the eligible neonates. Excluding neonates due to 
positive first swab is less likely to have caused selection bias, as they are more likely to 
be similar to the eligible neonates who were at risk of S. capitis colonisation. If there 
were bias, the estimated odds ratios in the nested case-control analysis would have been 
further from the null than the true value. Furthermore, as the ineligible neonate’s 
relationship with exposures is unknown, and we did not investigate exposures before 
the first swab in our study, the results from the retrospective study may not be 
generalisable to any neonates that were only swabbed once. 
Fortunately, we were able to collect baseline data for the neonates with unavailable 
weekly data using the electronic records on the Health Connect South online database. 
There were few differences between the neonates with available and unavailable 
weekly data in terms of ethnicity, multiple birth, and length of stay. It is unlikely that 
the relationship between treatment, co-morbidities, or staff contact and S. capitis 
colonisation for neonates with available weekly data was different from those with 
unavailable weekly data as their GA and birthweight were similar.  
Information bias in a retrospective study can occur from how the data were recorded 
and how the data were collected. Different professionals including nurses, consultants, 
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registrars, and allied health professionals recorded data in the neonate’s medical 
records. Within in each profession there were numerous individuals, which resulted in 
variation between what was recorded in the records. Data were only available from the 
medical records if they had been recorded. It was not always possible to determine 
whether the absence of information reflected unknown exposure or no exposure. Data 
such as antimicrobial usage and procedures were reliably recorded in the medical 
records, while data such as parental contact and other transmission data were recorded 
in a more haphazard manner. It is possible that there was some misclassification of 
exposures in our study due the data available in the medical records. Healthy neonates 
could have less recorded on their medical records, as the details of their condition may 
not be as important as it is for the fragile neonates. If this occurred, the 
misclassification of exposures would have been differential and caused the estimated 
values to be further from the null than the true values. Alternatively, bias could have 
been non-differential as it could have been the type of data collected that was 
unreliable, rather than a difference between the cases and controls. This would have 
caused the estimated values to be closer to the null than the true values.  
To reduce the potential effect of information bias from how data were collected, I 
created the CRF to have as few free-form questions as possible so the measures of 
exposure were standard. The majority of our weekly CRF questions required ‘yes’ or 
‘no’ responses, and the definitions for the medical history, procedures, and devices 
were not flexible. Additionally, I was the coordinating investigator of the retrospective 
study, and performed all the data collection and management, so there was minimal 
variation of responses between neonates. 
Blinding the person performing data collection to the objectives of the study and the 
outcomes of each neonate can reduce information bias. There was no practical way that 
I could have been blinded to the neonate’s outcome at the time of retrospective data 
collection. I stopped collecting data for each neonate when they either were discharged 
from the NICU, did not receive their scheduled swab test, or became positive for S. 
capitis colonisation. As almost half of the cases became positive of S. capitis in their 
first full week in the NICU, and none became positive in their last week in the NICU, 
being blinded to the outcome would have meant unnecessary data collection for weeks 
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after data was no longer required. Recruiting another person to perform data collection 
would have required substantially more resources. Blinding of the outcome is addressed 
in the prospective study, as the weekly S. capitis test result becomes available after the 
weekly CRF is completed.  
As the S. capitis swab test was performed every Monday morning, and the exposure 
week was Monday 5.59am to Monday 6am, the collection of exposures differed 
depending on the day of the week the neonate was born. For example, almost all low 
GA neonates who are admitted to the Dunedin Hospital NICU are treated with 
amoxicillin and gentamicin for 2-3 days after birth (personal communication, Roland 
Broadbent). However, this is not apparent in our results (Table 8) because if a neonate 
were born from Tuesday through Thursday for example, their antimicrobial treatment 
would not have been recorded in their first CRF. Additionally, neonates are most 
dependent during their first week in the NICU so other treatments such as ventilation 
may also have been missed from the first CRF. This could have caused non-differential 
misclassification of exposures. Additionally, the exposure week was an arbitrarily 
selected duration. As approximately half of the cases in the retrospective study became 
positive in their first full week in the Dunedin Hospital NICU, we know that 
colonisation can occur within a short period. However, some exposures may take 
longer for skin colonisation to be detected. For example if colonisation begins in the 
GIT, it may take longer for S. capitis to colonise the skin. We are planning to explore 
the nested case-control analysis with longer exposure periods in the future.  
The diagnostic test used to confirm S. capitis NRCS-A identification (section 4.3) has 
high specificity because it will only give a positive result if S. capitis is present in the 
sample. However, the sensitivity of the S. capitis axilla swab test is unknown. The 
NICU staff do not have a protocol for size of axilla surface area swabbed, swab pattern, 
or if one or both axillae are swabbed. Furthermore, as discussed in the literature review 
(section 2.1.1), the most populated sites of neonates, and the preferred niches of CONS 
species, are unknown. We cannot be certain that the axilla was the most appropriate site 
to identify colonisation, stool samples may be more appropriate than skin samples. If 
the test had low sensitivity, or the site of the test did not support the highest populations 
of S. capitis growth, there may have been misclassification of the outcome. 
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The controls were matched to the cases as described in the methods (section 4.17.3). 
We decided to match controls to cases to reduce the confounding, based on a 
hypothesis that the risk of S. capitis transmission between neonates that could fluctuate 
over time depending on the number of S. capitis positive neonates in the NICU. We 
planned to match the controls to cases using the exposure week only; however, there 
were not enough controls to match to each case, which would have reduced the number 
of cases in our study. We then matched the controls to cases using the exposure week, 
and three weeks previous, which gave us controls for every case. However, this method 
meant that an individual neonate could have multiple weeks of their control data 
matched to an individual case. Additionally, an individual neonate could have their own 
control data matched to their case data. This meant that in 14 (53.8%) of 26 risk sets, 
there were correlations between weeks which standard conditional logistic regression 
does not allow for, and from the resulting analysis, the p-values would likely be too 
small. I used robust standard errors within the conditional logistic regression, which 
will have accounted for this correlation to some extent.     
Matching reduced the number of non-colonised neonates who contributed control data. 
The small numbers and nested nature of the study design resulted in repeated baseline 
and weekly data for individual neonates, some contributing as many as 21 weeks of 
control data. Weekly data varied between study weeks more frequently than baseline 
data. If a neonate contributed twice as a control, their baseline data would be the same 
each time. The effect of this repetition in the baseline data is evident when the numbers 
and proportions between the cases and controls that provided weekly data (Table 5) are 
compared with the cases weeks and control weeks (Table 6). The neonates who 
contributed the most control data were those of low GA and low birthweight who were 
in the NICU for longer periods and therefore had more opportunity to match with cases 
on time, although we adjusted for this in the nested case-control adjusted analysis. 
Furthermore, colonised neonates contributed approximately 60% of the control data 
compared to non-colonised neonates who contributed approximately 40% (results 
section 5.3).  
We controlled for confounding of GA and length of stay in our adjusted analysis. 
Therefore, there may have been confounding from factors that were unmeasured or for 
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which our sample size was too small to include. We were unable to perform a 
multivariate analysis as our sample size was too small and would have produced 
unreliable results.  
We used categorical variables for the adjusted analysis as it was not likely that GA and 
length of stay fit a linear relationship with S. capitis colonisation. If GA fit a linear 
relationship, every week increase in GA would reduce the log odds of S. capitis 
colonisation. This may be applicable at low GA, but may not be applicable closer to 
term. Therefore, there may have been residual confounding from the use of categorical 
variables rather than continuous variables in the adjusted analysis.  
 Recommendations 
The increased risk of S. capitis colonisation associated with comorbidities and devices 
that may require more staff contact suggests that staff play a role in transmission. If this 
is the case, the standard precautions for infection prevention and control used by the 
Dunedin Hospital NICU may not be adequate for preventing S. capitis colonisation. 
The Dunedin Hospital NICU could strengthen their precautions using an education 
programme to improve hand hygiene practices, which has shown to work in another 
hospital ICU (91). Alternatively, the Dunedin Hospital NICU may want to consider 
transmission-based contact precautions (section 2.1.4). Cohorting neonates would 
require one or more dedicated rooms in the NICU for all colonised neonates, with non-
colonised neonates in separate rooms with standard and transmission-based precautions 
between these separate spaces. Ideally, staff who care for colonised neonates would not 
have contact with non-colonised neonates. Table 16 and Figure 8 show that 6 (23.1%) 
of 26 cases moved bedspaces during the exposure week. As neonates become colonised 
during the exposure week, unknown to staff until the next swab result, reducing the 
movement of neonates around the NICU would reduce the number of other neonates at 
risk. 
We identified the neonates most at risk of S. capitis colonisation as those born at low 
GA, low birthweight, and those with comorbidities. The NICU should continue to focus 
surveillance and interventions on preventing transmission of S. capitis to this group of 
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neonates. However, our retrospective study also showed that two neonates born at >36 
weeks’ GA became colonised, and therefore colonised high GA neonates may be 
missed by prospective study surveillance. As two neonates is a small number increasing 
the surveillance to all neonates may not be a reasonable use of resources, but the NICU 
should be aware of the possible role of the higher gestational age and birthweight 
neonates in transmission.  
I recommend that the prospective study continues until the sample size is large enough 
for adequate power in the study analysis (section 4.9). The Dunedin Hospital S. capitis 
NRCS-A strain encodes genes for biofilm formation (section 2.4), and has been isolated 
from incubators and stethoscopes in the NICU (section 2.4). It is possible that 
transmission to neonates occurs indirectly through fomites, however, we were unable to 
trace the use of incubators, cots, or stethoscopes in the retrospective study. As 
discussed in section 2.1.3, the clonality of S. capitis NRCS-A suggests global 
dissemination through either movement of healthcare workers or through a point source 
outbreak of contaminated NICU equipment, although none has been identified. The 
prospective study incorporates improvements from the retrospective study including 
available weekly data for all participants, tracing Dunedin Hospital NICU staff 
members, and tracing equipment such as incubators and stethoscopes. We hope to 
repeat analyses for the associations we found for oral NaCl use, PDA, CLD, invasive 
mechanical ventilation, multiple birth, skin inflammation, and enteral feeds with 
formula. Additionally, we hope to explore the role of antimicrobial use on risk of S. 
capitis colonisation. The prospective study has potential for transcription bias as the 
investigator of the study entering the data from the CRFs into the REDCap online 
database. It was not possible to perform double entry of the data due to our resources, 
however if the study continues as recommended, double entry of the data should be 
considered.  
Figure 8 shows that there were consecutive weeks of cases in room 11, for four weeks 
in a row. This suggests that being in the same room as a case during their exposure 
week may be risk factor for colonisation. To explore this concept further we would 
need to identify for each week of stay if a neonate was in the same room as a case or a 
control. However, as our study was not designed to investigate infant-infant 
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transmission, we do not have sufficient data for this investigation. We do not have the 
weekly data for half of the participants due to asbestos storage, the neonates who had a 
positive first swab, or the colonised neonates after they become positive, all of which 
are necessary for an analysis on transmission. For the prospective study, we collect the 
bed space number and colonisation status of neonates cared for by the same nurse as 
participants. Due to findings in our retrospective study, the NICU now records the 
incubator identification number on the NICU category 4 or 5 chart in the neonate’s 
medical records. During analysis of the prospective study, the incubators will be able to 
be traced. For the prospective study the incubator and bed space numbers should be 
recorded for the neonate’s entire stay, regardless of outcome, so that they can be traced 
to determine transmission among neonates and among rooms.  
Studies need to be done to confirm the sensitivity of the swab test. This is important to 
understand the misclassification of the outcome, if any, in the studies. Additionally, a 
longitudinal study with a large sample size looking at the site of neonates most 
populated with S. capitis is important. Six studies investigated which body sites of 
premature neonates had high CFU/area of CONS but they had small sample sizes and 
there was discordance of the sites swabbed (Table 1). Additionally, these studies were 
conducted from 1989-1996, and the predominance of S. capitis on neonates has 
changed in recent years (8). Such a study would be helpful in understanding if S. capitis 
has a niche environment or if it is spread over the whole body. The prospective study 
trialled testing neonates stool samples for colonisation of S. capitis. It is important to 
continue stool collection, especially with increasing evidence that CONS heavily 




We conducted a retrospective study to investigate the risk factors for S. capitis NRCS-
A colonisation among premature neonates in the Dunedin Hospital NICU. The 
retrospective study showed that oral NaCl use, having a comorbidity such as PDA or 
CLD, and requiring invasive mechanical ventilation were associated with increased risk 
of S. capitis NRCS-A colonisation. Although we had insufficient data for a full 
multivariate analysis, and the results were solely based on the retrospective study which 
is more likely than a prospective study to include bias, we hypothesised that neonates 
with comorbidities are likely the most premature, medically dependent neonates who 
require increased contact from Dunedin Hospital NICU staff or equipment. Our results 
suggest that the Dunedin Hospital NICU may need to strengthen their standard 
precautions for infection prevention and control or consider transmission-based contact 
precautions, such as cohorting neonates, to prevent transmission of S. capitis NRCS-A. 
In order to further understand the risk factors of S. capitis NRCS-A colonisation among 
neonates in the Dunedin Hospital NICU, we recommend that the findings from the 
retrospective study, along with the use of antimicrobials, and tracing contact from 
healthcare workers and the NICU environment be explored with an ongoing 
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Appendix 1: Prospective study S. capitis test result CRF 
 





Case Report Form – Test results 
 
Today’s date (dd/mm/yyyy): ___ /___ /______          
                                                                     
Person completing form (first name and surname): ________________________ 
 
 
Section 1: Axilla swab test results. 
 
1. What is the date of the axilla swab collection? (dd/mm/yyyy) __ / __ / _____ 
 
2. What is the S. capitis test result from the axilla swab?  




Appendix 2: Prospective study baseline CRF  
 
Case Report Form Participant ID:  _ _ _    
 
Case Report Form – Baseline 
 
Today’s date (dd/mm/yyyy): ___ /___ /______                                                                              
 
Person completing form (first name and surname): ________________________ 
 
General guidelines for filling out the Baseline case report forms.  
 
- If there is a yes/no option, make sure you tick one, do not leave unanswered.  
- If ‘yes’ is ticked for ‘other’ you must specify the procedure, equipment or medication 
etc. that was not provided in the list.  
- Pay attention to the time frames (either 24 hours or 7 days). Do not include anything 
that happened outside that time frame (e.g. nothing after 6am today).  
- Records are 6am - 6am (follows the shifts).  
- ‘7 days’ refers to the previous Monday at 6.00am, to Monday (today) at 5.59am.  
- ‘24 hours’ refers to the final 24 hours of the 7 day period i.e. Sunday (yesterday) 
6.00am to Monday 5.59am. When recording the date for the last ‘24 hours’ use 
Sunday’s date (yesterday’s date). 
 
 
Section 1: Information from Neonatal Records 
 
A. Demographic information - Infant 
 
1. Sex (must tick one):      Male       Female 
 
2. Date of birth (dd/mm/yyyy): ___ /___ /______ 
 
3. Date of admission (dd/mm/yyyy): ___ /___ /______ 
 
4. Gestational age at birth (fill in the number of weeks as well as the additional days):       
____ weeks ____ days 
 
5. Birth weight: ________ grams 
 
6. Infant ethnicity (tick all that apply):   
 NZ European    Māori    Samoan    Cook Island Māori    Tongan    
 Niuean    Chinese    Indian    Other: _________________________  
 
7. Does the neonate have siblings from other births?    Yes     No 
 















Case Report Form Participant ID:  _ _ _    
B. Birth history 
 
1. Delivery type (must tick one):    Caesarean section    Vaginal delivery   
 
If the infant was born by vaginal delivery, were any of the following included?                        
(tick all that apply):     Forceps    Scalp electrodes    Ventouse      None apply   
 
2. Did this pregnancy involve multiple births?    Yes        No  
 
If ‘yes’, how many births? (e.g. triplets = 3):    2    3    4    5 
 
Participant ID for other infant/s (IDs are printed on the case report forms for the other 
participants):   ___ ___ ___ ___ , ___ ___ ___ ___ , ___ ___ ___ ___  
 
3. Was the infant born in Dunedin Hospital:    Yes       No 
 
If ‘no’, where was the infant born? (the closest town or city): _________________________ 
 
If ‘no’ (select only one):    Health care facility    Other (e.g. at home): ______________ 
 
































Case Report Form Participant ID:  _ _ _    
Case Report Form – Baseline 
 
Today’s date (dd/mm/yyyy): ___ /___ /______                                                                              
 
Person completing form (first name and surname): ________________________ 
 
Section 2: Information from maternal records and maternal recall 
We need to have consent for the mother’s participation and to collect maternal records. 
 
A. Demographic information – Mother 
Information in section A can be collected by asking the mother. 
 
1. Mother’s date of birth (dd/mm/yyyy): ___ /___ /______ 
 
2. Mother’s ethnicity (tick all that apply):   
 NZ European    Māori    Samoan    Cook Island Māori    Tongan    
 Niuean    Chinese    Indian    Other: _________________  
 
B. Maternal antimicrobial use 
Information in Section B can be collected from the mother’s medical records and/or by 
asking the mother. 
 
1. Was the mother treated with antimicrobials during this pregnancy?    Yes      No 
       If ‘yes’, fill out the following table.  
 
IV – intravenous, PO – per oral, PR –per rectal 
Antimicrobial 
 (generic name) 
Route 





    
    
    
    
    
    
 
C. Maternal history of current pregnancy 
Information in Section C can be found in the infant’s notes, maternal medical records, and by 
asking the mother. More than one source may be needed to collect data for this question. 
 
1. Complications during this pregnancy.  
 
Tick either yes (Y) or no (N) for each of the following (do not leave blank). 
Y  N 
 Cerclage    Group B Strep colonisation    
 Chorioamnionitis  Premature delivery 
 Gestational diabetes  Premature delivery 
 Intrauterine growth restriction (IUGR)  
 Premature rupture of membranes (PROM) 
 Other: _____________________________________________ 
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Appendix 3: Prospective study weekly CRF 
 
Case Report Form Participant ID:  _  _  _ 
 
 1 
Case Report Form – Weekly 
 
Today’s date (dd/mm/yyyy): ___ /___ /______          
                                                                     
Person completing form (first name and surname): ________________________ 
 
General guidelines for filling out the Weekly case report forms.  
 
- If there is a yes/no option, make sure you tick one, do not leave unanswered.  
- If ‘yes’ is ticked for ‘other’ you must specify the procedure, equipment or medication 
etc. that was not provided in the list.  
- One day is recorded from 6am to 6am (follows the charts).  
- Pay attention to the time frames (either 24 hours or 7 days). Do not include anything 
that happened outside that time frame (e.g. nothing after 5.59am today). 
-  ‘7 days’ refers to the previous Monday at 6.00am, to Monday (today) at 5.59am.  
- ‘24 hours’ refers to the final 24 hours of the 7 day period i.e. Sunday (yesterday) 
6.00am to Monday 5.59am. When recording the date for the last ‘24 hours’ use 
Sunday’s date (yesterday’s date).  
- For dates in most of the tables you can write ‘ongoing’ if the dates are outside the 7 
day period. E.g. if the infant has been in the same incubator before and after the 7 day 
period, write ‘ongoing’ in both start and stop date columns.  
- For parental contact: if there are multiple Mothers/Fathers use A for genetic parent 
and B for partner.  
 
Section 1: Information from case notes 
Information will be found in the infant’s case notes. Ask the nurses assigned to the infant if 
you are unsure about any of the notes.  
 
A. Infant medical history 
 
1. Comorbidities in the last 7 days  (last Monday at 6am to today (Monday) at 5.59am) 
 
Tick either yes (Y) or no (N) for each of the following if the onset is in the last 7 days (do not 
leave blank). 
 Y  N                                                                        Y  N 
 Sepsis workup   Renal impairment   
 Apnoea of prematurity                     Retinopathy of prematurity (ROP)           
 Feed intolerance (feeds workup)        Sepsis diagnosis                                   
 Gastric aspirate (bile present)                        Skin injury                    
 Hypoglycemia    Area of inflamed skin 
 Neonatal encephalopathy                  Umbilical flare 
 Patent ductus arteriosis    Flaky skin 
 Temperature instability 
 Intracran. hemorrhage. If ‘yes’ grade:   1   2   3   4 
 Cardiac abnormalities (e.g. congenital heart disease): __________________________ 
 Pulmonary disease (e.g. CLD, HMD/RDS, meconium aspiration): _________________ 
 Gastrointestinal disease (e.g. NEC, gastroschisis, omphalocele): __________________ 
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2 
 
2. Did the infant have any of the following procedures or devices in situ in the last 7 days? 
(last Monday at 6am to today (Monday) at 5.59am) 
 
 Tick either yes (Y) or no (N) for each of the following if the procedure was in the last 7 days 
(do not leave blank).  
Y  N                                                                         Y N   
 Endotracheal (re)intubation, #: ____   Supplemental O2 
 Invasive mechanical ventilation           Retinopathy of prematurity screen          
 Nasal CPAP    Umbilical Artery Catheter (UAC) 
 Nasal cannula (Optiflow)                  Umbilical Vein Catheter (UVC)             
 Peripheral IV    Peripheral Inserted Central Catheter 
 Orogastric tube  
 Nasogastric tube 
 Blood tests. If ‘yes,’ total number: _____       
 RBC transfusion. If ‘yes,’ total number: _____ 
 Phototherapy. If ‘yes,’ duration: _______ hours (total), and bili blanket:  Yes  No 
 Syringe pump. If ‘yes,’ tick all that apply:   inside incubator    outside incubator 
 Other devices (must include if the device is inside or outside the incubator): _______ 
___________________________________________________________________________ 
 
If ‘yes’ to invasive mechanical ventilation, nasal CPAP or nasal cannula, record the ventilator 
asset number (asset number only): ____________________ 
 






B. Medication history 
 
1. Was the infant treated with any antimicrobials in the last 7 days? (last Monday at 6am to 
today (Monday) at 5.59am)    Yes    No       
-  If ‘yes’, fill out the following table. 
 
IV – intravenous, PO – per oral, PR –per rectal 
Start date/ongoing - If the infant started receiving the treatment before the 7 days period 
begun, write ‘ongoing’ 









    
    
    
    
    
    
    
    








2. Other medications, excluding injectables, received in the last 7 days. (last Monday at 
6am to today (Monday) at 5.59am)     Yes    No    
      -  If ‘yes’, fill out the following table. 
 
IV – intravenous, PO – per oral, PR –per rectal 
Start date/ongoing - If the infant started receiving the treatment before the 7 days period 
begun, write ‘ongoing’ 









    
    
    
    
    
    
    
    
    
 
3. Other injectables received in the last 7 days? (last Monday at 6am to today (Monday) at 
5.59am)        Yes    No       
- If ‘yes’, fill out the following table. 
 
Product example - TPN (Total Parental Nutrition), Lipids, 10% dextrose, insulin.  
Start date/ongoing - If the infant started receiving the treatment before the 7 days period 
begun, write ‘ongoing’ 
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C. Parental/family contact 
Contact refers to any physical contact with the infant, inside or outside the incubator. 
 
1. Did the neonate have any contact with its parents or guardians in the last 7 days? (last 
Monday at 6am to today (Monday) at 5.59am)        Yes         No        
 
If ‘yes’, fill out the following table. 
 
For ‘contacts’ ONLY use: ‘Mother’, ‘Father’ or ‘other family member’.  
Duration: short – 0-14 minutes, medium – 15-29 minutes, long – 30+ minutes. 
Do not include contact from cares – there is a section for this later in the form. 
Contacts  
(Mother, Father or  
other family member) 
Contact type  




(short, medium, long) 
Dates 
(dd/mm/yyyy) 
    
    
    
    
    
    
    
    
 
2. Comment on how much family contact (mother, father or other family member) there was 
in the last 24 hours  (a little, medium, a lot): ____________________________________ 
 
3. Did the infant have contact with its twin/multiple in the unit in the last 7 days? (last 
Monday at 6am to today (Monday) at 5.59am)       Yes       No 
 
Participant IDs are printed on the case report forms for the other participants 
Other infant’s 
participant ID 
Type of contact 
(skin to skin) 
Duration 
(short, medium, long) 
Dates 
(dd/mm/yyyy) 
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D. Enteral feedings 
 
The last 7 days:  (last Monday at 6am to today (Monday) at 5.59am) 
 
Infants are usually fed at regular intervals throughout the day. If fed regularly multiply the 
number of feeds per day by 7. (e.g. 2 hourly feds = 12 feeds per day, therefore they would be 
fed 84 times in the last 7 days).   
1. How many times was the infant fed in the last 7 days? ________________ 
 
If the feeding routine changed in the last 7 days, was it a routine change (e.g. specific date the 
routine changed)?  Tick either:    Routine change     Irregular change to routine 
 
If ‘routine change’ was ticked, record the date that the feeding routine changed. 
(dd/mm/yyyy) ___ /___ /______  
 
2. Was the infant fed donor human breast milk in the last 7 days?     Yes       No 
 
What type of donor human breast milk was used in the last 7 days? (select one or both)   
 Pasteurised, total number of feeds: _____  
 Frozen screened, total number of feeds: _____     
 
 
The last 24 hours:  (Sunday 6am – Monday 5.59am, use the date for Sunday) 
 
3. How many times was the infant fed breast milk in the last 24 hours?                              
(e.g. 01, 02, 03) ____ 
 
Fill in the following table if the infant was fed breast milk in the last 24 hours. 
 
Date – there will only be one date (last 24 hours- yesterday’s date). Please record it in the 
top row. 
Type - Fortified Human Breast Milk (FHBM) or Mothers Breast Milk (MBM), do not include 
donor breast milk. 
Number of feeds– Number of the same type and route of feed in the last 24 hours (if all feeds 













(per route and 
type) 
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4. How many times was the infant fed formula in the last 24 hours? (e.g. 01, 02, 03) ____ 
 
If the infant was fed formula (tick all that apply):    
 Ready To Feed (RTF)     Mixed by staff (MBS) 
 
Fill in the following table if the infant was fed formula in the last 24 hours. 
 
Date – there will only be one date (last 24 hours- yesterday’s date). Please record it in the 
top row 
Type – ready to feed (RTF) or mixed by staff (MBS) 








Number of feeds 
(per type) 
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E. Environment  
 
If the infant has changed bedspace/incubator/cot/stethoscope in the last 7 days please fill out 
both available rows on the table so we have a record of both bedspace numbers and when the 
change occurred. Make sure the dates are recorded.  
The last 7 days:  (last Monday at 6am to today (Monday) at 5.59am) 
 
1. Bedspace number  
 
Start date/ongoing - If the infant is in the same bedspace from before the 7 day period began, 
write ‘ongoing’ 
Stop date/ongoing - If the infant is in the same bedspace (post 7 day period) write ‘ongoing’ 
Bedspace number 
(e.g. 01, 02, 03) 
Start date and time/ongoing 
(dd/mm/yyyy, 24hr time) 
Stop date and time/ongoing 
(dd/mm/yyyy, 24hr time) 
   
   
   
 
2. Incubator number (only fill out the table if the infant is in an incubator) 
 
Start date/ongoing - If the infant is in the same incubator from before the 7 day period began, 
write ‘ongoing’ 
Stop date/ongoing - If the infant is in the same incubator (post 7 day period) write ‘ongoing’ 
Incubator number 
(e.g. 01, 02, 03) 
Start date and time/ongoing 
(dd/mm/yyyy, 24hr time) 
Stop date and time/ongoing 
(dd/mm/yyyy, 24hr time) 
   
   
 
3. Cot number (only fill out the table if the infant is in a cot) 
 
Start date/ongoing - If the infant is in the same cot from before the 7 day period began, write 
‘ongoing’ 
Stop date/ongoing - If the infant is in the same cot (post 7 day period) write ‘ongoing’ 
Cot number 
(e.g. 01, 02, 03) 
Start date and time/ongoing 
(dd/mm/yyyy, 24hr time) 
Stop date and time/ongoing 
(dd/mm/yyyy, 24hr time) 
   
   
 
4. What stethoscope number was used for the infant in the last 7 days? _________________ 
 
Were any other stethoscopes used for this infant in the last 7 days?     Yes     No 
 
If ‘yes’, what is the number of the new stethoscope(s)? __________________ 
 
Record the date(s) the stethoscope changed. Record all dates, if the stethoscope has changed 
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5. Was the infant weighed in the last 7 days? (last Monday at 6am to today (Monday) at 
5.59am)          Yes      No  
 
Please fill out for every time the infant was weighed (usually three times a week)  




   
   
   
   
 
6. Equipment used on the infant in the last 7 days? (last Monday at 6am to today (Monday) 
at 5.59am) 
 
Tick either yes (Y) or no (N) for each of the following (do not leave blank). 
 Y  N                                                               Y  N 
 Arterial line                                     Blood pressure (BP) cuff  
 Cardio/respiratory (CR) monitor       Electrocardiogram (ECG)  
 Leads                                                  Neopuff (Ambubag) 
 Probes SaO2                                                               Pumps (any) 
 Suction                                                  Tape measure 
 Thermometer 
 Temperature probe 
 Other: _________________________________________________ 
 
If ‘yes’ for thermometer, tick if it was the infants own thermometer or shared thermometer, 
and the asset number. Tick one or both:  Own thermometer, asset number: ____________  
 Shared thermometer, asset number: ____________ 
 
F. Infant cares 
 
1. What is the number of normal cares in the last 24 hours? (e.g. 01, 02, 03)  _______  
Cares over a 24 hour period is routine. If the infant needs cares every 3 hours, this will 
equal 08 cares  
 
2. Used in cares in the last 24 hours: 
 
Tick either yes (Y) or no (N) for each of the following (do not leave blank). 
 CPAP change (prongs/mask)                Feeding tube change                       
 Head-to-toe assessment                         IV cannula change 
 Linen change (any)                                 Nappy change 
 Observations                                            Suction 
 Temperature assessment                       Vent/CPAP circuit change 
 Washing/wipe 
 Other: ________________________________________________________________ 
 
3. Record if there was any parental contact for cares in the last 24 hours. 
Contacts (only use: ‘Mother’ or ‘Father’): ________________________________________  
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G. Apnoeas requiring stimulation 
 
1. Has the infant had any apnoeas requiring stimulation in the last 24 hours?  
       Yes      No 
 
If ‘yes,’ number in incubator in the last 24 hours (e.g. 01, 02, 03): ________  
 
If ‘yes,’ which staff were involved (tick all that apply):   
 Nurse    Registrar   Consultant 
 
Intervention type (tick all that apply):    
 Gentle     Vigorous     Bag and mask     Neopuff (Ambubag)   
 Other: ____________________ 
 
 
H. Other nursing procedures 
 
1. Other nursing procedures in the last 24 hours (e.g. suppositories, urine collection).  
       Yes       No   
 
If ‘yes’, what procedure(s) (list all)? _____________________________________________ 
 
If ‘yes’, total number of other nursing procedures in the last 24 hours (e.g. 01, 02, 03): _____ 
 
 
I. Other procedures 
 
1. Other procedures in the last 7 days (last Monday at 6am to today (Monday) at 5.59am).  
 
Tick either yes (Y) or no (N) for each of the following (do not leave blank). 
Y  N 
 Abdominal ultrasound                                    
 Echo cardiogram 
 Eye check                                                       
 Head Ultrasound Scan (HUS) 
 Scans                                                                  
 X-ray 
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J. Consultant and registrar contact 
 
1. Fill out the following table for infant contact by consultants and registrars in the last 7 
days. (last Monday at 6am to today (Monday) at 5.59am) 
 
For ‘staff’ ONLY record ‘registrar’ or ‘consultant’ 
For ‘exam/procedure’ use: ward rounds, sick baby re-evaluation, IV insertion etc.  
Record the exam/procedure even if it has been recorded earlier  
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Date of the second day (Tuesday) of the 7 day period (dd/mm/yyyy): __ /__ / _____ 
Shift 
 
Nurse code Number of 




(known or unknown) 
AM (0700 – 1500)                            +    -   
                          +    -   
                          +    -   
                          +    -   
DAY (0700 – 
1900) 
                           +    -   
                          +    -   
                          +    -   
                          +    -   
PM (1500 – 2300)                            +    -   
                          +    -   
                          +    -   
                          +    -   
NIGHT (1900 – 
0700) 
                           +    -   
                          +    -   
                          +    -   
                          +    -   
NIGHT (2300 – 
0700) 
                           +    -   
                          +    -   
                          +    -   
                          +    -   
 
 
Date of the third day (Wednesday) of the 7 day period (dd/mm/yyyy): __ /__ / _____ 
Shift 
 
Nurse code Number of 




(known or unknown) 
AM (0700 – 1500)                            +    -   
                          +    -   
                          +    -   
                          +    -   
DAY (0700 – 
1900) 
                           +    -   
                          +    -   
                          +    -   
                          +    -   
PM (1500 – 2300)                            +    -   
                          +    -   
                          +    -   
                          +    -   
NIGHT (1900 – 
0700) 
                           +    -   
                          +    -   
                          +    -   
                          +    -   
NIGHT (2300 – 
0700) 
                           +    -   
                          +    -   
                          +    -   
                          +    -   
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Date of the fourth day (Thursday) of the 7 day period (dd/mm/yyyy): __ /__ / _____ 
Shift 
 
Nurse code Number of 




(known or unknown) 
AM (0700 – 1500)                            +    -   
                          +    -   
                          +    -   
                          +    -   
DAY (0700 – 
1900) 
                           +    -   
                          +    -   
                          +    -   
                          +    -   
PM (1500 – 2300)                            +    -   
                          +    -   
                          +    -   
                          +    -   
NIGHT (1900 – 
0700) 
                           +    -   
                          +    -   
                          +    -   
                          +    -   
NIGHT (2300 – 
0700) 
                           +    -   
                          +    -   
                          +    -   
                          +    -   
 
 
Date of the fifth day (Friday) of the 7 day period (dd/mm/yyyy): __ /__ / _____ 
Shift 
 
Nurse code Number of 




(known or unknown) 
AM (0700 – 1500)                            +    -   
                          +    -   
                          +    -   
                          +    -   
DAY (0700 – 
1900) 
                           +    -   
                          +    -   
                          +    -   
                          +    -   
PM (1500 – 2300)                            +    -   
                          +    -   
                          +    -   
                          +    -   
NIGHT (1900 – 
0700) 
                           +    -   
                          +    -   
                          +    -   
                          +    -   
NIGHT (2300 – 
0700) 
                           +    -   
                          +    -   
                          +    -   
                          +    -   
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Date of the sixth day (Saturday) of the 7 day period (dd/mm/yyyy): __ /__ / _____ 
Shift 
 
Nurse code Number of 




(known or unknown) 
AM (0700 – 1500)                            +    -   
                          +    -   
                          +    -   
                          +    -   
DAY (0700 – 
1900) 
                           +    -   
                          +    -   
                          +    -   
                          +    -   
PM (1500 – 2300)                            +    -   
                          +    -   
                          +    -   
                          +    -   
NIGHT (1900 – 
0700) 
                           +    -   
                          +    -   
                          +    -   
                          +    -   
NIGHT (2300 – 
0700) 
                           +    -   
                          +    -   
                          +    -   
                          +    -   
 
 
Date of the seventh day (Sunday) of the 7 day period (dd/mm/yyyy): __ /__ / _____ 
Shift 
 
Nurse code Number of 




(known or unknown) 
AM (0700 – 1500)                            +    -   
                          +    -   
                          +    -   
                          +    -   
DAY (0700 – 
1900) 
                           +    -   
                          +    -   
                          +    -   
                          +    -   
PM (1500 – 2300)                            +    -   
                          +    -   
                          +    -   
                          +    -   
NIGHT (1900 – 
0700) 
                           +    -   
                          +    -   
                          +    -   
                          +    -   
NIGHT (2300 – 
0700) 
                           +    -   
                          +    -   
                          +    -   
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Section 2: Information from mother’s recall 
This section requires the mother’s participation. It requires you to ask the mother for 
information.   
 
A. Questions to ask the mother. 
 
1. If the infant was fed Human Breast Milk in the last 7 days, did the mother experience any 
of the following? (last Monday at 6am to today (Monday) at 5.59am)  
      (tick all that apply):  











Appendix 4: Prospective study weekly CRF guidelines 
 
Guidelines for completing the CRFs. 
General guidelines: 
- If there is a yes/no option, make sure you select one, do not leave unanswered.  
- If there is an ‘other’ tickbox, make sure you tick ‘yes’ or ‘no’.  
- If ‘yes’ is ticked for ‘other’ you must specify what the procedure, equipment or 
medication etc. is that was not provided in the list.  
- Pay attention to the time frames (either 24 hours or 7 days). Do not include anything 
that happened outside that time frame. 
- For dates in most of the tables you can write ‘ongoing’ if the dates are outside the 7 
day period. E.g. if the infant has been in the same incubator before and after the 7 day 
period, write ‘ongoing’ in both start and stop date columns.  
 
Baseline – Section 1. 
A. Demographic information – Infant. 
All information for section A will be in the infant’s case notes. 
- Fill out both date of birth and date of admission, even if they are the same.  
- Gestational age is the number of weeks and days the infant was gestating before the 
birth date. This is not for the current gestation.  
- For ‘sibling of the neonate’ only include siblings from other births. There is a 
question for multiple births (this pregnancy) in the next section.  
- When recording number of siblings only include living siblings.  
 
B. Birth history. 
All information for section B will be in the infant’s case notes. 
- If ‘yes’ for multiple births, we need the ID for the other infant participants. IDs are 
printed on the case report forms for the other infants. 
- Birth location will be in the infant’s notes, but you can ask the mother if it has not 
been recorded.  
- If you tick ‘other’ for not born in Dunedin Hospital or another health care facility, 
please specify where the infant was born. For example, at home.  
 
 
Baseline – Section 2. 
Maternal history will be in the infants notes, or the mothers memory (e.g. for ‘maternal 





Case Report Form – Weekly 
Information will be found in the infant’s case notes. Ask the nurses assigned to the infant if 
you are unsure about any of the notes. There is one question (part H), that requires you to ask 
the mother for information.   
A. Infant medical history. 
There will be room for additional comments at the end of this section. This can be used if 
there is not enough room to write on the lines provided.  
Comorbidities in the last 7 days. 
- Make sure you only tick ‘yes’ if the onset happened in the last 7 days (last Monday to 
Sunday). Do not tick ‘yes’ if it started before last Monday.  
- If the infant has not been screened for the comorbidity yet, please tick ‘no’.  
- Cardiac abnormalities, Pulmonary disease and Gastrointestinal disease: If you tick 
‘yes’, make sure you specify exactly what the abnormality/disease is.  
- If you tick ‘yes’ for other, please specify what comorbidity the infant has.  
Infant procedures in the last 7 days. 
- Make sure you only tick ‘yes’ if the onset happened in the last 7 days (last Monday to 
Sunday). Do NOT tick ‘yes’ if it started before last Monday.  
- Endotracheal (re)intubation: this is if the infant has been re-intubated in the last 7 
days. If ‘yes’, specify the total number of times. 
- Blood tests: how many total they have had in the past 7 days.  
- Phototherapy: write the total duration in hours of the phototherapy session. If there 
has been more than one session, add together the duration from both session. Tick if 
phototherapy included a bili blanket or not (yes/no).  
- Syringe pump: tick if the pump was used inside or outside of the incubator, or both.  
- For ‘other devices’: specify what the other procedure/device was and remember you 
must include if the procedure was inside or outside the incubator for each procedure.  
- Remember to include the incubator asset number if you have ticked ‘yes’ for any 
procedure requiring a ventilator (specified on the case report form).  
 
B. Medication history. 
Antimicrobials, other medication and injectables. 
- If the infant received antimicrobials/other medications/injectables in the last 7 days 
(ticked yes), please fill out the table(s). 
- Must include the start date and the stop date or ‘ongoing’.  
- If the infant begun the antimicrobial treatment before the 7 day period write 
‘ongoing’. If the infant is still receiving the antimicrobial (it has extended past the 7 
days) also write ‘ongoing’.  
- Injectables do not need to include the route.  





C. Parental/family contact 
Contact refers to any physical contact with the infant, inside or outside the incubator. 
- Duration is a time frame: short, medium or long (as explained on the case report 
form). We do not need a specific number of minutes.  
- Please specify the type of contact that occurred e.g. skin to skin contact.  
- You can put multiple dates in one row if it was the same contact (mum or dad), 
contact type and duration, otherwise please use different rows.  
- To comment on how much contact there was between the parents and infant in the last 
24 hours, say if there was a little, medium or a lot of contact. You may need to ask the 
nurse/s that have looked after the infant over this time. This question is to ensure the 
completed table reflects how much contact actually occurred.  
Infant/multiple. 
- Only answer this if the infant is a part of a multiple birth. If they were not then skip 
question 3.  
- Contact can be inside or outside the incubator.  
- In the ‘other infant’ column, write the participant ID for the other infant. This will be 
printed on the case report form for that infant.  
There is room for any extra comments about parental/family contact at the end of this section. 
 
D. Enteral feedings 
Last 7 days. 
- Infants are usually fed at regular intervals throughout the day. To answer Q1 multiply 
their feeding in a day by 7. For example, if they’re fed every 2 hours they would be 
fed 84 times in the past 7 days.   
- Infants are usually fed at regular intervals so the number of times they are fed a day 
should be routine over the last 7 days. 
- If the routine of the infants feedings changed in the last 7 days (e.g. fed every 3 hours 
instead of every 2), please record the date that this changed or tick ‘irregular changes’. 
- Donor human breast milk: this will be less common than mother’s breast milk so the 
question asks for the last 7 days. Include number of times the infant was fed donor 
human breast milk. 
Last 24 hours. 
Breast milk 
- Number of times the infant was fed breast milk in the last 24 hours.  
- Only need to enter the date in the first date column as it will be the same for all of the 
feeds. 
- Do not include donor breast milk in the table. 





- The number of times the infant was fed formula is for the last 24 hours.  
- Only need to enter the date in the first date column as it will be the same for all of the 
feeds.  
- ‘Number of feeds’ column is for the number of feeds of the same type (ready to feed 
or mixed by staff) and duration.  
 
E. Environment 
This section asks for information from the last 7 days.  
Bedspace, incubator, cot, and stethoscope. 
- If the infant has been in the same bedspace/incubator/cot/stethoscope for more than 
the 7 day period, the start date will be ‘ongoing’ and the stop date will be ‘ongoing’. 
- If the infant has changed bedspace/incubator/cot/stethoscope in the last 7 days please 
fill out both available rows on the table so we have a record of both bedspace numbers 





If the infant has been weighed in the last 7 days complete the table.  
- This should happen three times a week so there should be three records in the table.  
- Write whether the scale is inbuilt or external. Do not need to record the number of the 
scales.  
Equipment. 
- If ‘yes’ is ticked for ‘other’ make sure the type of equipment is recorded.  
- Record if the thermometer was shared or the infants own, and the asset number. 
 
F. Estimated infant contact 
Cares. 
- Cares over a 24 hour period is routine. If the infant needs cares every 3 hours this will 
equal 08 cares.  
- Family/parental contact: If there has been any parent contact for cares in the last 24 
hours record the family members involved. Only record ‘mother’, ‘father’ as other 
family members are not usually involved. Do not record the mother or father in any 
other way e.g. do not write their first or last names.  
- Make sure the contact person and type of cares that contact was used for (e.g. nappy 




Apnoeas requiring stimulation. 
- Period we are investigating is 24 hours.  
- Can tick more than one intervention type. 
- If ‘other’ is selected, please specify what other equipment was used.  
Other nursing procedures. 
- Other nursing procedure would include anything not already covered e.g. 
suppositories and urine collection. 
- Specify the procedures and the total number in the last 24 hours. 
Other procedures. 
- Tick ‘yes’ or ‘no’ for the other procedures, do not leave anything blank. If you tick 
‘other’ specify what other procedure (not already included) the infant was involved in.  
 
G. Consultant and registrar contact 
This section is for contact of consultants and registrars.  
- In the ‘staff’ column write only ‘consultant’ or ‘registrar’. Do not write their first or 
last names.  
- Record which shift the staff member was working so that their code number can be 
found.  
- Record the type of exam/procedure that the staff member was involved in, even if it 
has been recorded earlier, the duration of the procedure and the date. 
- Can put multiple dates in one column if it is the same staff, shift, exam and duration. 
 
H. Nurse contact 
This section is for contact of nurses. 
- In the ‘nurse’ column write the nurses code. 
- For ‘number of other infants,’ record the number of other infants in the nurse’s 
workload.  
- Record the other infants in separate rows e.g. if there are two others fill in the first 
row with ‘1’ and the second row with ‘2’. 
- For ‘swab results’, record if the S. capitis test result is ‘known’ or ‘unknown.’  
- If the test result is known (the infant has a result from the previous week) circle + for 
a positive result or circle – for a negative result.  
- If the test result is unknown (the infant has not had a result from the previous week) 
do not circle + or - 
 
I. Questions to ask the mother.  
- The question regarding mastitis and other conditions of the breast while breast-
feeding needs to be answered by the mother. 
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Appendix 5: Retrospective study baseline CRF 
 
Case Report Form Participant ID:  R _  _  _ 
 
 
Case Report Form – Baseline 
 
 
A. Demographic information  
 
1. Is the infant eligible for the study?      Yes     No  
 
No: why is the infant not eligible?  
 Not swabbed their first week in the NICU 
 Not in the NICU for a full week (Monday to Monday) 
 Only swabbed once   Positive first swab   Other: __________________ 
 
No: did the infant have a positive swab during their stay in the NICU?  Yes     No 
 
If yes, what was the date of the first positive swab? (dd/mm/yyyy): __ /__ /____ 
 
2. Were the paper notes available for this infant?   Yes     No 
 
No: why were they unavailable?   Asbestos in store room    Other: ____________ 
 
Not available but eligible: How many weeks of data would we collect if the notes were 
available:  1  2  3  4  5  6  7  8+ 
 
Not available but eligible: did the infant have a positive swab during their stay in the 
NICU?  Yes     No 
 
If yes, what was the date of the first positive swab? (dd/mm/yyyy): __ /__ /____ 
 
3. Sex (must tick one):      Male       Female 
 
4. Date of birth (dd/mm/yyyy): ___ /___ /______ 
 
5. Date of admission (dd/mm/yyyy): ___ /___ /______ 
 
6. Date of discharge (dd/mm/yyyy): ___ /___ /______ 
 
7. Status at discharge:  Alive    Deceased 
 
8. Reason for discharge:  Ready for home    Transferred 
 
If transferred, where: __________________ 
 
9. Was the infant re-admitted to the NICU?    Yes     No  
 
If yes, date of admission and discharge (dd/mm/yyyy):  
___ /___ /______ to ___ /___ /______ 
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If yes, reason for second discharge:  Ready for home    Transferred 
 
If transferred, where: __________________ 
 
10. Gestational age at birth (fill in the number of weeks as well as the additional days):       
____ weeks ____ days 
 
11. Birth weight: ________ grams 
 
12. Infant ethnicity (tick all that apply):   
 NZ European    Māori    Samoan    Cook Island Māori    Tongan    
 Niuean    Chinese    Indian    Other: _________________________  
 
13. Does the neonate have siblings from other births?    Yes     No 
 






B. Birth history 
 
1. Delivery type (must tick one):    Caesarean section    Vaginal delivery   
 
Was the delivery an emergency?      Yes        No 
 
If the infant was born by vaginal delivery, were any of the following included?                        
(tick all that apply):     Forceps       Ventouse      None apply 
 
2. Did this pregnancy involve multiple births?    Yes        No  
 
If ‘yes’, how many births? (e.g. triplets = 3):    2    3    4    5 
 
3. Was the infant born in Dunedin Hospital:    Yes       No 
 
If ‘no’, where was the infant born? (the closest town or city): _________________________ 
 
If ‘no’ (select only one):    Health care facility    Other (e.g. at home): ______________ 
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Case Report Form Participant ID:  _  _  _ 
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Case Report Form – Weekly 
 
Participant ID: R __ __ __ 
 
Date of the Monday of the week of interest (dd/mm/yyyy): __ /__ /____ 
 
Result from the S. capitis swab test:   Positive    Negative 
 
Date of the S. capitis swab test (dd/mm/yyyy): __ /__ /____ 
 
 
A. Infant medical history 
 
1. Comorbidities in the last 7 days (last Monday at 6am to today (Monday) at 5.59am) 
 
Tick either yes (Y) or no (N) for each of the following if the onset is in the last 7 days (do not 
leave blank). 
 Y  N                                                                         Y  N 
 Sepsis workup 
 Apnoea of prematurity                             
 Feed intolerance (feeds workup)                                         
 Gastric aspirate (bile present)                                        
 Hypoglycemia   
 Neonatal encephalopathy                                                              
 Patent ductus arteriosis 
 Renal impairment                                      
 Retinopathy of prematurity (ROP) 
Sepsis diagnosis                                                       
Skin injury 
 Area of inflamed skin: __________ 
 Umbilical flare 
 Flaky skin 
 Temperature instability 
 Intracran. hemorrhage. If ‘yes’ grade:   1   2   3   4 
 Cardiac abnormalities (e.g. congenital heart disease): __________________________ 
 Pulmonary disease (e.g. CLD, HMD/RDS, meconium aspiration): _________________ 
 Gastrointestinal disease (e.g. NEC, gastroschisis, omphalocele): __________________ 
 
2. Did the infant have any of the following procedures or devices in situ in the last 7 days? 
(last Monday at 6am to today (Monday) at 5.59am) 
 
 Tick either yes (Y) or no (N) for each of the following if the procedure was in the last 7 days 
(do not leave blank).                                                                  
Y  N                                                                          Y  N 
 Endotracheal (re)intubation 
 Invasive mechanical ventilation                  
 Nasal CPAP  
 Nasal cannula (Optiflow)                            
 Peripheral IV  
 Supplemental O2                                                             
 Retinopathy of prematurity screen               
 Umbilical Artery Catheter (UAC)               
 Umbilical Vein Catheter (UVC)  
 Peripheral Inserted Central Catheter 
 Orogastric tube  
 Nasogastric tube 
 Blood tests. If ‘yes,’ total number: _____       
 RBC transfusion. If ‘yes,’ total number: _____ 
 Phototherapy. If ‘yes,’ duration: _______ days (total) 
 Syringe pump. If ‘yes,’ tick all that apply 
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B. Medication history 
 
1. Was the infant treated with any antimicrobials in the last 7 days? (last Monday at 6am to 
today (Monday) at 5.59am)    Yes    No       
-  If ‘yes’, fill out the following table. 
 
IV – intravenous, PO – per oral, PR –per rectal 
Start date/ongoing - If the infant started receiving the treatment before the 7 days period 
begun, write ‘ongoing’ 









    
    
    
    
    
    
    
    
    
 
2. Other medications, excluding injectables, received in the last 7 days. (last Monday at 
6am to today (Monday) at 5.59am)     Yes    No    
      -  If ‘yes’, fill out the following table. 
 
IV – intravenous, PO – per oral, PR –per rectal 
Start date/ongoing - If the infant started receiving the treatment before the 7 days period 
begun, write ‘ongoing’ 
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3. Other injectables received in the last 7 days? (last Monday at 6am to today (Monday) at 
5.59am)        Yes    No       
- If ‘yes’, fill out the following table. 
 
Product example - TPN (Total Parental Nutrition), Lipids, 10% dextrose, insulin.  
Start date/ongoing - If the infant started receiving the treatment before the 7 days period 
begun, write ‘ongoing’ 







   
   
   
   
   
   
   
   
   
 
 
C. Enteral feedings 
 
The last 7 days:  (last Monday at 6am to today (Monday) at 5.59am) 
 
1. How many times was the infant fed in the last 7 days? ________________ 
 
What type of food was the infant fed in the last 7 days? (choose all that apply):    
 Breast milk     Expressed breast milk    Formula      Donor breast milk   
 Other: __________ 
 
Was fortifier used in the last 7 days?     Yes    No 
 
What route was used for feeds in the last 7 days?   
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D. Environment  
 
The last 7 days:  (last Monday at 6am to today (Monday) at 5.59am) 
 
1. Bedspace number  
 
Start date/ongoing - If the infant is in the same bedspace from before the 7 day period began, 
write ‘ongoing’ 
Stop date/ongoing - If the infant is in the same bedspace (post 7 day period) write ‘ongoing’ 
Bedspace number 
(e.g. 01, 02, 03) 
Start date and time/ongoing 
(dd/mm/yyyy, 24hr time) 
Stop date and time/ongoing 
(dd/mm/yyyy, 24hr time) 
   
   
   
 
2. Was the infant in an incubator or a cot in the last 7 days?   Incubator      Cot  
 
If the infant moved to a cot in the last 7 days, when was the change? (dd/mm/yyyy):  
___ /___ /______ 
 
3. Was the infant weighed in the last 7 days? (last Monday at 6am to today (Monday) at 
5.59am)          Yes      No  
 











E. Apnoeas requiring stimulation 
 
1. Has the infant had any apnoeas requiring stimulation in the last 7 days?  
       Yes      No 
 
If ‘yes,’ number in incubator in the last 24 hours (e.g. 01, 02, 03): ________  
 
Intervention type (tick all that apply):    
 Gentle     Vigorous     Bag and mask     Neopuff (Ambubag)   
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F. Other procedures 
 
1. Other procedures in the last 7 days (last Monday at 6am to today (Monday) at 5.59am).  
 
Tick either yes (Y) or no (N) for each of the following (do not leave blank). 
Y  N                                                                           
 Abdominal ultrasound                                    
 Echo cardiogram 
 Eye check                                                       
 Head Ultrasound Scan (HUS) 
 Scans                                                                  
 X-ray 











Appendix 7: Prospective study participant consent form 
 
Consent Form 1 
 
Risk factors of Staphylococcus capitis 
colonisation, Neonatal Intensive Care 
Unit, Dunedin Hospital. 
 
Co-ordinating Investigator: Louise Thorn, Masters student  
(louise.m.thorn@gmail.co.nz, Ph 0273111874) 
Co-investigators: Prof John Crump, Dr James Ussher, Associate Prof Roland Broadbent and 
Associate Prof Katrina Sharples 
 
CONSENT FORM FOR PARTICIPANTS 
Following signature and return to the research team this form will be stored in a secure place for ten years. 
 
Name of infant participant:……………………………………… 
 
1. I have read the Information Sheet concerning this study and understand the aims of this research 
project. 
2. I have had sufficient time to talk with other people of my choice about participating in the study.   
3. All my questions about the project have been answered to my satisfaction, and I understand that I am 
free to request further information at any stage.  
4. I know that my child/dependants participation in the project is entirely voluntary, and that I am free to 
withdraw from the project at any time without disadvantage. 
5. I know that as a parent or guardian of the infant participant I consent to data from the weekly S. capitis 
screening being used in the study. I also consent to clinical data and medical information being 
collected. 
6. The mother of the neonate provides consent to their antenatal and demographic data being collected  
 Yes     No   
7. I consent to a faecal sample from my child being collected  Yes   No  




Consent Form 2 
1. I know that all samples and clinical information will be stored in a de-identified form (ie myself or my 
child will not be able to be identified from them).  
2. When the project is completed all the paper records and electronic files which represent the data 
from the project will be placed in secure storage and kept for at least ten years.  
3. I understand that the results of the project may be published and be available in the University of 
Otago Library, but that but my anonymity will be preserved. 
4. I know that there is no remuneration offered for this study, and that no commercial use will be made 
of the data.  
5. I am aware some Iwi disagree with storage of tissue or blood samples citing whakapapa, and advise 
their people to consult prior to participation in research where this occurs, and that it is 
acknowledged that individuals have the right to choose to participate. 
6. I would like to receive the results of the study at its completion. Yes    No  
If “Yes”, please provide your email address: _______________________________________ 
 
I agree for my child to take part in this project. 
 
 
      .............................................................................      ............................... 
                     (Signature of Parent/Guardian)                             (Date) 
 
 
      .............................................................................      ............................... 
                     (Signature of Witness)                             (Date) 
 
      .............................................................................   
(Name of Witness)   
              
 
I agree to take part in this project. 
 
 
      .............................................................................      ............................... 
                     (Signature of Mother)                               (Date) 
 
 
      .............................................................................      ............................... 
                     (Signature of Witness)                             (Date) 
 
      .............................................................................   




This project has been approved by the Health and Disability Ethics Committee. If you have 
any concerns about the ethical conduct of the research you may contact the University of 
Otago Human Ethics Committee Administrator (ph 03 479 8256).  Any issues you raise will 
be treated in confidence and investigated and you will be informed of the outcome. 
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Appendix 8: Prospective study participant information sheet 
 
 
Participant Information Sheet, version 2.0 1 
 
Participant Information Sheet 
 
Study title: Risk factors of Staphylococcus capitis 




Louise Thorn, Department of 
Preventive and Social Medicine, 
University of Otago 
Email: louise.m.thorn@gmail.com 
Contact phone number: 
027 311 1874 
Co-investigators: Associate Prof Roland 
Broadbent, Women’s and 
Children’s Health.  
Prof John Crump, Department of 
Preventive and Social Medicine.  
Associate Prof Katrina Sharples, 
Department of Mathematics and 
Statistics.  
Doctor James Ussher, 





Thank you for your interest in this project.  Please read this information sheet carefully. Take time to think about 
whether or not you want your child to participate in this project and, if you wish, talk with whanau, friends, hapu 
or iwi. Please be aware that this study is part of a Master’s research project. The results will have no immediate 
benefits to you or your child. However it may contribute to improved health for future premature babies.  
If you decide to allow your child to participate we thank you.  If you decide not to allow them to participate there 






Participant Information Sheet, version 2.0 2 
What is the aim of this research project? 
The aim of the project is to determine the risk factor for Staphylococcus capitis (S. capitis) colonisation of 
neonates (premature babies) in the Dunedin Hospital Neonatal Intensive Care Unit (NICU). S. capitis is a type 
of bacteria that lives on the skin, usually without causing harm (known as colonisation). However, it can cause 
blood poisoning in susceptible neonates with catheters or other intravascular devices. Low birthweight neonates 
in NICUs are susceptible to severe disease due to their immature immune systems and their increased 
requirement for catheters. The Dunedin Hospital NICU has been checking for S. capitis on the skin by swabbing 
the neonate’s armpits. This testing has shown that more than a third of admitted neonates get the bacteria on their 
skin. To control the spread of S. capitis, we would like to complete a study to help us understand where the 
bacteria is coming from and how it gets spread between patients.   
 
Who is funding this project? 
Data collection will be hosted by the Dunedin Hospital NICU, who will provide support for participant consent 
and enrolment, and resources for study materials. Southern Community Laboratories will provide S. capitis 
surveillance testing of the neonates.  
Who are we seeking to participate in the project? 
We are seeking all neonates admitted to the Dunedin Hospital NICU at under 36 week’s gestation. The neonate 
will be eligible for participation if they are admitted to the NICU for two or more rounds of swabbing (8-14 days 
minimum post-admission).  
 
If you allow your child to participate, we will also ask the child’s mother to participate in the study.  
 
If you participate, what will you be asked to do? 
If you agree for your child to participate in this project, we will have access to the results from the routine S. 
capitis test. An armpit swab will be collected from your child as routine procedure in the NICU. If you choose 
to allow you child to participate, we will have access to the results of the swab. We will continue to collect the 
data until your child leaves the study or the swab is positive for S. capitis bacteria. Faecal samples will also be 
collected from dirty nappies and tested for S. capitis (consent for this will be included on the consent form). 
Participation also provides consent for clinical data and medical information to be collected by NICU staff. We 
will inform clinical staff of your child’s involvement in the study.  
 
If you, as the child’s mother, agrees to participate, clinical staff will ask you some basic demographic questions, 
questions about your pregnancy and relevant medical history. The clinical staff will also ask for access to your 
relevant medical records.  
 
Please be aware that you may decide not to take part in the project without any disadvantage to yourself, or your 
child, of any kind. Participation is entirely voluntary. In particular, your child’s clinical care will be not affected 
by either refusal or agreement to participate. 
 
 
Is there any risk of discomfort or harm from participation? 







Participant Information Sheet 3 
 
What specimens, data or information will be collected, and how will they 
be used?  
Currently, as part of ongoing surveillance in the NICU, screening swabs are taken from the armpits of infants 
in the NICU on a weekly basis and sent to Southern Community Laboratories for the identification of S. capitis 
bacteria. This is routine procedure in the Dunedin Hospital NICU. We will collect the data from the testing to 
determine which infants have S.capitis on their skin and which do not. We will also have access to clinical data 
and medical information for the completion of case report forms. Case report forms collect information on the 
potential risk factors for the spread of S. capitis. The forms will be completed by clinical staff on behalf of 
your child. One form will be collected as the start of participation and will include the mothers antenatal data 
and the other will be completed weekly for the duration of your childs participation. We will use this 
information to inform infection control practices to prevent the risk of S. capitis colonisation and associated 
bloodstream infections.  
 
Pending the availability funding, we will collect faecal specimens. The faecal sample will be used for additional 
information about the spread of S.capitis. If you wish to give consent for the study, however do not consent to 
the faecal sample, this is presented as an option on the consent form.  
 
Information about age, gender, and ethnicity will be collected. Clinical information that may influence the 
findings of the study will be collected.  
 
Please be aware that as the parents or guardians of the infant you will have access to the health information that 
we are collecting. It is routine procedure for the parents to be informed of the results of the screening swab and 
this will not be affected by participation in this study.  
 
 
What about anonymity and confidentiality? 
 
The participants will each be given an individual study number. During the study we will be able to identify the 
participant. However, when data collection is complete we will destroy the link between the participant and their 
study number,  making it impossible to identify the participant from the data. This will also apply to any data 
collected from the mother.  
 
Results of this project will be published but the data will be completely anonymous. Anonymised data will be 
submitted to an online public database. At the end of the project all data will be stored for a minimum of 10 years 
prior to destruction, as required by the University. 
 
If you agree to participate, can you withdraw later? 
 
Yes, you may withdraw your child from the study at any stage during their admission in the Dunedin Hospital 
NICU. Withdrawal will prevent us from accessing data from any further S. capitis testing or case report forms. 
However, once the data collection is completed it will not be possible to withdraw as it will be impossible to 

















If you have any questions, concerns or complaints about the study at any stage, you can contact:  
 
 Louise Thorn, Master’s student 
Department of Preventive and Social Medicine, University of Otago 
 Phone:  027 311 1874 
 Email:  louise.m.thorn@gmail.com 
 
If you want to talk to someone who isn’t involved with the study, you can contact an independent health and 
disability advocate on: 
 
Phone:   0800 555 050 
Fax:   0800 2 SUPPORT (0800 2787 7678) 
Email:   advocacy@hdc.org.nz 
 
For Maori Health Support, or to discuss any concerns or issues regarding this study, please contact Te Ara Hauora 
(Maori Health Liaison Service) at Dunedin Hospital:  
 
Phone:   (03) 4740999 ext 8649 
 
You can also contact the health and disability ethics committee (HDEC) that approved this study on: 
 
 Phone:  0800 4 ETHICS 
 Email:  hdecs@moh.govt.nz 
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Appendix 9: Prospective study ethics approval 
 
 
Health and Disability Ethics Committees 
 Ministry of Health 
133 Molesworth Street 




 0800 4 ETHICS 
hdecs@moh.govt.nz 
 
A - 17/NTB/59 – Approval of Application – 26 May 2017 Page 1 of 4 
 
26 May 2017 
 
Miss Louise Thorn  




Dear Miss Thorn  
 
Re: Ethics ref: 17/NTB/59 
 Study title: Risk factors of Staphylococcus capitis colonisation, Neonatal 
Intensive Care Unit, Dunedin Hospital. 
 
I am pleased to advise that this application has been approved by the Northern B Health 
and Disability Ethics Committee.  This decision was made through the HDEC-Full Review 
pathway. 
 
Conditions of HDEC approval 
 
HDEC approval for this study is subject to the following conditions being met prior to the 
commencement of the study in New Zealand.  It is your responsibility, and that of the 
study’s sponsor, to ensure that these conditions are met.  No further review by the 




1. Before the study commences at any locality in New Zealand, all relevant 
regulatory approvals must be obtained. 
 
2. Before the study commences at a given locality in New Zealand, it must be 
authorised by that locality in Online Forms.  Locality authorisation confirms that 
the locality is suitable for the safe and effective conduct of the study, and that 




 2 typos on page 1 of the Participant Information Sheet – should be ‘weeks’ not 
‘week’s’ and ‘agree’ not ‘agrees’. 
 
Non-standard conditions must be completed before commencing your study. Non-
standard conditions do not need to be submitted to or reviewed by HDEC before 
commencing your study.  
 
If you would like an acknowledgement of completion of your non-standard conditions 
letter you may submit a post approval form amendment. Please clearly identify in the 
amendment that the changes relate to non-standard conditions and ensure that 
supporting documents (if requested) are tracked/highlighted with changes.  
 
For information on non-standard conditions please see section 128 and 129 of the 










A - 17/NTB/59 – Approval of Application – 26 May 2017 Page 2 of 4 
 
 
After HDEC review  
 
Please refer to the Standard Operating Procedures for Health and Disability Ethics 
Committees (available on www.ethics.health.govt.nz) for HDEC requirements relating to 
amendments and other post-approval processes.   
 
Your next progress report is due by 25 May 2018. 
 
Participant access to ACC 
 
The Northern B Health and Disability Ethics Committee is satisfied that your study is not 
a clinical trial that is to be conducted principally for the benefit of the manufacturer or 
distributor of the medicine or item being trialled.  Participants injured as a result of 
treatment received as part of your study may therefore be eligible for publicly-funded 
compensation through the Accident Compensation Corporation (ACC). 
 
Please don’t hesitate to contact the HDEC secretariat for further information.  We wish 








Northern B Health and Disability Ethics Committee 
 
 
Encl: appendix A: documents submitted 



















Manager, Academic Committees, Mr Gary Witte
HD16/050
Dr J Ussher
Department of Microbiology and Immunology
Otago School of Medical Sciences
University of Otago Medical School
Dear Dr Ussher,
I am writing to you concerning your proposal entitled “Investigation of an outbreak of
Staphylococcus capitis in the Dunedin Hospital NICU”, Ethics Committee reference
number HD16/050.
The above research was submitted and reviewed as a ‘Minimal Risk Health Research – Audit
and Audit related studies’ proposal. The outcome of that consideration was that the
Committee was of the view that the study as described is consistent with Rule 11(2) (c) of the
Health Information Privacy Code 1994 and was approved.
While approving the study please could you confirm whether locality approval is required in
order to undertake the work.
The standard conditions of approval for all human research projects reviewed and approved
by the Committee are the following:
Conduct the research project strictly in accordance with the research proposal submitted and
granted ethics approval, including any amendments required to be made to the proposal by
the Human Research Ethics Committee.
Inform the Human Research Ethics Committee immediately of anything which may warrant
review of ethics approval of the research project, including: serious or unexpected adverse
effects on participants; unforeseen events that might affect continued ethical acceptability of
the project; and a written report about these matters must be submitted to the Academic
Committees Office by no later than the next working day after recognition of an adverse
occurrence/event. Please note that in cases of adverse events an incident report should also
be made to the Health and Safety Office:
http://www.otago.ac.nz/healthandsafety/index.html








Make no change to the project as approved in its entirety by the Committee, including any
wording in any document approved as part of the project, without prior written approval of the
Committee for any change. If you are applying for an amendment to your approved research,
please email your request to the Academic Committees Office:
gary.witte@otago.ac.nz
jo.farrondediaz@otago.ac.nz
Approval is for up to three years from the date of this letter. If this project has not been
completed within three years from the date of this letter, re-approval or an extension of
approval must be requested. If the nature, consent, location, procedures or personnel of your






 c.c. Professor C W Ronson    Department of Microbiology and Immunology
 161 
Appendix 13: Retrospective study locality approval 
 
 
 
